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Abstract 
Idiopathic Parkinson’s disease (IPD) is a progressive neurodegenerative 
disorder, secondary to dopaminergic depletion, which primarily affects motor 
control via the basal ganglia. It is a multi system disease affecting dopaminergic 
neurones throughout the body. The Parkinsonian syndromes are associated 
with excess morbidity and mortality from respiratory causes. Pulmonary function 
studies have yielded conflicting results in IPD. There is a lack of high quality 
research examining the effect of exercise on pulmonary function and aerobic 
capacity in IPD. Understanding the pattern of any respiratory dysfunction and 
impairment in cardiorespiratory fitness in IPD, and interventions that could 
modify these, are of importance in dyspnoea, hypoxia, hypercapnia, 
pneumonia, speech, swallowing, sleep disordered breathing, daytime 
somnolence, acute respiratory failure, extubation difficulties, increased 
respiratory infections and reduced exercise tolerance and functional capacity.  
We recruited 103 individuals with IPD, at different disease stages, from the 
Northumbria Parkinson’s Disease Service to define the pattern of pulmonary 
dysfunction and respiratory muscle strength. 100 participants completed a 
cross-sectional study comprising demographics, questionnaires and 
comprehensive pulmonary function testing, including spirometry, flow volume 
loops, lung volume assessment and respiratory muscle strength testing. Of 
these 100, 32 volunteered for a randomised control trial (RCT) with additional 
measurements of aerobic capacity, assessed by cardiopulmonary exercise 
testing, and exercise capacity, assessed by six minute walk testing. The 
participants were randomised, 1:1, control:intervention. The intervention group 
participated in a 12 week, 3 times weekly, exercise intervention. The baseline 
assessments were repeated in both groups immediately after the intervention, 
with 27 completing the RCT. 
The cross-sectional pulmonary function study revealed an increased prevalence 
of obstructive spirometry, upper airway obstruction and inspiratory muscle 
weakness in this population. The randomised control trial demonstrated 
statistically significant improvements in the intervention group only in; aerobic 
capacity, exercise capacity, subjective parkinsonian symptoms, quality of life, 
depression, anxiety, sleep and sleepiness. 
iv 
 
Dedication 
 
 
 
 
 
 
 
 
 
 
 
 
 
For everyone affected by Parkinson’s  
 
 
 
 
 
v 
 
Acknowledgements 
 
I would like to express my sincere gratitude to everyone who has been involved 
with the study. I would like to thank my supervisors, Professor Richard Walker 
and Professor Michael Trenell, for their enthusiasm, support, guidance and 
patience. I would also like to thank Keith Gray, who provided very welcome 
advice on statistical analysis. Sincere thanks go to the entire Northumbria 
Parkinson’s disease team, but in particular Parkinson’s specialist nurses Karen 
Ullyart and Catherine Jones, who dedicated a large amount of time and effort to 
recruitment and assessment for the study. Thanks also go to Djordje Jakovljevic 
and Sarah Moore of the Movelab for their knowledge and assistance, and Dr 
Stephen Bourke of Northumbria Healthcare for his knowledge and advice. 
Sincere thanks also go to the Northumbria lung function department, led by 
Helen Morrow, for their expert assessments and flexibility. Personally, and from 
the participants in the randomised control trial, I would like to thank the Healthy 
Living Centre staff, led by Maureen Turner, for their enthusiastic, friendly, safe 
and welcoming delivery of the exercise intervention. Vitally I would like to 
express my sincere gratitude to the patients who willingly and generously gave 
their time and enthusiasm to participate in this research, I have met amazing 
and inspiring people affected by Parkinson’s during this study and you have 
taught me a huge amount.   
Finally I would like to thank my family; my mother, Sue, my brother, Carey,  and 
my late father, Peter, for their unconditional love, support and encouragement 
which has got me to where I am today and to my wonderful husband, 
Christopher, I will never be able to thank you enough for your love, support, 
encouragement and patience. I am so very grateful, thank you. 
vi 
 
vii 
 
Publications and presentations 
 
Publications 
 
A.K. O’Callaghan, D.G. Jakovljevic, M.I. Trenell, R.W. Walker. The effect of an 
exercise intervention on aerobic capacity in idiopathic Parkinson’s disease. 
Movement Disorders 2014; 29 S1: S255. 
 
A.K. O’Callaghan, D.G. Jakovljevic, M.I. Trenell, R.W. Walker. The effects of an 
exercise intervention on cardiovascular system and skeletal muscle function in 
idiopathic Parkinson’s disease. Movement Disorders 2014; 29 S1: S255. 
 
O’Callaghan A, Jakovljevic D, Trenell M, Walker R. Maximum heart rate in 
idiopathic Parkinson’s disease. Abstract Book 20th World Congress on 
Parkinson’s Disease and Related Disorders, Geneva, Switzerland, December 8-
11, 2013; no. 081: page 26. 
 
O’Callaghan A, Walker R. First-degree atrioventricular block in idiopathic 
Parkinson’s disease. Abstract Book 20th World Congress on Parkinson’s 
Disease and Related Disorders, Geneva, Switzerland, December 8-11, 2013; 
no. 084: page 27. 
 
O’Callaghan A, Walker R. Electrocardiographic artefact in idiopathic Parkinson’s 
disease. Abstract Book 20th World Congress on Parkinson’s Disease and 
Related Disorders, Geneva, Switzerland, December 8-11, 2013; no. 082: page 
26. 
 
White R, O’Callaghan A, van Hees V, Gray W, Jakovljevic D, Trenell M, Walker 
R. The relationship between aerobic capacity, exercise capacity and physical 
activity in idiopathic Parkinson’s disease. Abstract Book 20th World Congress 
on Parkinson’s Disease and Related Disorders, Geneva, Switzerland, 
December 8-11, 2013; no. 279: page 77. 
 
 
viii 
 
Presentations 
2015 Platform presentation - Exercise and cardiorespiratory function in idiopathic 
Parkinson’s disease. British Geriatric Society Movement Disorders Section Meeting, 
Birmingham. 
 
2014 Poster presentation - A randomised control trial of structured exercise therapy 
on quality of life, sleep and mood in Parkinson’s. Parkinson’s UK research 
conference, York. 
 
2014 Poster presentation - The effect of an exercise intervention on aerobic 
capacity in idiopathic Parkinson’s disease. 18th International Congress of Parkinson's 
Disease and Movement Disorders, Stockholm, Sweden. 
 
2014 Poster presentation - The effects of an exercise intervention on cardiovascular 
system and skeletal muscle function in idiopathic Parkinson’s disease. 18th 
International Congress of Parkinson's Disease and Movement Disorders, Stockholm, 
Sweden.  
 
2014 Platform presentation - The effect of an exercise intervention on 
cardiopulmonary outcome measures in idiopathic Parkinson’s disease. Three Rivers 
Parkinson’s meeting, Durham. 
 
2013 Platform presentation - Maximum heart rate in idiopathic Parkinson’s disease. 
XX World Congress on Parkinson’s Disease and Related Disorders, Geneva, 
Switzerland. 
 
2013 Poster presentation - First-degree atrioventricular block in idiopathic 
Parkinson’s disease. XX World Congress on Parkinson’s Disease and Related 
Disorders, Geneva, Switzerland. 
 
2013 Poster presentation - Electrocardiographic artefact in idiopathic Parkinson’s 
disease. XX World Congress on Parkinson’s Disease and Related Disorders, 
Geneva, Switzerland. 
 
ix 
 
2013 Poster presentation - The relationship between aerobic capacity, exercise 
capacity and physical activity in idiopathic Parkinson’s disease. XX World Congress 
on Parkinson’s Disease and Related Disorders, Geneva, Switzerland.
x 
 
Statement of work undertaken 
Previous training in respiratory medicine, prior to geriatric medicine with a 
specialist interest in movement disorders, fostered my interest in pulmonary 
function and cardiorespiratory fitness in this group. I devised the concept for the 
study. The design of both parts of the study, cross-sectional and randomised 
control trial, was collaborative between myself and with input from my 
supervisors, Professor Walker and Professor Trenell. The funding for the project 
was applied for by myself from Parkinson’s UK and The British Geriatrics 
Society and awarded in the forms of an innovation grant and a SpR start up 
grant respectively. I applied for ethical approval and attended the Research 
Ethics Committee with Professor Walker.  
I oversaw the running of the cross-sectional and randomised control trial 
sections of the study. The assessment visits were conducted by either myself or 
one of the Northumbria Parkinson’s specialist nurses. The pulmonary function 
testing was performed by the Pulmonary Function Department at North 
Tyneside General Hospital. All testing was performed by qualified, experienced 
respiratory physiologists accredited to the Association for Respiratory 
Technology and Physiology (ARTP). The cardiopulmonary exercise testing was 
performed by myself accompanied by either an exercise physiologist or 
physiotherapist. The exercise intervention was supervised by Moor Park 
Healthy Living Centre (HLC) staff (trained to British Association of Cardiac 
Rehabilitation level 4 and GP referral qualification level 3) and frequently myself 
also.     
Processing and analysis of data was my own work. Statistical analysis was 
undertaken by myself, with invaluable advice from Keith Gray. 
xi 
 
 
Table of Contents 
Abstract .............................................................................................................. iii 
Dedication .......................................................................................................... iv 
Acknowledgements ............................................................................................. v 
Publications and presentations ......................................................................... vii 
Statement of work undertaken ............................................................................ x 
List of tables ...................................................................................................... xv 
List of figures....................................................................................................xvii 
Abbreviations .................................................................................................. xviii 
Chapter 1. Overview ...................................................................................... 1 
1.1 Background and rationale to study ........................................................ 1 
1.2 Outline of study aims and hypotheses ................................................... 2 
Chapter 2. Introduction and literature review ................................................. 3 
2.1 General introduction .............................................................................. 3 
2.2 Parkinson’s disease ............................................................................... 3 
2.2.1 Epidemiology ................................................................................... 4 
2.2.2 Aetiology ......................................................................................... 5 
2.2.3 Pathophysiology .............................................................................. 7 
2.2.4 Clinical features ............................................................................. 10 
2.2.5 Diagnosis ...................................................................................... 16 
2.2.6 Treatment ...................................................................................... 19 
2.2.7 Prognosis ...................................................................................... 22 
2.3 Pulmonary function .............................................................................. 24 
2.3.1 Quantification of pulmonary function ............................................. 25 
2.3.2 Spirometry ..................................................................................... 25 
2.3.3 Flow volume loops ......................................................................... 28 
2.3.4 Lung volumes ................................................................................ 32 
xii 
 
2.3.5 Diffusion capacity .......................................................................... 34 
2.3.6 Respiratory muscle function .......................................................... 36 
2.3.7 Pulmonary function and ageing ..................................................... 38 
2.3.8 Pulmonary function and neurodegenerative disease .................... 40 
2.3.9 Pulmonary function and Parkinson’s disease ................................ 43 
2.4 Cardiorespiratory fitness ...................................................................... 64 
2.4.1 Quantification of cardiorespiratory fitness ..................................... 66 
2.4.2 Cardiorespiratory fitness and ageing ............................................. 68 
2.4.3 Cardiorespiratory fitness and neurodegenerative disease ............ 68 
2.4.4 Cardiorespiratory fitness and Parkinson’s disease ........................ 69 
Chapter 3. Methods: Cross-sectional study; the pattern of pulmonary 
dysfunction in idiopathic Parkinson’s disease ................................................... 73 
3.1 Participant recruitment ......................................................................... 73 
3.2 Inclusion criteria ................................................................................... 73 
3.3 Exclusion criteria .................................................................................. 74 
3.4 Study journey, assessments, questionnaires and outcome measures 74 
3.4.1 Assessment document .................................................................. 75 
3.4.2 MDS-UPDRS ................................................................................ 77 
3.4.3 PDQ-39 ......................................................................................... 77 
3.4.4 SCOPA-SLEEP ............................................................................. 78 
3.4.5 HADS ............................................................................................ 78 
3.5 Pulmonary function measurement ....................................................... 79 
3.5.1 Spirometry ..................................................................................... 80 
3.5.2 Lung volumes ................................................................................ 81 
3.5.3 Diffusion ........................................................................................ 82 
3.6 Respiratory muscle strength ................................................................ 83 
Chapter 4. Results, Discussions and Conclusions: Cross-sectional study; 
The pattern of pulmonary dysfunction in idiopathic Parkinson’s disease .......... 84 
xiii 
 
4.1 Demographic features.......................................................................... 85 
4.2 UPDRS Results ................................................................................... 87 
4.2.1 Discussion ..................................................................................... 90 
4.3 PDQ-39, SCOPA-SLEEP, HADS Results ............................................ 91 
4.3.1 Discussion ..................................................................................... 92 
4.4 Pulmonary Function Results ................................................................ 95 
4.4.1 Discussion ................................................................................... 110 
4.5 Strengths and limitations .................................................................... 119 
4.6 Conclusion ......................................................................................... 119 
Chapter 5. Methods: Randomised control trial; the effect of an exercise 
intervention on pulmonary function, cardiorespiratory fitness and exercise 
capacity in idiopathic Parkinson’s disease ...................................................... 121 
5.1 Participant recruitment ....................................................................... 121 
5.2 Inclusion criteria ................................................................................. 121 
5.3 Exclusion criteria ................................................................................ 122 
5.4 Study journey, assessments, questionnaires and outcome measures
 122 
5.4.1 Assessment document ................................................................ 125 
5.4.2 MDS-UPDRS .............................................................................. 125 
5.4.3 PDQ-39 ....................................................................................... 125 
5.4.4 SCOPA-SLEEP ........................................................................... 125 
5.4.5 HADS .......................................................................................... 125 
5.4.6 ECG ............................................................................................ 126 
5.5 Pulmonary function measurement ..................................................... 126 
5.6 Cardiorespiratory fitness measurement ............................................. 126 
5.7 Exercise capacity, six minute walk testing ......................................... 128 
5.8 The structured exercise therapy intervention ..................................... 129 
5.9 Follow up 12 week assessments ....................................................... 132 
5.10 Sample size calculations ................................................................ 132 
xiv 
 
Chapter 6. Results: Randomised control trial; The effect of an exercise 
intervention on pulmonary function, cardiorespiratory fitness and exercise 
capacity in idiopathic Parkinson’s disease ...................................................... 133 
6.1.1 Discussion ................................................................................... 146 
6.1.2 Discussion: Effect of an exercise intervention on cardiorespiratory 
fitness and exercise capacity ................................................................... 147 
6.1.3 Discussion: Effect of an exercise intervention on pulmonary 
function and respiratory muscle strength ................................................. 149 
6.1.4 Discussion: Effect of an exercise intervention on parkinsonian 
symptoms, Parkinson’s disease stage, quality of life, sleep, anxiety and 
depression ............................................................................................... 150 
6.1.5 Discussion: Heart rate response to exercise ............................... 152 
6.2 Strengths and limitations ................................................................... 153 
6.3 Conclusion ......................................................................................... 155 
Chapter 7. Conclusion and future studies .................................................. 156 
7.1 Overall conclusions ............................................................................ 156 
7.2 Future studies .................................................................................... 156 
Appendix A. Cross-sectional study; participant information sheet, consent form 
and assessment document ............................................................................. 157 
Appendix B. Rating scales .............................................................................. 165 
Appendix C. Randomised control trial; participant information sheet, consent 
form and assessment document ..................................................................... 166 
Appendix D. Additional work resulting from thesis and ongoing analyses ...... 178 
References ..................................................................................................... 180 
xv 
 
List of tables 
Table 1: UK Brain Bank Parkinson's disease diagnostic criteria ....................... 17 
Table 2: Pharmacological therapy options ........................................................ 21 
Table 3: Summary of the literature on pulmonary function in Parkinson's disease
 .......................................................................................................................... 47 
Table 4: Comparison of the basic demographics between non-smokers and 
smokers ............................................................................................................ 87 
Table 5: Comparison of UPDRS, Hoehn and Yahr and motor phenotype 
between non-smokers and smokers ................................................................. 88 
Table 6: Comparison of PDQ-39 summary index, SCOPA-SLEEP and HADS 
between non-smokers and smokers ................................................................. 92 
Table 7: Comparison of group median results of spirometry and lung volumes 
between non-smokers and smokers ................................................................. 97 
Table 8: Summary of pattern of lung function in non-smokers and smokers .... 99 
Table 9: Severity of obstruction in non-smokers and smokers with obstructive 
spirometry ....................................................................................................... 101 
Table 10: Demographics, motor phenotype and UPDRS scores comparison; 
non-smokers and smokers, normal lung function and obstructive lung function
 ........................................................................................................................ 103 
Table 11: PDQ-39, SCOPA-SLEEP and HADS scores comparison; non-
smokers and smokers, normal lung function and obstructive lung function .... 104 
Table 12: Prevalence of indicators of UAO in non-smokers and smokers ...... 106 
Table 13: Cumulative numbers of UAO criteria in non-smokers and smokers 107 
Table 14: Respiratory muscle strength in non-smokers and smokers ............. 109 
Table 15: The exercise intervention ................................................................ 131 
Table 16: Demographics of the control and intervention groups pre and post the 
exercise intervention ....................................................................................... 136 
Table 17: UPDRS and Hoehn and Yahr scores pre and post intervention ...... 137 
Table 18: Resting cardiovascular parameters and peak heart rate pre and post 
intervention ..................................................................................................... 139 
Table 19: Cardiorespiratory fitness and exercise capacity pre and post 
intervention ..................................................................................................... 140 
xvi 
 
Table 20: PDQ 39 single index, SCOPA-SLEEP and HADS scores pre and post 
intervention ..................................................................................................... 143 
Table 21: Pulmonary function and respiratory muscle strength pre and post 
intervention ..................................................................................................... 144 
Table 22: Heart rate response to cardiopulmonary exercise test .................... 145 
 
xvii 
 
List of figures 
Figure 1: Normal Spirometry ............................................................................. 26 
Figure 2: Obstructive spirometry ....................................................................... 27 
Figure 3: Restrictive Spirometry ........................................................................ 28 
Figure 4: Labelled flow volume loop .................................................................. 29 
Figure 5: Normal flow volume loop .................................................................... 30 
Figure 6: Obstructive flow volume loop ............................................................. 30 
Figure 7: Restrictive flow volume loop .............................................................. 30 
Figure 8: Flow volume loops: a.Fixed UAO b.Variable extrathoracic UAO 
c.Variable intrathoracic UAO ............................................................................. 31 
Figure 9: Static lung volumes and capacities .................................................... 33 
Figure 10: Volume-time display illustrating plethysmography sequence ........... 34 
Figure 11: Flow-volume curves illustrating Type A and Type B pattern ............ 49 
Figure 12: Cross-sectional study patient journey .............................................. 75 
Figure 13: Cross-sectional study recruitment, drop-out and completion ........... 84 
Figure 14: Motor phenotype of smokers group ................................................. 89 
Figure 15: Motor phenotype of non-smokers group .......................................... 89 
Figure 16: Pattern of lung function in non-smokers ......................................... 100 
Figure 17: Pattern of lung function in smokers ................................................ 100 
Figure 18: Cumulative numbers of UAO criteria in non-smokers and smokers
 ........................................................................................................................ 108 
Figure 19: Randomised control trial patient journey ........................................ 124 
Figure 20: The electromagnetically controlled recumbent bicycle ergometer 
(Corival, Lode, Groningen, Netherlands) ........................................................ 128 
Figure 21: The Metalyzer (Cortex, Leipzig, Germany) .................................... 128 
Figure 22: Randomised control trial; recruitment, drop out and completion .... 134 
Figure 23: Effects of exercise intervention on median change from baseline 
anaerobic threshold percentage of VO2max predicted ................................... 141 
Figure 24: Effects of exercise intervention on median change from baseline on 
VO2peak, cardiorespiratory fitness ................................................................. 141 
xviii 
 
Abbreviations 
ABG = Arterial blood gas 
ALS = Amyotrophic lateral sclerosis 
ANS = Autonomic nervous system  
ARTP = Association for Respiratory Technology and Physiology    
ATS = American Thoracic Society 
a-vO2 diff = Arterial-venous oxygen difference 
BDNF = Brain derived neurotrophic factor 
BMI = Body Mass Index  
BTS = British Thoracic Society 
cmH2O = cm water pressure 
CBD = Corticobasal degeneration 
CO = Carbon monoxide 
CO2 = Carbon dioxide 
COMT = Catechol-O-methyl transferase 
COPD = Chronic obstructive pulmonary disease 
CPET = Cardiopulmonary exercise test 
CT = Computed tomography 
DBP = Diastolic blood pressure 
DLB = Dementia with Lewy bodies 
DLCO = Diffusing capacity of the lung for carbon monoxide 
ECCS = European Community for Coal and Steel 
ECG = Electrocardiogram 
ERS = European Respiratory Society 
ERV = Expiratory reserve volume 
FBC = Full blood count 
FEF = Forced expiratory flow 
FEV = Forced expiratory volume 
FEV1 = Forced expiratory volume in one second 
FH = Family history 
FIF = Forced inspiratory flow 
FRC = Functional residual capacity 
FVC = Forced vital capacity 
xix 
 
HADS = Hospital Anxiety and Depression Scale  
Hb = Haemoglobin 
He = Helium 
HIT = High intensity interval training 
HLC = Healthy Living Centre  
HR = Heart rate 
IC = Inspiratory capacity  
ICD = Impulse control disorders 
IPD = Idiopathic Parkinson’s disease 
IRV = Inspiratory reserve volume 
ITGV = Intrathoracic gas volume 
IVC = Inspiratory vital capacity 
KCO = Transfer coefficient 
kPa = kilopascal 
LBs = Lewy bodies 
LLN = Lower limit of normal 
LNs = Lewy neurites 
LRRK2 = Leucine rich repeat kinase 2 
MDS-UPDRS = Movement Disorders Society Unified Parkinson's Disease 
    Rating Scale 
MEF = Maximum expiratory flow  
MEP = Maximal expiratory pressure 
MET = Metabolic equivalent 
MG = Myasthenia gravis 
MIF = Maximum inspiratory flow 
MIP = Maximal inspiratory pressure 
MMEF = Maximum mid expiratory flow 
MMSE = Mini mental state examination 
MND = Motor neuron disease 
MoCA = Montreal Cognitive Assessment 
MPPP = Desmethylprodine 1,3-Dimethyl-4-phenyl-4-propionoxypiperidine   
MPTP = 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
MRI = Magnetic resonance imaging 
MS = Multiple sclerosis 
MSA = Multiple system atrophy 
xx 
 
MVV = Minute ventilatory volume  
N2 = Nitrogen 
NICE = National Institute for Health and Care Excellence 
NIV = Non-invasive ventilation  
OSA = Obstructive sleep apnoea 
O2 = Oxygen  
Psniff = Sniff nasal inspiratory pressure 
PaO2 =Partial pressure of oxygen 
PaCO2 = Partial pressure of carbon dioxide 
PCF = Peak cough flow 
PD = Parkinson’s disease 
PDQ-39 = Parkinson’s Disease Questionnaire 
PDSS = Parkinson’s Disease Sleep Scale  
PEmax = Maximal expiratory pressure 
PEF = Peak expiratory flow 
PFT = Pulmonary function test 
PImax = Maximal inspiratory pressure 
PIF = Peak inspiratory flow 
PIGD = Postural instability gait difficulty 
PINK1 = PTEN-induced putative kinase 1 
PMH = Past medical history 
PSP = Progressive supranuclear palsy 
QT = Cardiac output 
RAW = Airway resistance  
RCT = Randomised control trial 
RBD = REM sleep behaviour disorder 
REM = Rapid eye movement 
RMW = Respiratory muscle weakness 
RV = Residual volume 
SBP = Systolic blood pressure 
SH = Social history 
SMR = Standardised mortality ratio 
SNc = Substantia nigra pars compacta 
SNCA = α-Synuclein 
SNIP = Sniff nasal inspiratory pressure 
xxi 
 
SPECT = Single-photon emission computed tomography 
SV = Stroke volume 
SVC = Slow vital capacity 
TD = Tremor dominant 
TGV = Thoracic gas volume  
TLC = Total lung capacity 
TLCO = Transfer factor of the lung for carbon monoxide 
TV = Tidal volume 
UAO = Upper airway obstruction 
UK = United Kingdom 
UPDRS = Unified Parkinson’s Disease Rating Scale 
VA = Alveolar volume 
VC = Vital capacity 
VO2max = Maximal oxygen consumption 
VO2peak = Peak oxygen consumption 
VTA = Ventral tegmental area 
 
6MWD = Six minute walk distance  
6MWT = Six minute walk test 
1 
 
Chapter 1. Overview 
1.1 Background and rationale to study 
Pulmonary complications associated with idiopathic Parkinson’s disease (IPD) 
are a common reason for hospital admission (Woodford and Walker, 2005, Tan 
et al., 1998). Lee et al 2007, evaluated symptom burden experienced by 
patients with IPD with 35.8% reporting shortness of breath on exertion, 17.9% 
reporting cough and 13% reporting sputum production (Lee et al., 2007). A 
higher proportion of patients with IPD die from pneumonia than in the general 
population (Pennington et al., 2010). Previous research into the effect of PD on 
pulmonary function has produced varied and conflicting results. Obstructive and 
restrictive ventilatory defect patterns and upper-airway and intercostal muscle 
problems have all been reported. 
A recent review of exercise and parkinsonism underlined the improvements 
pertaining to both the functional deficits and neurological biomarker 
manifestations of the disorder and concluded that physical exercise co-
administered with antiparkinsonian medication ought to contribute to an 
enrichment of aspects of functioning and the quality of life of PD patients 
(Archer et al., 2011). The review however mentioned little evidence of the effect 
of exercise on pulmonary function, aerobic capacity, respiratory muscle strength 
and breathlessness and literature review has found this area to be lacking in 
high quality studies. The potential benefits of an exercise intervention on factors 
that relate to poor quality of life in Parkinson’s disease should not be 
underestimated. Literature review has indicated the negative impact of PD on 
quality of life, with many contributing factors: bradykinesia, tremor, rigidity, gait 
disturbance, postural instability, pain, fatigue, depression, cognitive alterations, 
sleep disturbances, drooling, limitations to social functioning and economic 
implications (Chrischilles et al., 2002, Whetten-Goldstein et al., 1997, Schrag et 
al., 2000, Leibner et al., 2010, Karlsen et al., 1999, Schenkman et al., 2001, 
Morimoto et al., 2003). 
Thus further research looking at pulmonary function, respiratory muscle 
strength, aerobic capacity, and exercise capacity in different stages of the 
disease, and the response to an exercise intervention in IPD, was indicated. 
With the significant impact of IPD symptoms on quality of life there was further 
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justification in assessing this secondary outcome measure of an exercise 
intervention also. A cross-sectional study of pulmonary function and respiratory 
muscle strength in IPD was undertaken. Additionally a randomised control trial 
(RCT) to research the effect of structured exercise therapy on cardiorespiratory 
fitness (aerobic capacity), exercise capacity and pulmonary function was also 
undertaken.  The background, methods, results and conclusions of the cross-
sectional study and the RCT are discussed in this thesis. 
1.2 Outline of study aims and hypotheses 
The aims of this study were; to establish if pulmonary function is impaired in IPD 
and secondly to establish whether pulmonary function, cardiorespiratory fitness 
and exercise capacity can be improved in IPD with structured exercise therapy.  
These aims were achieved through the following objectives; to define the 
pattern of respiratory dysfunction in IPD and to establish whether a community 
based structured exercise therapy programme improves pulmonary function, 
cardiorespiratory fitness (aerobic capacity) and exercise capacity in people with 
IPD. 
The hypotheses of this study were: 
1. Pulmonary function is impaired in IPD 
2. Structured exercise therapy can improve cardiorespiratory fitness in IPD 
3. Structured exercise therapy can improve exercise capacity in IPD 
4. Structured exercise therapy can improve pulmonary function in IPD 
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Chapter 2. Introduction and literature review 
2.1 General introduction 
This thesis details a cross-sectional study of pulmonary function and respiratory 
muscle strength in IPD, and a RCT to research the effect of structured exercise 
therapy on cardiorespiratory fitness (aerobic capacity), exercise capacity and 
pulmonary function in IPD. Chapter 2 is the introduction and literature review 
that is divided into 3 sections; Parkinson’s disease, pulmonary function and 
cardiorespiratory fitness. The PD section focuses on; epidemiology, aetiology, 
pathophysiology, clinical features, diagnosis, treatment and prognosis. The 
pulmonary function section focuses on; quantification of pulmonary function, 
spirometry, flow volume loops, lung volumes, diffusion capacity, respiratory 
muscle function, pulmonary function and ageing, pulmonary function and 
neurodegenerative disease and pulmonary function and PD. The 
cardiorespiratory fitness section focuses on; quantification of cardiorespiratory 
fitness, cardiorespiratory fitness and ageing, cardiorespiratory fitness and 
neurodegenerative disease and cardiorespiratory fitness and PD. Chapter 3 
details the methods of the cross-sectional study; the pattern of pulmonary 
dysfunction in IPD. Chapter 4 reports the results, discussion and conclusion of 
the cross-sectional study. Chapter 5 details the methods of the RCT; the effect 
of an exercise intervention on pulmonary function, cardiorespiratory fitness and 
exercise capacity in IPD. Chapter 6 reports the results, discussion and 
conclusion of the RCT. Finally, prior to the references and appendices, chapter 
7 is the overall conclusions and suggestions for further studies.  
2.2 Parkinson’s disease 
Parkinson’s disease (PD) is a complex, progressive, neurodegenerative 
disorder, secondary to dopaminergic depletion, which primarily affects motor 
control via the basal ganglia. PD has both motor and non-motor symptoms due 
to a spreading process of neuronal loss (Dexter and Jenner, 2013). It is a multi-
system disease affecting dopaminergic neurones throughout the body. To date 
only symptomatic treatment exists, the degenerative process cannot be 
arrested and the cause remains elusive (Dexter and Jenner, 2013). Although 
the UK Brain Bank Criteria for PD diagnosis focuses mainly on motor 
symptoms, it is accepted that non-motor symptoms also contribute to the 
significant symptom burden experienced by patients with PD. The myriad of 
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potential non-motor symptoms associated with PD has led to increasing 
research in this area in attempts to improve quality of life in those affected. 
2.2.1 Epidemiology 
The median age of onset of PD is 60 years and the incidence of PD rises with 
age up to the start of the ninth decade after which there is a decrease (Lees et 
al., 2009, Taylor et al., 2005). A wealth of data exists supporting that men are 
more likely to develop PD than women, however a systematic review of twenty 
five incidence studies highlighted that this difference may be restricted to 
western populations and is more pronounced in those over 70 years of age, 
with only five of the reviewed studies reporting a significantly higher incidence in 
men (Twelves et al., 2003).  
The reported prevalence of PD varies throughout the world. This variance is 
likely multifactorial due to populations and ages studied, methodological and 
diagnostic criteria differences. In the United Kingdom (UK) PD is the second 
most common neurodegenerative disorder after Alzheimer’s disease (Archibald 
and Burn, 2008). Local incidence and prevalence studies in the North east of 
England found the crude incidence of PD in more urban areas (Newcastle and 
Gateshead) to be 15.9 per 100 000 persons per year or 12.0 per 100 000 when 
age standardised to European studies and in a more rural population crude and 
age-adjusted prevalence estimates of 148 cases and 139 cases per 100,000 
respectively (Duncan et al., 2014, Porter et al., 2006). A systematic review of 39 
European incidence and prevalence studies found 87% reported estimates of 
prevalence rates, while only 13% reported incidence rates with crude 
prevalence rate estimates ranging from 65.6 per 100,000 to 12,500 per 100,000 
and incidence estimates from 5 per 100,000 to 346 per 100,000 (von 
Campenhausen et al., 2005). Despite prevalence rate calculations being crude, 
PD appears less common in Asian countries (Chen and Tsai, 2010). In 2009, 
using the world’s largest anonymised longitudinal computerised database of 
medical records, UK PD prevalence rates were found to be 30.9/10,000 for 
males and 24.1/10,000 for females translating to 69,850 males and 57,043 
females with the condition (Parkinson's UK, 2009). A 2017 Parkinson’s UK 
publication updated UK incidence and prevalence figures using data taken from 
the May 2016 static version of the Clinical Practice Research Datalink (CPRD) 
using the primary care database (GOLD). The data included patients aged 20 or 
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over with a record for Parkinson’s in their file from the 1st January 1988 to the 
31st December 2015. Prevalence rates refer to that in 2015, incidence rates 
use combined data over a 5 year period (2011-2015) to give more reliable 
estimates. The data revealed that in the UK in 2015 approximately 2 in 1000 
people live with PD.  This can be broken down more specifically into 18 in every 
10000 females and 25 in every 10000 males. Focussing on the adult population 
alone this is approximately 3 in every 1000 people (22 in every 10000 women 
and 32 in every 10000) men. This data indicates that in 2015 there were around 
137000 people in the UK with PD (57.7% male). Incidence figures concluded 
that around 3 in every 10000 women and 4 in every 10000 men will have a new 
diagnosis of PD each year with incidence numbers suggesting around 17300 
new diagnoses of PD in the UK each year (Parkinson'sUK, 2017).  
Thus between the 2009 and 2017 Parkinson’s UK publications the prevalence 
of PD in the UK has risen by over 10000. The most likely reason for this 
increase and the increase in incidence is that the UK population is increasingly 
ageing with increasing life expectancy, and with the median age of onset of PD 
being 60 years PD is more common in this older expanding age group. 
Improvements in the way PD is diagnosed both with improved clinical 
knowledge and the introduction of improved tests, for example DaTSCANTM, 
this has likely contributed to higher diagnosis rates and thus increased 
prevalence and incidence. With projected increases in the elderly population 
and increasing research into knowledge and diagnostic testing, the prevalence 
and incidence of PD is set to increase. 
2.2.2 Aetiology  
Although biblical texts vaguely describe cases that may be consistent with what 
we now identify as PD, no clear, succinct case series describing clinical 
features was published until the 1817 “An Essay on the Shaking Palsy” by 
Hoxton surgeon and apothecary, James Parkinson (Stern, 1989, Parkinson, 
2002). Subsequent neurologists advanced our knowledge of the disease, most 
notably the eminent Jean-Martin Charcot who advocated the label “maladie de 
Parkinson” or Parkinson’s disease in place of “Paralysis Agitans” or the 
“Shaking Palsy” (Lees, 2007). Despite advances, the large time scale and 
extensive research, the cause of PD remains elusive. As highlighted, age is a 
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major risk factor however the cause of PD is likely a complex interaction 
between genetic and environmental factors. 
Considered a sporadic disease, the cause of PD in 95% of cases remains 
unknown and is so called idiopathic Parkinson’s disease (IPD). Only as recently 
as the last two decades have susceptibility factors and causative factors been 
identified in familial PD in the remaining 5% (Schapira, 2006, Lesage and Brice, 
2009). Increasing research evidence supports conclusions that PD development 
is contributed to by abnormal handling of misfolded proteins by the ubiquitin-
proteasome and autophagy-lysosomal systems, increased oxidative stress, 
mitochondrial and lysosomal dysfunctions (Lesage and Brice, 2009). After age, 
family history remains the second largest risk factor for developing PD with 
those with PD being four times more likely to have an affected first degree 
relative (Payami et al., 1994). 
Genetic studies have identified a number of genetic mutations associated with 
autosomal dominant and autosomal recessive familial PD. Mutations inherited 
in an autosomal dominant manner include those in the α-Synuclein (SNCA) and 
leucine rich repeat kinase 2 (LRRK2) genes (Polymeropoulos et al., 1997, 
Zimprich et al., 2004). Those inherited in an autosomal recessive manner 
include mutations in Parkin, PTEN-induced putative kinase 1 (PINK1), DJ-1 and 
ATP13A2  (Kitada et al., 1998, Valente et al., 2004a, Valente et al., 2004b, 
Bonifati et al., 2003, Ramirez et al., 2006). Mutations in LRRK 2 are the most 
common, particularly in north African Arabs, Ashkenazi Jews and in the 
Portuguese, with Parkin mutations being the second commonest genetic cause 
(Healy et al., 2008, Lees et al., 2009). Genetic mutations are more common in 
those with young onset parkinsonism however their clinical presentation, 
associated features and pathology vary between mutations. Mutations in LRRK 
2 resemble sporadic PD but tend to follow a more benign course with reduced 
incidence of dementia (Lees et al., 2009). Unfortunately current PD genetics 
nomenclature is a constant source of confusion and misinterpretation with an 
incomplete list of genes, and inconsistencies with confirmed, non-confirmed and 
duplicated loci (Marras et al., 2012, Klein and Westenberger, 2012).  
A selection of environmental factors have been implicated in the aetiology of 
PD. Dating back over 30 years, prospective and retrospective studies have 
demonstrated an inverse correlation between PD and smoking concluding there 
is a reduced risk of developing PD in smokers (Checkoway et al., 2002, Marttila 
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and Rinne, 1980, Baumann et al., 1980). A more recent study including 305,468 
participants, of whom 1,662 had PD, found compared with never smokers, the 
multivariate odds ratios (OR) were 0.78 for past smokers and 0.56 for current 
smokers and on close inspection of the data found that smoking duration was 
more associated with lower PD risk than smoking intensity (Chen et al., 2010). 
Epidemiological, clinical and animal studies also support the antiparkinsonian 
potential of caffeine, an adenosine A2A receptor antagonist, with data to 
suggest that caffeine may confer protection against dopaminergic neuron 
degeneration and delay disease onset and progression (Prediger, 2010). 
Istradefylline, a caffeine analog and adenosine A2A receptor antagonist, has 
recently received approval for use in limited countries (Dungo and Deeks, 
2013). With dopamine’s links to pleasure seeking behaviour, some debate 
remains as to whether the reduced caffeine and smoking in the premorbid state 
are epiphenomena rather than causally related and reflect premorbid attitude 
and low sensation seeking character traits (Evans et al., 2006, Jimenez-
Jimenez et al., 1992).   
In 1976 a Maryland scientist made an error whilst trying to manufacture 
Desmethylprodine 1,3-Dimethyl-4-phenyl-4-propionoxypiperidine  (MPPP), an 
illegal synthetic opioid, and instead created 1-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine (MPTP) having injected this he rapidly developed symptoms 
of PD within days, a similar effect was noted in a group of heroin users in 1982 
who injected MPTP contaminated heroin (Langston, 1996, Langston et al., 
1983). Pathological data showed MPTP was selectively neurotoxic to 
dopaminergic neurons in the substantia nigra (Langston et al., 1983). The 
discovery of the neurotoxic effect of MPTP created a research rejuvenation in 
PD particularly focused on potential environmental neurotoxins. Research 
supports, in varying strengths, the associations between pesticide exposure, 
rural living, farming, well-water drinking and the development of PD, however 
further research is warranted in this area as stronger associations were noted in 
those with genetic susceptibility (Priyadarshi et al., 2001, Gorell et al., 1998, 
Semchuk et al., 1992, Freire and Koifman, 2012).  
2.2.3 Pathophysiology  
Movement occurs in response to signals from the corticospinal and 
reticulospinal tracts, with the corticospinal being of most importance. The 
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corticospinal tract, whilst having contributions from some pre-motor areas, 
originates predominantly from the primary motor cortex. The primary motor 
cortex receives input from cortical and subcortical structures. The basal ganglia 
is one of the major subcortical systems that receives input from the cortex and 
sends processed information via the thalamus back to the cortex and mainly 
influences the magnitude of, and which, movements to make (Wolters and 
Baumann, 2014).  
The basal ganglia is composed of four main nuclei; striatum, pallidum, 
subthalamic nucleus and substantia nigra. The striatum is comprised of the 
caudate nucleus, putamen and nucleus accumbens. The pallidum is comprised 
of the ventral pallidum and internal and external globus pallidus. The substantia 
nigra consists of the pars compacta, which contains the dopaminergic neurons, 
and the pars reticulata. The basal ganglia receive inputs from almost all parts of 
the cerebral cortex with the striatum being the main input structure. Dopamine 
fibres stemming from the substantia nigra pars compacta (SNc) and the ventral 
tegmental area (VTA), medial to the substantia nigra, modulate information 
transfer at striatum level (Wolters and Baumann, 2014). Whilst the majority of 
projections terminate in the striatum and pallidum, other projections extend to 
the cortex, thalamus and alternative brainstem areas (Archibald and Burn, 
2008). Deficiency of dopamine is the characteristic hallmark of PD, from 
profound dopaminergic cell loss in the SNc causing degeneration of these 
projections (Archibald and Burn, 2008). The effect of this dopamine loss is 
malfunction of the extremely complex direct and indirect pathways, excitatory 
and inhibitory circuits.   
Accompanying this selective loss of dopaminergic neurons, pathological 
confirmation of diagnosis focuses on the finding of Lewy bodies (LBs) and Lewy 
neurites (LNs) (Dickson et al., 2009). LBs are cytoplasmic inclusions whilst LNs 
are abnormal neuritic depositions (Dijkstra et al., 2014). The major component 
of LBs and LNs is a protein called α-synuclein (Spillantini et al., 1997). α-
synuclein is normally highly abundant in the brain and other tissues, however 
the exact physiological function of this protein is not yet fully understood but is 
considered to have a role in neurotransmitter release including dopamine 
(Marques and Outeiro, 2012). In LBs and LNs, α-synuclein forms abnormal 
aggregations leading to cellular dysfunction. Although research continues into 
the actual pathological role of LBs and LNs, the most probable conclusion is 
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that they lead to cell death (Cookson, 2009). Whilst α-synuclein is the main 
component of these inclusions, over 70 other components have also been 
identified including; synphilin-1-binding proteins and components of the 
ubiquitin-proteasome system (Wakabayashi et al., 2007, Beyer et al., 2009). As 
discussed the aetiology in 95% of cases of PD is unknown, with identified 
genetic mutations, including mutations in the α-synuclein gene, in the remaining 
5%. In this remaining 95% evidence suggests a role for inflammation, oxidative 
stress, environmental toxins, excitotoxicity and loss of neurotrophic support in 
promoting this abnormal protein misfolding within the brains of individuals 
affected by PD (Brundin et al., 2008). 
The pathological processes occurring in PD begin years, even decades, before 
the appearance of the classical motor features and presentation of the affected 
individual to medical services. This period is often termed the premotor phase. 
Research over the last two decades has confirmed that the pathological lesions 
associated with PD are far more widespread and extensive than just involving 
the SNc. Heiko Braak and colleagues described a theory of pathological 
progression involving six stages marked by the continued development of LBs 
and LNs. Stages I and II incorporate pathology in the olfactory regions and 
lower brain stem (dorsal motor nucleus of the vagus nerve, intermediate 
reticular zone, coeruleus-subcoeruleus complex). In stages III and IV 
aggregations progress to basal portions of the midbrain and forebrain (notably 
the SNc), and the temporal mesocortex including the transentorhinal region and 
also involving the hippocampus. In stages V and VI, we see the final stages and 
the greatest topographic disease extent, with the temporal mesocortex as a 
beginning point lesions progress to involve the entire neocortex (Braak et al., 
2004). The progression of LB and LN pathology has been correlated with the 
appearance and progression of motor and non-motor symptoms of PD (Halliday 
and McCann, 2010). Initially termed the presymptomatic phase, when pathology 
would be restricted to Braak stages I-III, non-motor symptoms may be apparent, 
for example anosmia, and thus this is better termed the premotor phase (Braak 
et al., 2004, Halliday and McCann, 2010). Braak stages IV-VI herald the more 
recognisable motor symptoms, with later stages showing cognitive disturbances 
(Halliday and McCann, 2010, Halliday et al., 2011).  
Although there is widespread support for the Braak hypothesis, questions 
remain around the lack of correlation between the staging and clinical severity 
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highlighted by many asymptomatic elderly with widespread α-synuclein 
deposition (Burke et al., 2008). Importantly not all familial cases of PD have LB 
pathology but all have SNc degeneration (Santpere and Ferrer, 2009). The 
propagation of cellular pathology in PD continues to receive considerable 
research interest. Post mortem studies of individuals with advanced PD who 
received fetal nigral mesencephalic cell transplantation demonstrated Lewy 
pathology within the grafted neurons and laboratory and animal studies have 
confirmed that α-synuclein can transfer from affected to unaffected nerve cells 
which supports the hypothesis that α-synuclein is a prion-like protein and PD 
thus a prion-like disorder (Olanow and Brundin, 2013). Acknowledged by Braak 
and colleagues, Lewy pathology is not restricted to the brain, with involvement 
of the enteric nervous system and early positive biopsies of the gastrointestinal 
system (Braak et al., 2003, Hawkes et al., 2007, Lebouvier et al., 2010). Lewy 
pathology has also been found to affect the autonomic nervous system, 
including the cardiovascular autonomic system, with research in this area 
importantly continuing to answer currently elusive questions surrounding why 
not all individuals with PD suffer autonomic dysfunction and why presence of 
pathology does not always translate into symptoms (Ferrer, 2011). As well as 
the widely known dopaminergic depletion, PD is also associated with impaired 
noradrenergic, cholinergic and serotoninergic innervation (Ferrer, 2011).  
Once considered a motor disorder, PD is increasingly recognised as a complex 
multi system disease and the complexity and scale of the identified pathology 
correlates with the vast array of potential signs and symptoms of the disease. 
The identification of potentially quantifiable or accessible markers of PD, 
including neurotransmitters and biopsy targets, remains of high importance 
particularly in potentially identifying those in the so called premotor or 
presymptomatic phase of the disease if neuroprotective therapy is developed. 
2.2.4 Clinical features 
There is considerable heterogeneity in the clinical phenotype of PD and the 
multisystem disease pathology leads to a wide range of possible signs and 
symptoms (Foltynie et al., 2002). PD is characterised by a multifaceted picture 
of motor and non-motor symptoms that is not only different between patients but 
along the course of disease in individual patients (Moustafa and Poletti, 2013).  
11 
 
The four cardinal clinical features and motor symptoms of PD are; bradykinesia, 
tremor at rest, rigidity and postural instability, with bradykinesia being the key 
clinical feature in order to make a diagnosis.  Bradykinesia strictly means 
slowness of a performed movement however the term is often used 
interchangeably with akinesia or hypokinesia (Berardelli et al., 2001). Akinesia 
refers to paucity of a spontaneous movement or associated movement, for 
example facial movement or arm swing with gait respectively; and hypokinesia 
means movements are small in addition to being slow (Berardelli et al., 2001). 
The classical tremor associated with PD is a tremor of 4-6 Hz at rest that begins 
unilaterally. Hand tremors are often described as “pill rolling” and tremor can be 
evident in the legs, lips, chin and jaw with postural re-emergent tremor also a 
feature. (Jankovic, 2008). The classical tremor characteristically disappears or 
improves with action or on sleeping (Jankovic, 2008). Rigidity in PD refers to 
increased resistance when passively stretching a muscle (Berardelli et al., 
1983). This rigidity is frequently described as “lead pipe rigidity” describing 
rigidity present throughout the full range of movement. A cogwheel sensation 
represents tremor superimposed on rigidity. Rigidity may be felt in the limbs or 
more proximally, termed axial rigidity, in the neck and trunk. Postural instability 
is a particularly disabling feature with many contributory factors, in addition to 
loss of postural reflexes, contributing to balance impairment and falls (Bloem, 
1992). 
Freezing, considered an akinesia, is a debilitating motor symptom that 
predominantly affects gait but can affect other actions including speech. 
Although more common in the “off” state, it can also occur in the “on” state and 
affected individuals describe a sudden feeling that their feet are glued to the 
floor and they are unable to move them. Freezing is a transient phenomenon 
during which individuals may have to implement sensory tricks or cues to 
continue the intended movement (Nieuwboer, 2008). Widely acknowledged and 
frequently termed secondary motor symptoms seen in PD include; hypomimia, 
bulbar dysfunction (manifested as dysarthria, dysphagia, sialorrhea and 
hypophonia), gait disturbances (shuffling, festination), reduced arm swing, 
difficulty standing from a sitting position, difficulty turning in bed, micrographia, 
slow activities of daily living, glabellar reflex, dystonia, neuro-ophthalmological 
problems (reduced blink rate, eyelid opening apraxia and blepharospasm which 
is considered focal dystonia), striatal deformity, scoliosis and camptocormia 
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(Jankovic, 2008). Camptocormia, caused by axial dystonia in PD, is an 
abnormal flexion of the trunk that appears in the standing position, worsens on 
walking and abates when supine (Lenoir et al., 2010). Originally thought to be a 
rare symptom, a recent single centre study of 275 patients reported prevalence 
rates of Camptocormia of 6.9% (Tiple et al., 2009).  
The importance of the identification of non-motor symptoms in PD is becoming 
increasingly recognised. Non-motor symptoms are sometimes present pre-
diagnosis, almost always occur with advancing disease and significantly 
contribute to impaired quality of life, morbidity and mortality (Chaudhuri et al., 
2006, Chaudhuri and Schapira, 2009). Non-motor symptoms are under 
recognised and under reported resulting in under treatment, with up to 62% of 
non-motor symptoms remaining undeclared due to embarrassment or lack of 
knowledge of their association with PD (Chaudhuri et al., 2010). Potential 
individual non-motor symptoms are so numerous that they are best considered 
in groups; neuropsychiatric, sleep disorders, autonomic symptoms, 
gastrointestinal symptoms and sensory symptoms.   
Neuropsychiatric symptoms are wide ranging from depression, apathy, anxiety, 
anhedonia, fatigue, repetitive behaviour, delirium, hallucinations, delusions  and 
dementia (Chaudhuri et al., 2006). Depression is more prevalent in PD than in 
the general population and also a diagnosis is more common in PD patients 
before the onset or diagnosis of their PD (Ishihara and Brayne, 2006). The 
prevalence of dementia in PD is high and is associated with a more rapid 
decline (Aarsland et al., 2003, Aarsland et al., 2004). Some of the myriad of 
potential neuropsychiatric symptoms, including delirium, obsessional 
behaviours and impulse control disorders may also be a consequence of drug 
treatment for other PD symptoms.   
Rapid eye movement (REM) sleep behaviour disorder (RBD) is seen in 
association with PD and remains an important potential preclinical marker for 
researchers with 40% of individuals with a diagnosis of idiopathic RBD 
developing an alpha-synuclein pathology after an average of five years follow 
up (Britton and Chaudhuri, 2009). Nocturnal sleep disturbances also include 
insomnia, nightmares, restless legs, vivid dreaming and sleep disordered 
breathing and day time symptoms of excessive sleepiness are common 
(Chaudhuri et al., 2006, Kumar et al., 2002, Chotinaiwattarakul et al., 2011). 
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Urinary symptoms associated with autonomic disturbance, are the most 
commonly reported non-motor symptom in PD (Martinez-Martin et al., 2007). 
Urinary symptoms include urgency, nocturia and frequency, with additional 
autonomic symptoms of sweating, orthostatic hypotension, sexual dysfunction 
and dry eyes (Chaudhuri et al., 2006). Symptoms of orthostatic hypotension 
also increase risk of falls and subsequent injury and loss of confidence. 
Gastrointestinal non-motor symptoms; nausea, constipation, reflux, 
incontinence, share commonality with autonomic symptoms as part of the 
disease complex (Chaudhuri et al., 2006).  
Sensory symptoms, particularly pain, are frequently not recognised as part of 
the PD complex and can be difficult to quantify and categorise. Pain, of varying 
characteristics, is a frequent sensory symptom observed in PD (Beiske et al., 
2009). Musculoskeletal, dystonic, neuropathic and central pains have all been 
reported with musculoskeletal pain present in up to 70% (Beiske et al., 2009). 
Like RBD, olfactory dysfunction with hyposmia is a common finding in PD and a 
diagnosis of idiopathic olfactory dysfunction is associated with an increased risk 
of developing PD and thus may also prove to be an important pre-clinical 
marker when researching neuroprotective agents (Ponsen et al., 2004).  
By the time motor symptoms are recognised the pathological process in PD is 
advanced. The duration of this pre-motor phase, during which 
neurodegeneration is occurring, remains contentious with estimations ranging 
from 3.1 to 20 years (Hoehn and Yahr, 1967, Fearnley and Lees, 1991, 
Vingerhoets et al., 1994, Morrish et al., 1996). It is accepted that motor 
symptoms occur when dopaminergic cell loss in the SNc reaches a critical level 
and this is most frequently quoted to be 50-60% loss. Non-motor symptoms 
predominate in this pre-motor phase and identification of these could provide 
the key for neuroprotection. In addition to RBD and hyposmia, there is strong 
evidence for constipation and depression as pre-motor characteristics and 
increasing evidence that urinary and sexual dysfunction and chronotropic 
insufficiency may also serve as potential pre-motor PD biomarkers (Chaudhuri 
et al., 2006, Palma et al., 2013, Palma and Kaufmann, 2014). Weaker evidence 
exists for the suggested links of restless-legs syndrome, apathy, fatigue and 
anxiety to the pre-motor phase (Chaudhuri et al., 2006). 
The symptom burden experienced by individuals with PD is easily apparent and 
with the absence of curative treatment, reduction of symptom load remains the 
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aim. The most common tool for assessing symptom load in PD is the Unified 
Parkinson’s Disease Rating Scale (UPDRS) however this is more focussed on 
motor rather than non-motor symptoms. Prior to 2006 there was no single 
instrument for comprehensive assessment of non-motor symptoms thus the 
Non Motor Symptoms Screening Questionnaire (NMSQuest) was developed 
and validated (Martinez-Martin et al., 2007). An observational, multicentre, 
international cross-sectional study of 545 PD patients used the NMSQuest to 
quantify the prevalence of non-motor symptoms and reported urinary symptoms 
to be the most prevalent, in particular nocturia reported in 61.9% (Martinez-
Martin et al., 2007). The NMSQuest has 9 domains with a number of questions 
in each domain. In the afore mentioned study the percentage of individuals 
scoring the maximum for each domain was reported as; urinary 59%, 
depression/anxiety 48%, apathy/attention/memory 42%, sleep disorder 37%, 
sexual function 33%, cardiovascular 32%, digestive 29%, miscellaneous 25%, 
hallucinations/delusions 17% and importantly only 1.6% (8 individuals) reported 
no non-motor symptoms at all (Martinez-Martin et al., 2007).  
While no unequivocally neuroprotective or neurorestorative treatments for PD 
exist, the management remains that of symptom control. Symptom control is 
one of the central goals of palliative medicine and assessment tools from this 
specialty can provide important information to help manage PD patients. 
Despite the introduction of the NMSQuest and the use of the UPDRS, not all 
potential PD associated symptoms are identified with these tools. A descriptive 
cross-sectional survey using a standard palliative care assessment tool 
highlighted the frequency of other symptoms in a representative population with 
IPD (n=123) including shortness of breath on exertion (35.8%), cough (17.9%) 
and sputum (13%) (Lee et al., 2007). The use of this alternative tool reported 
concerning percentages reporting respiratory symptoms, a domain not covered 
in alternative assessments. 
Categorising patients can be very useful particularly when considering 
treatment and prognosis. With the myriad of potential symptoms in IPD, 
categorising individuals on clinical (motor) phenotype, based on signs and 
symptoms, into tremor dominant (TD) or postural instability gait difficulty (PIGD) 
subtypes is a recognised technique. Formulas have been developed to 
categorise TD and PIGD phenotypes from the UPDRS making this widely used 
(Stebbins et al., 2013). Large studies provide support for these clinical 
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phenotypes that have in addition been reported to have differences on 
molecular imaging and basal ganglia output (Jankovic et al., 1990, Zaidel et al., 
2009, Schillaci et al., 2011).  
Whilst formulas have been developed, research continues to identify clinical 
features associated with different phenotypes that may have prognostic and 
treatment implications. Prior to interpretation of extrapolated data from the 
Tracking Parkinson’s study, no large scale studies (n > 400) had specifically 
focused on the association of vascular risk factors and vascular disease with 
motor features and cognition in early PD. Cardiovascular disease describes a 
group of diseases of the heart and blood vessels for example; angina, 
myocardial infarction, stroke, transient ischaemic attack and peripheral arterial 
disease. Vascular risk factors are characteristics or exposures that increase the 
likelihood of developing vascular disease or diseases. Vascular risk factors are 
numerous and include for example; smoking, hypertension, 
hypercholesterolaemia, obesity and diabetes. Common cerebrovascular 
pathologies, including macroscopic infarcts, microinfarcts, and 
arteriolosclerosis, often seen in older persons, can cause mild parkinsonian 
signs, particularly parkinsonian gait (Buchman et al., 2011). This is often termed 
vascular parkinsonism. Malek et al reported,from 1759 PD cases, patients with 
cerebrovascular disease, in the manner of previous stroke or transient 
ischaemic attack, were more likely to have PIGD phenotype and cognitive 
impairment, this however failed to reach statistical significance after age, sex 
and disease duration adjustments. They also reported more than 2 vascular risk 
factors were associated with worse UPDRS 3 motor scores and cognitive 
impairment. In those who had had structural brain imaging, the presence of 
white matter change was associated with PIGD and cognitive impairment. The 
latter two associations reached statistical significance (Malek et al., 2016). 
Differentiating between the TD and PIGD phenotypes, and identifying risk 
factors for these phenotypes, is important both clinically and in research 
settings as they have been correlated to different associated features, 
progression and prognosis. 
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2.2.5 Diagnosis 
Parkinson’s disease is a clinical diagnosis which can only be pathologically 
confirmed by the findings of LB pathology on post mortem. Advances in 
structural and functional neuroimaging have provided support in the diagnosis 
of PD and differential diagnosis of other parkinsonian disorders. To make a 
diagnosis of PD requires the essential finding of bradykinesia with at least one 
of: rest tremor, rigidity or postural instability. The UK Brain Bank developed 
criteria to aid diagnosis, which are illustrated in Table 1. 
UK Brain Bank clinical diagnostic criteria 
 
Step 1. Diagnosis of Parkinsonian Syndrome 
Bradykinesia 
At least one of the following: 
 Muscular rigidity 
 4-6 Hz rest tremor 
 Postural instability not caused by primary visual, vestibular, cerebellar, or 
proprioceptive dysfunction 
 
Step 2. Exclusion criteria for Parkinson’s disease 
 History of repeated strokes with stepwise progression of parkinsonian 
features 
 History of repeated head injury 
 History of definite encephalitis 
 Definite encephalitis or oculogyric crisis on no drug treatment 
 Neuroleptic treatment at onset of symptoms 
 More than one affected relative 
 Sustained remission 
 Strictly unilateral features after 3 years 
 Other neurological features: early severe autonomic involvement, 
Babinski sign, cerebellar signs, supranuclear gaze palsy, early severe 
dementia with disturbances of memory, language, and praxis 
 Presence of cerebral tumour or communicating hydrocephalus on 
imaging  
 Negative response to large doses of levodopa in absence of 
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malabsorption 
 Exposure to known neurotoxin 
 
Step 3. Supportive prospective positive criteria for Parkinson’s disease 
Three or more required for diagnosis in combination with step one: 
 Unilateral onset 
 Rest tremor present 
 Progressive disorder 
 Persistent asymmetry affecting side of onset most 
 Excellent response (70-100%) to levodopa 
 Severe levodopa-induced chorea (dyskinesia) 
 Levodopa response for 5 years or more 
 Clinical course of ten years or more 
Table 1: UK Brain Bank Parkinson's disease diagnostic criteria 
Clinicopathological studies have reported significant false-positive and false-
negative rates for diagnosing parkinsonian disorders, particularly in the early 
stages of disease (Litvan et al., 2003). Misdiagnosis can arise for numerous 
reasons and it is imperative to remember that parkinsonism describes the 
clinical features seen in PD and does not necessarily imply the diagnosis is IPD, 
and that tremor is not needed to diagnose PD and the presence of tremor does 
not necessarily imply IPD (Archibald and Burn, 2008).  
Parkinson’s disease may be considered to be either idiopathic PD (IPD), 
sometimes termed sporadic accounting for 95% of cases, or genetic PD 
accounting for only 5% of cases. There are multiple differential diagnoses to 
consider when assessing an individual with parkinsonism or tremor, and 
comprehensive history taking can provide vital clues. The clinical features of 
parkinsonism can be secondary, caused by another event or substance, and 
include vascular parkinsonism and drug induced parkinsonism. Vascular 
parkinsonism, caused by ischaemic cerebrovascular insults, accounts for 2.5-
5% of cases of parkinsonism and usually presents with a step-wise deterioration 
predominantly affecting the lower limbs (Gupta and Kuruvilla, 2011). Drug 
induced parkinsonism is frequently symmetrical and temporally associated with 
causative drug use (Archibald and Burn, 2008). Initially reported as a 
complication of neuroleptics, it has subsequently been described with a diversity 
18 
 
of drugs including antiemetics, anti- vertigo drugs, antidepressants, calcium 
channel antagonists, antiarrhythmics, antiepileptics and others. Whilst 
traditionally considered reversible after drug withdrawal it persists in excess of 
10% of people which may indicate drug-unmasked PD (Mena and de Yebenes, 
2006).  
Parkinson-plus syndromes, also known as atypical parkinsonian disorders or 
disorders of multiple system degeneration, display the classical features of a 
parkinsonian disorder but with extra features that differentiate them from IPD. 
The Parkinson-plus syndromes include; multiple system atrophy (MSA), 
progressive supranuclear palsy (PSP), corticobasal degeneration (CBD) and 
dementia with Lewy bodies (DLB). Accompanying the parkinsonism and 
amongst other symptoms, MSA is associated with cerebellar features and early 
autonomic features, PSP with early backward falls and supranuclear 
opthalmoplegia, CBD with apraxia, alien limb phenomena and aphasia, and 
DLB with hallucinations and early cognitive decline (Poewe and Wenning, 
2002). Further differential diagnoses that need to be considered include 
functional or non-organic disorders, normal pressure hydrocephalus and 
Wilson’s disease (Archibald and Burn, 2008). In the presence of tremor, 
essential tremor, cerebellar disorders, physiological causes of tremor (e.g. 
thyrotoxicosis) and dystonic tremor need to be excluded (Bhidayasiri, 2005). 
Advances in functional imaging techniques over recent years have assisted in 
improving diagnostic accuracy and thus guiding appropriate management. 
Conventional structural imaging techniques, for example magnetic resonance 
imaging (MRI), are useful in the investigation of suspected vascular 
parkinsonism or for the exclusion of space occupying lesions. By labelling the 
dopamine transporters in the basal ganglia with radioisotopes, Ioflupane (123I) 
(DaTSCANTM), single-photon emission computed tomography (SPECT) images 
can be obtained to assess the integrity of the dopaminergic system. Normal 
images suggest a diagnosis not involving nigrostriatal neurodegeneration, for 
example essential tremor, vascular parkinsonism or drug induced parkinsonism 
(Cummings et al., 2011). Abnormal imaging indicates underlying nigrostriatal 
neurodegeneration thus supports a diagnosis of PD or a Parkinson-plus 
syndrome but cannot differentiate between these (Cummings et al., 2011). 
Further imaging techniques, not necessarily brain imaging, can be useful in 
attempting to distinguish between PD and a Parkinson-plus syndrome. These 
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include autonomic testing and myocardial MIBG scintigraphy which measures 
the postganglionic sympathetic cardiac innervation, which can be a helpful test 
to differentiate PD from MSA. Despite imaging test advances, these remain 
imperfect and whilst very useful the diagnosis remains clinical. 
2.2.6 Treatment 
The management of Parkinson’s disease requires a comprehensive multi-
disciplinary approach. Over the course of the disease involvement can include; 
specialist Parkinson’s clinic (usually consultant neurologist or consultant 
geriatrician), specialist nurses, physiotherapy, speech and language therapy, 
occupational therapy, dieticians and palliative care. Support groups are 
available to provide input for both individuals with PD and their carers, families 
and friends. Management focuses on treatment of motor symptoms and non-
motor symptoms, complications of PD and also side effects of pharmacological 
therapy. It is very important to address and manage non-motor symptoms 
individually as although the pharmacological therapies used to treat motor 
symptoms can improve a selection of non-motor symptoms they can also 
conversely cause or exacerbate others.  
No pharmacological therapy has been proven to be unequivocally 
neuroprotective and thus treatment remains guided by symptoms. In view of this 
not all patients require treatment initiation at diagnosis. NICE refer to ‘early 
disease’ as those individuals who have developed functional disability and 
require symptomatic therapy, and ‘later disease’ as those on levodopa who 
have developed motor complications (NICE, 2006). Whilst dopaminergic 
replacement therapy remains the basis of pharmacological management, 
guidelines to date have been unable to recommend one specific universal first 
line treatment in early disease or adjuvant for later disease further highlighting 
the need for individuals with PD to be managed by experienced teams. 
Pharmacological treatment options are summarised in Table 2, adapted from 
NICE guidance and Archibald and Burn (NICE, 2006, Archibald and Burn, 
2008). 
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In advanced disease if severe motor fluctuations, arising from pulsatile 
dopaminergic stimulation, become unmanageable despite optimising oral or 
subcutaneous therapy, consideration can be given to the use of deep brain 
stimulation or continuous infusion of levodopa/carbidopa intestinal gel 
(Duodopa) via a percutaneous tube. 
As illustrated in Table 2, potential side effects of dopaminergic therapy are 
numerous and a number are specific to anti-parkinsonian medication for 
example impulse control disorders. Clinicians need to remain aware of the rare 
iatrogenic disturbance of dopamine dysregulation syndrome, where individuals 
develop an addiction to dopaminergic therapy and self-administer doses in 
excess of those required to control motor symptoms (O'Sullivan et al., 2009). 
Ergot derivative dopamine agonist drugs which are no longer prescribed, 
including pergolide and cabergoline, are associated with valvular heart disease 
and lung fibrosis in addition to the other possible side effects from the drug 
class. Only in recent years has their prescription discontinued thus it must be 
remembered that many individuals with PD may have already been treated with 
these drugs for protracted periods. 
Dopaminergic therapy must not be abruptly withdrawn as abrupt discontinuation 
and occasionally reduction of dose can precipitate neuroleptic malignant 
syndrome (Healy et al., 2008). With this is mind it is important to not allow 
medication to fail or a failure in administration of dopaminergic therapy. 
Alternative methods of administration of medication need to be considered and 
planned, for example in those who cannot swallow or are undergoing 
operations. Transdermal applications and nasogastric tubes are possible 
options. The complexity of PD, disease progression and antiparkinsonian 
medication titration, combination and potential side-effects make PD best 
managed by specialist services.   
2.2.7 Prognosis 
By definition PD is a neurodegenerative disease and while no neuroprotective 
agents exist, the disease process will continue to progress. Prognosis 
significantly varies between individuals with PD, however the commonly 
described clinical phenotypes of TD and PIGD are associated with differing 
decline rates notably in motor, non-motor and cognitive symptoms. Tremor 
progresses more slowly than other motor features (Vu et al., 2012).  
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The PIGD phenotype usually presents a more severe pattern of non-motor 
features, faster motor deterioration, a higher risk of developing mild cognitive 
impairment, faster rate of cognitive decline and is a risk factor for developing 
dementia (Moustafa and Poletti, 2013, Vu et al., 2012, Poletti et al., 2012, Burn 
et al., 2006). Depression, apathy and hallucinations are more prominent in the 
PIGD phenotype (Reijnders et al., 2009). PIGD appears to be less treatment 
responsive in those patients in the early stages of disease (Vu et al., 2012).In 
contrast, the TD phenotype is characterised by a less severe picture, slower 
motor decline, slower cognitive decline, lower dementia incidence and lower 
rates of depression, apathy and hallucinations (Moustafa and Poletti, 2013). 
Older age at onset, PIGD, dementia and depression are associated with 
progression of disability and a negative impact on survival (Auyeung et al., 
2012, Post et al., 2007).  
Individuals with PD are hospitalised in reported frequencies of up to 28% per 
annum, approximately 1.5 times more frequently, and generally up to 14 days 
longer, than non PD patients (Gerlach et al., 2011). Whilst in hospital, 
medication errors are frequent adverse events and after surgery PD patients 
have increased incidence of infection, confusion and falls (Gerlach et al., 2011). 
Not only does the increased hospitalisation have a negative clinical impact on 
the individual but also a socioeconomic one. A local study of emergency 
hospital admissions in IPD patients over a 4 year period, identified 246 
emergency admissions accounted for by 129 patients (Woodford and Walker, 
2005). The most common reasons for admission in this population were falls 
(13%) and pneumonia (11%) (Woodford and Walker, 2005). International 
retrospective studies corroborated the high frequency of these reasons to 
precipitate admission in PD with pneumonia or chest infection reported as the 
reason for admission in up to 22% and aspiration pneumonia rates more than 6 
times higher than in controls (Vossius et al., 2010, Guneysel et al., 2008, 
Temlett and Thompson, 2006, Guttman et al., 2004, Tan et al., 1998). Other 
infections (including urinary tract), delirium, psychological symptoms, motor 
complications and PD related symptoms were also responsible for precipitating 
admissions.  
A longitudinal, multicentre study in Australia followed PD patients, who were 
initially levodopa naïve at recruitment and had a mean pre-study disease 
duration of 23.5 months, over a 15 year period (Hely et al., 2005). One-third of 
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the patients had survived 15 years with non-dopaminergic problems dominating 
the clinical picture at that time; falls occurs in 81%, cognitive decline in 84%, 
dementia in 48% and choking, hallucinations and depression each in 50% (Hely 
et al., 2005). Hely et al, reported a significantly elevated standardised mortality 
ratio (SMR) at 1.86 with pneumonia being the most common cause of death in 
27% with a SMR >10 (Hely et al., 2005). A local study (n=143) looked at cause 
of death in IPD over an 8 year period finding pneumonia as the terminal event in 
45% and for those that died in hospital pneumonia was the reason for 
admission in 30% (Pennington et al., 2010). Previous studies corroborated high 
death rates from pneumonia in PD reporting rates from 20% to 27% in PD 
compared to 7% to 9% in control populations (Pennington et al., 2010, D'Amelio 
et al., 2006, Fall et al., 2003, Beyer et al., 2001). With individuals with PD 
demonstrating higher death rates from pneumonia, and conversely lower death 
rates from ischaemic heart disease, as well as higher rates of admission for 
chest infection and pneumonia than the general population, further research 
into cardiopulmonary function in IPD is indicated.  
2.3 Pulmonary function 
The respiratory or pulmonary system is comprised of the airways, lungs, 
muscles of respiration and the associated vasculature. The airways include the 
nose, nasal cavities, mouth, pharynx, larynx, trachea and bronchi. Within the 
lungs the bronchi branch into secondary then tertiary bronchi that divide into 
bronchioles. The bronchioles branch repeatedly into terminal bronchioles that 
subdivide into microscopic respiratory bronchioles and further subdivide into 
alveolar ducts. Surrounding these ducts are alveoli and alveolar sacs. These 
alveoli, the building blocks of the lungs’ sponge like structure, are surrounded 
by a mesh of capillaries and are the site of gas exchange with the blood. The 
muscles involved in respiration include the diaphragm, intercostal muscles and 
the accessory muscles in the neck and surrounding the upper airway.   
Dysfunction of the respiratory system leads to increased morbidity and mortality 
and deterioration in quality of life. Signs and symptoms of respiratory 
dysfunction vary dependent on the part or parts of the pulmonary system 
involved. Potential signs and symptoms are numerous and may include; cough, 
difficulty coughing, dyspnoea, pneumonia, aspiration, reduced exercise 
tolerance, speech difficulties, hypophonia, atelectasis, hypoxia, hypercapnia, 
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sleep disordered breathing, excessive daytime somnolence, acute respiratory 
failure and difficulty in extubation. Iatrogenic causes of pulmonary dysfunction 
by medication may also be temporary or permanent.  
Concomitantly with history and examination, measurement of respiratory 
function can be used to establish if any abnormality is present and identify 
particular disorders. Respiratory testing can be used to assess severity, 
prognosticate and serial measurements are useful to assess response to 
treatment or progression of disease. 
2.3.1 Quantification of pulmonary function 
Pulmonary function tests (PFTs) are a collection of non-invasive tests that 
measure airflow, lung volumes, gas exchange and respiratory muscle strength. 
Interpretation of tests should always begin with a review of test quality 
(Pellegrino et al., 2005). Quality control is important and technicians must have 
sufficient education and training to understand the fundamentals of the tests, 
signs of pulmonary disease and management of the acquired data (Miller et al., 
2005a). Interpretation of PFTs is based on comparisons of measured data with 
reference values based on healthy subjects. Reference or predicted values 
should be obtained from studies of healthy subjects with the same 
anthropometric and ethnic characteristics as the subjects being tested 
(Pellegrino et al., 2005). When performing PFTs, dynamic studies (spirometry, 
flow volume loops, peak expiratory flow rates) are performed first followed by 
lung volumes and subsequently diffusion capacity (Ranu et al., 2011). 
Bronchodilator response and respiratory muscle strength testing may also be 
done in appropriate subjects.  
2.3.2 Spirometry 
Spirometry measures lung function by quantifying the volume and flow of air, 
measuring volume against time. Measurements most importantly include forced 
expiratory volume in one second (FEV1), forced vital capacity (FVC) and the 
subsequent ratio of these values. FEV1 is the maximal volume of air exhaled in 
the first second of a forced expiration from a situation of maximal inspiration and 
is measured in litres. FVC is the maximal volume of air exhaled with maximally 
forced effort from a maximal inspiration, also measured in litres. FVC can also 
be thought of as vital capacity (VC) performed with a maximally forced 
expiratory effort (Miller et al., 2005b). VC is the volume change at the mouth 
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from full inspiration to complete expiration (Wanger et al., 2005). VC may also 
be referred to as relaxed or slow vital capacity (SVC). Although in normal 
individuals a small difference can be present in VC and FVC, this is notably 
exaggerated, with FVC comparatively lower than VC, in those with airflow 
obstruction reflecting hyperinflation and air trapping (Chhabra, 1998) 
 
 
Figure 1: Normal Spirometry  
(Ranu et al., 2011)  
Spirometry assists in the diagnosis of ventilatory defects which, if not normal, 
may be obstructive, restrictive or mixed. Obstructive lung disease is 
characterised by lower airway obstruction and is caused by any disease that 
obstructs the airflow, for example by narrowing the airways. Chronic obstructive 
pulmonary disease (COPD), asthma and bronchiectasis are all examples of   
obstructive lung diseases. An obstructive ventilatory defect is represented by a 
disproportionate reduction in expiratory maximal airflow in relation to maximal 
volume, i.e. FEV1 is reduced more than FVC and thus FEV1/FVC is lowered 
(Ranu et al., 2011, Pellegrino et al., 2005). This reduction in the volume of air 
that can be forcibly exhaled in the first second suggests airway narrowing 
during exhalation (Pellegrino et al., 2005). Airflow obstruction is defined as a 
reduced FEV1/FVC ratio such that FEV1/FVC is less than 0.7 or 70% (NICE, 
2010). While the British Thoracic Society (BTS) and National Institute for Health 
and Care Excellence (NICE) use the cut off of FEV1/FVC <0.7, the American 
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Thoracic Society (ATS) and European Respiratory Society (ERS) propose using 
a threshold below the lower limit of normal (LLN) adjusted for age (Bhatt et al., 
2014). The spirometry results of the National Health and Nutrition Examination 
Survey (NHANES) III cohort were used to define the LLN as the fifth percentile 
of reference values (Hankinson et al., 1999). Debate continues into whether 
using the fixed ratio or LLN is superior in diagnosing obstruction, particularly in 
avoiding misclassification at the far ends of the age spectrum (Swanney et al., 
2008, Cerveri et al., 2008, Bhatt et al., 2014). When airflow obstruction is 
identified with a FEV1/FVC <0.7, this can be further categorised into severity 
according to the reduction in FEV1. Categorised based on  FEV1 %predicted; 
≥80% mild or stage 1, 50-79% moderate or stage 2, 30-49% severe or stage 3,  
<30% very severe or stage 4 whilst noting that symptoms should be present to 
diagnose someone with COPD if FEV1 %predicted is ≥80% (NICE, 2010). 
 
 
Figure 2: Obstructive spirometry 
(Ranu et al., 2011) 
Restrictive lung diseases are characterised by reduced lung volumes and have 
a variety of potential pulmonary and extrapulmonary causes. Potential 
pulmonary causes include interstitial lung disease, pulmonary oedema and 
vasculitis. Extrapulmonary causes reducing volume and expansion include 
neuromuscular disorders (e.g. amyotrophic lateral sclerosis (ALS), myasthenia 
gravis (MG), muscular dystrophies), skeletal deformities, obesity and phrenic 
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nerve injury. By spirometric indices a restrictive defect may be suspected if FVC 
is reduced <LLN or <80% predicted in the context of a normal or increased  
FEV1/VC or FEV1/FVC >LLN or >0.7 (Ranu et al., 2011, Johnson and Theurer, 
2014, Pellegrino et al., 2005, GOLD, 2010). A restrictive pattern can only be 
confirmed by full lung volume testing confirming a reduction in total lung 
capacity (TLC) <LLN or <80% predicted (Barreiro and Perillo, 2004, Johnson 
and Theurer, 2014, Pellegrino et al., 2005). Although can infer a restrictive 
defect, FVC or VC alone have poor positive predictive value with low VC being 
associated with low TLC no more than fifty percent of the time (Aaron et al., 
1999, Glady et al., 2003).  
 
 
Figure 3: Restrictive Spirometry 
(Ranu et al., 2011) 
Mixed ventilatory defects are the co-occurrence of both obstruction and 
restriction with reduced FEV1/VC and reduced TLC. The measurement of TLC 
is necessary to accurately diagnose a mixed defect as VC or FVC can be 
reduced in both restriction and obstruction (Pellegrino et al., 2005). 
2.3.3 Flow volume loops 
Flow volume loops or curves are produced by a maximal inspiratory manoeuvre 
followed by a maximal expiratory manoeuvre and displayed graphically with a 
positive expiratory limb and a negative inspiratory limb (Ranu et al., 2011). Flow 
volume curves are frequently used to obtain peak expiratory flow (PEF) and the 
29 
 
mean forced expiratory flow between 25%-75% of FVC (FEF25-75%), the latter 
is also referred to as maximum mid expiratory flow (MMEF). Abnormalities in 
the mid-range flow measurement FEF25-75% provides information about the 
small airways and a reduction in this measurement can be an early change 
reflecting airflow obstruction in these small airways (Ranu et al., 2011, 
Pellegrino et al., 2005). Outwith FEV1, FVC, PEF and FEF25-75% the other 
numerical indices from the flow volume loop are less clinically relevant, but 
rather the shape of the loops, which include forced inspiratory manoeuvres, 
become helpful in detecting upper airway obstruction and for assessing the 
quality of the test (Miller et al., 2005b).  
 
 
Figure 4: Labelled flow volume loop 
(Wikipedia, 2004) 
In obstructive lung diseases, slowing of expiratory flow is illustrated by a 
concave shape on the flow volume loop. Restrictive disorders produce a convex 
expiratory limb at reduced volumes reflecting preservation of flow rates in the 
context of volume loss.  
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      Figure 5: Normal flow volume loop 
 
   
    Figure 6: Obstructive flow volume loop 
 
                                                 
   Figure 7: Restrictive flow volume loop 
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The shape of maximal flow volume loops can be helpful in diagnosing an upper 
airway obstruction (UAO) and differentiating this from lower airway. The shape 
can help classify the location, being extrathoracic or intrathoracic, and the 
nature, being fixed or variable of the obstruction. The airway can be considered 
in three sections, firstly the peripheral airways of 2mm diameter or less, 
secondly the larger or major airways from 2mm up to the carina and thirdly the 
upper airways including trachea, larynx, pharynx and nose or mouth (Acres and 
Kryger, 1981).  A fixed UAO, intra or extrathoracic, is not changed by the phase 
of respiration. With a variable extrathoracic UAO the obstruction is worse during 
inspiration as the pressure inside the trachea falls on inspiration. Where as the 
extrathoracic upper airway is surrounded by atmospheric pressure, the 
intrathoracic upper airway is surrounded by pleural pressure which rises during 
forced expiration and hence exceeds the intratracheal pressure making a 
variable intrathoracic UAO worse during expiration (Acres and Kryger, 1981). 
The worsening of UAO during phases of respiration is reflected in the shape of 
the flow volume loop. Flow oscillations represented by a saw tooth pattern are 
occasionally observed and may represent a mechanical instability of the airway 
wall (Pellegrino et al., 2005). 
 
 
Figure 8: Flow volume loops: a.Fixed UAO b.Variable extrathoracic UAO 
c.Variable intrathoracic UAO 
(Pellegrino et al., 2005) 
Whilst the shape of the flow volume loop is most useful in the detection of UAO, 
some numerical indices are also helpful in the indication of UAO. Terminology 
varies between authors when reporting these indices, for example some refer to 
forced expiratory flow at 50% of FVC (FEF50) as maximum expiratory flow at 
50% of FVC (MEF50) and likewise for inspiratory flows MIF50 for FIF50 which 
has to be considered when reading papers. This terminology is more pertinent 
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to the 25% and 75% values with the background to this variation being currently 
that the recommended measure is FEF when X% of the FVC has been expired 
(FEFX%) in contrast to the previous recommendation in Europe of use of MEF 
when X% of the FVC remains to be expired (MEFX%) (Miller et al., 2005b). 
Lung function parameters aid in the differentiation of extrathoracic and 
intrathoracic obstruction as highlighted in figure 1; fixed extrathoracic UAO 
presents with decreased PEF, decreased MIF50 and MIF50/MEF50 ~1; 
variable extrathoracic UAO normal or decreased PEF, decreased MIF50 and 
MIF50/MEF50 <1; while intrathoracic UAO demonstrated decreased PEF, 
normal or decreased MIF50 and MIF50/MEF50 >1 (Pellegrino et al., 2005). With 
PEF being proportionally more affected than FEV1 in UAO, an increased ratio 
of FEV1/PEF >8ml/L/min should prompt flow volume loop examination 
(Pellegrino et al., 2005, Acres and Kryger, 1981). Although a figure of 
FEV1/PEF >8-8.5 ml/L/min is predominantly quoted, some studies have used a 
figure of up to >10 to indicate UAO (Acres and Kryger, 1981, Rotman et al., 
1975). In addition to MIF50/MEF50 ratio, reduced MIF50, reduced PEF and 
FEV1/PEF >8ml/L/min indicating UAO, other numerical indices are also helpful 
indicators including FEV1/FEV0.5 >1.5, PIF <3L/s and PEF/MEF50 <2(Rotman 
et al., 1975, Mellisant et al., 1990, Acres and Kryger, 1981, Vincken et al., 1984, 
Herer et al., 2001). 
Neuromuscular disorders, vocal cord dysfunction, sleep disorders, goitres, 
tumours, tracheal and post intubation stenosis, tracheomalacia, polychondritis, 
episodic laryngeal dyskinesia and laryngeal oedema are amongst a plethora of 
potential causes of upper airway obstruction and dysfunction. Thus accurate 
evaluation and characterisation of flow volume loops is vital in diagnosis and 
management (Vincken et al., 1984, Ramirez et al., 1986, Magnenat and Junod, 
1991, Sterner et al., 2009, Tillie-Leblond et al., 1998, Blair et al., 1986). 
2.3.4 Lung volumes 
Spirometric measurements of inspired and expired lung volumes are very useful 
as highlighted above however, measurements of absolute lung volumes in 
certain circumstances are essential for accurate diagnoses (Pellegrino et al., 
2005, Wanger et al., 2005). Different techniques of static lung volume 
measurement are available including nitrogen washout and helium dilution, but 
whole body plethysmography is the preferred technique. As previously 
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discussed, TLC calculation is required to accurately diagnose restrictive lung 
disorders and this can only be done by static lung volume measurements. 
Figure 9 illustrates static lung volumes and capacities on a volume-time 
spirogram of an inspiratory vital capacity (IVC) and shows total lung capacity 
(TLC), inspiratory capacity (IC), functional residual capacity (FRC), residual 
volume (RV), inspiratory reserve volume (IRV), tidal volume (TV) and expiratory 
reserve volume (ERV) (Wanger et al., 2005).  
 
 
Figure 9: Static lung volumes and capacities 
(Wanger et al., 2005). 
TV is the volume of gas inhaled or exhaled during normal breathing, FRC is the 
volume of gas in the lung at the end of expiration during TV, ERV is the volume 
that can be exhaled from FRC, IC is the volume that can be inspired from FRC, 
RV is the volume of air remaining in the lungs after a maximal expiration and 
finally TLC is the total volume of air in the lungs after a maximal inspiration, i.e. 
the sum of the RV and vital capacity or can be considered the sum of the 
volume compartments (Wanger et al., 2005, Ranu et al., 2011).  
Body plethysmography is based on Boyle’s law stating that at a fixed 
temperature, pressure and volume of a given mass of gas are inversely 
proportional (Ranu et al., 2011, Criee et al., 2011). The patient sits inside an 
airtight box, inhales or exhales to a specified volume (usually FRC), and then a 
shutter drops across the breathing tube.  
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Figure 10: Volume-time display illustrating plethysmography sequence 
(Wanger et al., 2005) 
In the measurement of FRC, the patient makes respiratory efforts against the 
closed shutter causing their chest volume to expand and reduce the box volume 
and thus increases the pressure in the box (Ranu et al., 2011). The volume is 
the FRC assessed by plethysmography which should be more correctly termed 
FRCPLETH and it must be remembered that on occasions intrathoracic gas 
volume (ITGV) is used as a synonym for FRCPLETH (Criee et al., 2011). When 
the shutter is reopened, ideally without resting between manoeuvres, the patient 
performs an ERV followed by a slow IVC manoeuvre (Wanger et al., 2005). 
These sequences allow measurement and derivation of lung volumes. 
Measurement of RV and TLC are essential in the accurate diagnosis of 
restrictive lung disorders characterised by a reduction in TLC, but are also very 
useful in diagnosing obstructive lung diseases where an increase in RV, 
suggesting air trapping, TLC or the RV/TLC ratio may suggest the presence of 
obstruction caused for example by asthma or emphysema (Pellegrino et al., 
2005). 
2.3.5 Diffusion capacity  
The diffusing capacity of the lung for carbon monoxide (CO) is commonly 
abbreviated to DLCO and depending on country is also known as the transfer 
factor for carbon monoxide (TLCO). The test is primarily to assess how well 
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oxygen moves in an out of the lungs by measuring gas diffusion across the 
alveolar membrane. Gas diffusion is affected by the pulmonary vascular bed 
and the surface area and integrity of the alveolar membrane (Ranu et al., 2011). 
DLCO is normally reported as the absolute number and also when divided by 
alveolar volume (VA), the DLCO/VA, referred to as the transfer coefficient 
(KCO) (Kaminsky et al., 2007). KCO is most useful in interpretation of results, 
for example an individual who had had a pneumonectomy would have a falsely 
low DLCO if not corrected for VA as the remaining lung may be functioning 
normally. Neither KCO nor VA are constants and thus it must be remembered 
that the same DLCO can occur with different combinations of KCO and VA 
whilst at the same time suggesting different pathologies (Hughes and Pride, 
2012). A critical part of diffusion capacity testing is the binding of CO to 
haemoglobin (Hb) and as such the presence of anaemia may decrease DLCO, 
or polycythaemia may increase DLCO thus correction equations are usually 
done to account for differences in Hb.  
Diffusion capacity is measured by the single breath technique which involves 
measuring CO uptake over a breath hold phase. MacIntyre et al (2005), as part 
of the ATS/ERS task force series on standardisation of lung volume, review and 
discuss the technique of DLCO testing in great detail. The test system has a 
source of test gas, a method of measuring inspired and expired volume over 
time and gas analysers. The test gas comprises known concentrations of the 
CO and a tracer gas (commonly helium (He),) to measure VA, with the balance 
of the gas including oxygen (O2) and nitrogen (N2). With nose clip and 
mouthpiece in place the DLCO test begins with unforced exhalation to RV, the 
mouthpiece is connected to the test gas source and the patient inhales rapidly 
to TLC. It is important that the inspired volume is as close to known VC as 
possible and that inspiration is rapid. The patient then is asked to breath-hold 
for 10 ± 2 seconds prior to an unforced, smooth expiratory manoeuvre which 
should be less than 4 seconds. The DLCO calculations are then based on 
alveolar gas samples from the expired collected gases, with the first amount of 
gas from the physiological dead-space being discarded to collect a valid sample 
(Macintyre et al., 2005).  
Large lung volumes, asthma and obesity are the commonest causes of a high 
DLCO, whilst polycythaemia, left-right shunt and pulmonary haemorrhage 
although causative are observed less frequently (Saydain et al., 2004). 
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Conditions that reduce one or more of volume of pulmonary capillary blood, 
membrane conductivity and CO-Hb chemical reaction rate can all lead to 
reduced DLCO including; anaemia, pulmonary emboli, emphysema, interstitial 
lung disease, pulmonary oedema, pulmonary vasculitis and pulmonary 
hypertension (Macintyre et al., 2005). Extrapulmonary reduction in lung inflation, 
for example respiratory muscle weakness, reduced effort or thoracic deformity, 
resulting in reduced VA can reduce DLCO and in this context highlights the 
importance of reviewing the KCO and clinical picture to form an appropriate 
diagnosis (Macintyre et al., 2005, Hughes and Pride, 2012, Siegler and Zorab, 
1982, Hart et al., 2002).  
2.3.6 Respiratory muscle function  
Respiratory muscle function tests should be performed as part of a more 
comprehensive diagnostic process including examination, spirometry, lung 
volumes and diffusion capacity. Respiratory muscle dysfunction is to be 
differentiated from lung function abnormalities (Troosters et al., 2005). In 
generalised neuromuscular disorders it is unusual for the respiratory muscles to 
be unaffected (Polkey et al., 1995). Severe generalised respiratory muscle 
weakness manifests as breathlessness and tachypnoea, and when sufficiently 
severe nocturnal hypoventilation disturbs sleep, cognitive function and causes 
daytime somnolence (Polkey et al., 1995, Smith et al., 1988). The final sequelae 
are ventilatory failure and cor pulmonale (Polkey et al., 1995). Inspiratory 
muscle weakness can in part explain dyspnoea and poor exercise tolerance 
(Troosters et al., 2005). Expiratory muscle and bulbar weakness leads to 
speech problems and impairs cough and predisposes to mucus retention, 
pneumonia and aspiration (Troosters et al., 2005, Polkey et al., 1995). Poor 
respiratory muscle strength has been shown to be a predictive factor for 
mortality in both neuromuscular disease, for example ALS and non 
neuromuscular disorders such as congestive cardiac failure (Polkey et al., 2016, 
Meyer et al., 2001).  
Respiratory muscle strength tests should be performed in those at risk of 
weakness, for example neuromuscular and metabolic disorders and in those 
with clinical signs and symptoms suggestive of respiratory muscle weakness; 
unexplained reduction in VC, Carbon dioxide (CO2) retention (especially in the 
absence of airflow obstruction), orthopnoea, short sentences whilst speaking, 
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dyspnoea during bathing/swimming, tachypnoea, paradoxical abdominal and 
chest wall movements, problems with cough and recurrent infections and 
generalised muscle weakness (Troosters et al., 2005).  
Respiratory muscles strength is generally measured by the pressures 
generated during inspiration or expiration and is commonly measured in either 
cm water pressure (cmH2O) or kilopascals (kPa). Pressure is most commonly 
measured at the mouth and nose but can be further assessed by oesophageal, 
gastric and transdiaphragmatic pressures. The maximal expiratory pressure and 
maximal inspiratory pressure measured at the mouth are commonly abbreviated 
to MEP or PEmax and MIP or PImax respectively. Sniff nasal inspiratory pressure 
(SNIP or Psniff) measures inspiratory muscle function and being a natural 
manoeuvre can often be found easier to perform by many patients (Verin et al., 
2001, Miller et al., 1985). Portable pressure meters facilitate easy bedside or 
departmental measurement.  
The procedure must be explained clearly to the patient. Via a mouthpiece 
attached to the pressure meter, which is typically flanged, the patient performs 
the maximal effort manoeuvres and is asked to maintain the pressure. Multiple 
efforts are recorded, looking for reproducibility and the maximum pressure. 
Conventionally MIP is measured (Mueller manoeuvre) from RV and MEP 
(Valsalva manoeuvre) is measured from TLC (Polkey et al., 1995). The 
pressure maintained for at least one second, plateau pressure, is usually 
reported for MIP and MEP (Troosters et al., 2005). To measure SNIP a nasal 
plug is attached to the portable pressure device. Sniff nasal inspiratory pressure 
measurement is a simple procedure. From end expiration, a nasal plug is 
placed in one occluded nostril and a maximal sniff manoeuvre is performed 
through the contralateral nostril (Fitting, 2006, Heritier et al., 1994). In normal 
subjects maximal expiratory pressures are expected to be higher than 
inspiratory pressures, however SNIP results are generally higher than MIP 
results (Fitting, 2006, Troosters et al., 2005). This paradox is probably explained 
by the ease in which SNIP is performed compared to MIP and the subsequent 
more complete neuromuscular activation (Fitting, 2006). In patients with severe 
neuromuscular weakness, such as in advanced ALS, the SNIP manoeuvre can 
be more feasible and a determinant of VC (Fitting, 2006, Fitting et al., 1999, 
Stefanutti et al., 2000). 
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It is important that respiratory muscle testing is interpreted in the context of 
other pulmonary function tests as, with the exception of patients with severe 
neuromuscular disease in the advanced stages, respiratory muscle dysfunction 
does not correlate with lung function impairment (Troosters et al., 2005). It 
should be remembered that respiratory muscle test results must be interpreted 
with caution for a number of reasons. Patients may have had difficulty 
performing the tests for either physiological reasons or difficulty in 
understanding the instructions. If appropriate equipment or technique is not 
used, cheek and buccal muscles contribute to pressure generation and 
particular mouthpieces may result in additional leaks (Troosters et al., 2005, 
Koulouris et al., 1988). In the testing of inspiratory or expiratory muscles, the 
pressure is generated by all the muscles being tested and is, as such, not 
muscle specific. Furthermore, neuromuscular junction, muscle fibre, peripheral 
nerve, anterior horn, spinal cord or cerebral dysfunction may manifest as 
reduced respiratory muscle strength (Troosters et al., 2005).  
2.3.7 Pulmonary function and ageing 
In the majority of populations throughout the world life expectancy is increasing 
with a resultant increase in the population over the age of 65. The presence of 
disease will lead to functional decline and with advancing age comes reduced 
capacity to deal with disease. Ageing makes individuals more vulnerable as it is 
also associated with loss of protective mechanisms including a reduction in 
response to hypoxia and hypercapnia (Peterson et al., 1981). To distinguish 
from abnormal pathology it is important to understand the physiological changes 
that occur in normal ageing and their clinical manifestations. Changes in 
pulmonary function with ageing are important to appreciate particularly in areas 
such as anaesthesia in the elderly.  
 The lung matures to optimal function between the ages of 20 and 25 years, 
plateaus to age 35 and thereafter there is a progressive decline in lung function 
(Sharma and Goodwin, 2006). Ageing affects a number of parameters of lung 
function and thus ventilation, gas exchange and compliance. Ageing brings a 
reduction in chest wall compliance through changes to the thoracic cage. 
Calcification of the costal cartilages and chondrosternal junctions, osteoporotic 
height loss and kyphosis reduce the ability of the thoracic cage to expand 
(Estenne et al., 1985, Edge et al., 1964, Sharma and Goodwin, 2006). 
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Respiratory muscle strength and performance declines with age concomitantly 
with the geometric modifications (Janssens, 2005). Respiratory muscle, 
particularly diaphragmatic, strength decline may predispose older individuals to 
ventilatory failure during periods of increased ventilatory load on the respiratory 
system (Sharma and Goodwin, 2006). Respiratory muscle strength is related to 
both nutritional status and peripheral muscle strength which are important 
considerations in ageing (Enright et al., 1994, Enright et al., 1995).   
The duration and range of possible inhaled pollutants creates a challenge in 
differentiating the effects of ageing versus environmental exposure on lung 
parenchyma (Janssens, 2005). The effects of ageing on the lungs have been 
described as similar to those that are seen in mild COPD, so called “senile 
emphysema” or “senile hyperinflation”.  The changes seen in the ageing lung 
are homogenous rather than the irregular distribution seen in typical 
emphysema (Janssens, 2005). The change in the supporting structures within 
the lung parenchyma, with reduced recoil pressure of elastic fibres, causes 
distension of alveolar spaces, wider shallower alveoli and wider alveolar ducts 
(Verbeken et al., 1992, Kurozumi et al., 1994). As described, although these 
changes are histologically different from those seen in emphysema, the 
resulting change in lung compliance is similar (Janssens, 2005).  
After the plateau stage in lung function, FEV1 and FVC decline with age. 
Whether this decline is linear or non-linear and accelerates with ageing is 
debated between evidence from cross-sectional and longitudinal studies 
(Dockery et al., 1985, Burrows et al., 1986). Given the changes described, an 
obstructive pattern may be seen in flow volume loops. Although PEF shows a 
tendency to decrease with age, there is substantial variability in predicted peak 
flow values and prediction equations that have to be considered (Enright et al., 
2001, Bellia et al., 2003). Although TLC remains fairly constant, with the loss of 
elastic recoil of the lung parenchyma RV and FRC increase and VC decreases 
(Janssens, 2005, Sharma and Goodwin, 2006). Gas exchange also deteriorates 
with ageing with a declining DLCO contributed to by loss of alveolar surface 
area and change in the distribution of pulmonary blood flow (Butler and 
Kleinerman, 1970, Guenard and Marthan, 1996). Immunological changes also 
occur in addition to anatomical changes in ageing.   
Extensive research in lung function in normal ageing, disease and populations 
has led to development of a large number of published reference equations. 
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Reliability in interpretation of lung function results in identifying normal from 
disease states relies on the selection of appropriate reference data. In the 
United Kingdom and throughout Europe the European Community for Steel and 
Coal reference is most widely used and accepted (Quanjer et al., 1993, 
Stanojevic et al., 2010).  
2.3.8 Pulmonary function and neurodegenerative disease 
Many neurological disorders can cause respiratory complications. Some 
manifest late in disease where as others may be an early sign. Unfortunately 
pulmonary complications are the leading cause of mortality in the majority of 
neurological disorders. The way each disease affects pulmonary function varies 
with the pathophysiology. Anatomically characterising the chronic 
neuromuscular disorders can be helpful in understanding this pathophysiology. 
Disorders that can affect the respiratory system include; cerebral cortex (stroke, 
neoplasm, seizures), brainstem/basal ganglia (Parkinson’s disease, MSA, 
multiple sclerosis (MS), stroke, neoplasm, central alveolar hypoventilation, 
progressive bulbar palsy), spinal cord (trauma, infarction, haemorrhage, 
demyelination, syringomyelia), motor nerves/anterior horn cell (motor neuron 
disease (MND), ALS, spinal muscular atrophy, Charcot-Marie-Tooth disease), 
neuromuscular junction (myasthenia gravis, Lambert-Eaton syndrome, 
botulism) and myopathies/muscle (muscular dystrophies, polymyositis, 
dermatomyositis, mitochondrial myopathy, glycogen storage diseases) 
(Aboussouan, 2005, Benditt and Boitano, 2013).    
In central neurological diseases, for example MS, abnormalities in central 
respiratory control may have a more direct role in the pathology of respiratory 
dysfunction (Aboussouan, 2005). Disorders that affect the corticospinal tracts, 
for example a mid-pontine stroke, can result in loss of voluntary breathing 
control due to the effect on the connection between the voluntary respiratory 
centres of the cortex and the spinal motor neurons (Benditt and Boitano, 2013, 
Schjolberg and Sunnerhagen, 2012). Extrapyramidal disorders can also affect 
voluntary breathing (Benditt and Boitano, 2013). Central hypoventilation 
syndrome, also known as Ondine’s curse, may be congenital or acquired. 
Congenital cases are rare and disrupt autonomic but not voluntary breathing. 
Injury to the automatic respiratory centres causes central sleep apnoea on 
sleeping (Liess et al., 2008). Spinal cord pathology can affect ventilation 
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because of the direct influence on control of motor nerves controlling respiratory 
function (Benditt and Boitano, 2013).  
In addition to respiratory muscles, neurological diseases can affect the bulbar 
muscles, the masticatory muscles and the larynx (Aboussouan, 2005). 
Respiratory muscle weakness (RMW) firstly causes sleep related 
hypoventilation and progresses to daytime respiratory failure. Particularly during  
rapid eye movement (REM) sleep, RMW can disrupt sleep by causing 
hypoventilation, apnoeas and hypopnoeas (Bourke, 2014). Irrespective of the 
primary diagnosis, a high prevalence of sleep disordered breathing has been 
reported in neuromuscular diseases (Bourke and Gibson, 2002). Difficulty with 
speech, swallowing and recurrent aspiration are sequelae of bulbar muscle 
weakness (Bourke, 2014). Sleep related hypoventilation also causes day time 
symptoms of sleepiness, lethargy, poor concentration and mood problems and 
if hypercapnia is present headaches can be a sequelae. Signs of RMW may 
include accessory muscle use, rapid shallow breathing, reduced chest 
expansion, reduced breath sounds, paradoxical abdominal movement, weak 
cough and weak sniff (Lyall et al., 2001b, Bourke and Gibson, 2002, Bourke, 
2014). 
Lung function, bulbar function and respiratory muscle strength are routinely 
monitored in a handful of neurodegenerative disorders, such as MND and 
Duchenne muscular dystrophy, however not in all. This may be a reflection of 
specific diseases not requiring pulmonary function monitoring but may also be 
due to a lack of research and evidence. Guidance issued by NICE, for the 
management of MND particularly highlights assessment and monitoring of 
respiratory function and consideration of non-invasive ventilation (NIV). 
Respiratory function monitoring in MND, with ALS being the most common 
subtype, is usually conducted every 2-3 months, however this may be adjusted 
dependent on the rate of decline. In MND any of the following should prompt 
respiratory review, with consideration of referral to the ventilation service, sleep 
studies and consideration for NIV; FVC or VC <50% predicted, FVC or VC 
<80% predicted plus any symptoms or signs of respiratory impairment, SNIP or 
MIP <40cmH2O, SNIP or MIP <65cmH2O for men or <55cmH2O for women plus 
any signs or symptoms of respiratory impairment, SNIP or MIP rate of decline 
more than 10cmH2O per 3 months, nocturnal hypoventilation, partial pressure of 
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carbon dioxide in arterial blood (PaCO2) >6kPa or PaCO2 <6kPa plus signs of 
respiratory impairment especially orthopnoea (NICE, 2016).  
Type-II respiratory failure is the sequela of severe respiratory muscle weakness. 
Research suggests that NIV improves quality of life and extends life, particularly 
in non bulbar patients (Bourke et al., 2006, Lyall et al., 2001a, Mustfa et al., 
2006). It is generally accepted that NIV should be offered to those with MND 
with daytime hypercapnia, however the occurrence of daytime hypercapnia can 
be a late sign in MND. In view of this, simple and accessible methods to predict 
nocturnal hypercapnia are very important particularly given the availability of, 
and time involved in performing, sleep studies (Murphy et al., 2010). In 
individuals without severe bulbar weakness, spirometry, MIP, MEP and SNIP 
should be used for monitoring progression. Compared with VC and MIP, SNIP 
is more sensitive in the prediction of daytime hypercapnia (Lyall et al., 2001b). 
The measurement of SNIP is also more sensitive to early RMW and a better 
predictor of death (Morgan et al., 2005). A fall in VC of >20% in the supine 
position is abnormal, is a marker of inspiratory muscle weakness and a good 
index of diaphragmatic function. Vital capacity also predicts survival (Allen et al., 
1985, Bourke, 2014). In individuals with significant bulbar involvement, due to 
the difficulties in performing volitional lung function tests with the inability to form 
a tight lip seal around a mouthpiece, suboptimal results occur and tests of 
respiratory strength do not predict hypercapnia (Lyall et al., 2001b). In these 
individuals greater confidence is placed on results of oxygen saturations, blood 
gas analysis, transcutaneous pCO2 and nocturnal oximetry and sleep studies 
(Bourke, 2014). The mortality and morbidity associated with pulmonary 
dysfunction in neurodegenerative disorders highlights the need for assessment 
and monitoring of lung function and respiratory muscle strength in these 
disorders.   
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2.3.9 Pulmonary function and Parkinson’s disease 
“He fetched his breath rather hard” was noted as a clinical feature by James 
Parkinson in his initial description of the disease in his 1817 essay on the 
shaking palsy (Parkinson, 1817). Despite this early recognition of respiratory 
involvement in PD little remains known and debate continues about the pattern 
of ventilatory dysfunction associated with the disease. Obstructive patterns, 
restrictive patterns, upper airway obstruction, respiratory muscle weakness and 
sleep breathing disorders have all been described but there is little consensus 
across the studies. Patterns of ventilatory dysfunction in previous research are 
summarised in table 3 below, however the complexity and variety of the 
techniques used and outcome measures in each study warrants significant 
further discussion.  
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Given the morbidity and mortality from pulmonary complications in PD, and the 
identification in 1817, it is surprising that Interest in pulmonary function tests in 
PD only seemed to begin in the late 1960’s with the 1967 study by Neu et al, 
comprising 23 patients with Parkinsonism (Neu et al., 1967). The patients 
included had a diagnosis of Parkinsonism rather than IPD and no smoking 
history was documented. The measurement techniques, interpretation and 
reference values are different to those used currently. Notwithstanding this, the 
authors concluded the pattern was predominantly one of obstructive ventilatory 
defect based on the airway resistance being almost double the predicted values 
and more consistently present than any reduction in VC. This was heralded as 
precisely the pattern found in individuals with bronchial asthma or emphysema. 
They also commented on significant reductions in MIP, MEP, MIF and MEF and 
increasing dysfunction correlated with severity of disease. Parasympathetic 
hyperactivity was postulated as the cause of the obstructive pattern (Neu et al., 
1967). A basic 1970 study of 22 patients with Parkinsonism, demonstrated an 
improvement in minute ventilatory volume (MVV) following administration of 
levodopa. Although change was seen in MVV, VC was not significantly altered 
following levodopa, however it must be noted that little detail was given about 
the participants including pre-existing lung disease and smoking history 
(Paulson and Tafrate, 1970). 
Obenour et al, 1972, performed spirometry and plethysmography on 31 patients 
with PD and noted expiratory flow obstruction in 11 of the 31. In both the 
obstructed and non-obstructed groups increased RV and FRC were consistent 
with air trapping. Airway resistance (RAW) was higher in the obstructed group 
and lung recoil at TLC was lower in this group also. The baseline lung function 
was assessed without the individuals on levodopa therapy. After 6 weeks of 
levodopa therapy all assessments were repeated and despite an improvement 
in neurological outcome measures there was no improvement in pulmonary 
function. Unfortunately smokers and individuals with known obstructive lung 
disease were not excluded from the study and whilst the authors concluded the 
air trapping was a result of neurologic effects of PD on chest wall mechanics, it 
is likely that the expiratory flow obstruction was a result of co-existing lung 
disease (Obenour et al., 1972) 
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Previous studies highlighting an obstructive ventilatory defect but no agreement 
on cause or site, led to interest in the involvement of upper airway musculature 
in airflow limitation in extrapyramidal disorders prompting a 1984 paper by 
Vincken et al. Spirometry, lung volumes, single-breath nitrogen wash out, MIP 
and MEP were performed in 27 patients with extrapyramidal disorders, of which 
21 had IPD. Upper airway obstruction (UAO) was considered present when an 
increased helium response was accompanied by 2 or more abnormal flow ratios 
(FEV1/PEF >8.5ml/l/min or FEV1/FEV0.5 >1.5 or MEF50/MIF50 >1) and a 
PIF<3l/sec. A helium response and either abnormal ratios or reduced PIF 
sufficed for a diagnosis of UAO if the flow volume loop also showed a pattern of 
UAO. The patterns of UAO described on the flow-volume loops were 
categorised as either type A, respiratory flutter, with regular consecutive flow 
accelerations and decelerations or type B, irregular abrupt changes in flow often 
dropping to zero.  
 
Figure 11: Flow-volume curves illustrating Type A and Type B pattern 
(Vincken et al., 1984)      
Most commonly noted, in 24 of 27 (89%), was an abnormal flow volume loop 
pattern, with 18 type A and 6 type B patterns. Based on the authors UAO 
criteria above, 10 had UAO and it was noted that those with PD and UAO were 
more disabled by their disease, with higher Hoehn and Yahr scores than those 
without UAO. The proposed cause was that the intrinsic laryngeal muscles, and 
probably most of the other muscles surrounding the upper airway, are involved 
in the involuntary movements characteristic of extrapyramidal disorders and 
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airflow resistance is also exacerbated by contraction of upper airway muscles 
out of phase of those with the chest wall (Vincken et al., 1984) 
Tzelepis et al, 1988, identified the lack of studies looking at respiratory muscle 
dysfunction and undertook a 9 person study in mild to moderate PD, with the 
benefit of a control group. In this small study there was no evidence of 
obstructive or restrictive dysfunction and it was concluded that while the 
patients were able to perform single respiratory efforts well, demonstrating 
normal lung volumes and MIP, they had problems performing repetitive 
inspiratory resistive-loaded ventilatory efforts associated with an increased 
oxygen cost of breathing and decreased efficiency compared to controls. 
Proposed mechanisms included altered neural drive to the muscles, alterations 
of muscle fibre composition and abnormal agonist-antagonist muscle activity 
(Tzelepis et al., 1988). 
Prior to 1989, studies had predominantly included patients with mild disease 
which was highlighted by Hovestadt and Bogaard et al who studied pulmonary 
function in 31 patients with more advanced disease, at least Hoehn and Yahr III. 
They also excluded those with known lung disease or any structural upper 
airway abnormality. All patients were on levodopa and anticholinergic drugs. 
Interestingly, like the previous studies, there was heavy use of anticholinergic 
drugs in the management of PD. This is no longer standard practice. They 
reported a trend for most parameters to decrease with increasing Hoehn and 
Yahr stage. Significant differences between the means of the groups were only 
seen for the effort dependent variables of PIF, PEF, MIP and MEP, with MIP, 
MEP, PEF and MEF50 significantly below normal values. Forced inspiratory 
volume in 1 second, VC and FEV1/VC were relatively normal. This study was 
reported in two different papers and there was some inconsistency in reporting 
(Hovestadt et al., 1989, Bogaard et al., 1989). Both papers reported, according 
to the classification by Vincken et al, 4 patients had a type A flow-volume curve, 
however one paper reported 16 had a type B curve while the other reported 18 
had a type B curve (Bogaard et al., 1989, Hovestadt et al., 1989, Vincken et al., 
1984). The reason for this inconsistency was not apparent. The authors 
considered PIF, FEV1/PEF and MEF50/MIF50 to be indicators of  UAO and 
reported 9 patients had an abnormal value for 1 parameter, 8 patients 2 and 1 
patient all 3 parameters (Hovestadt et al., 1989). They hypothesized that 
muscle weakness and hypokinesia resulted in a lower and less explosive 
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muscle force which reflected the lower values of the effort dependent variables. 
Upper airway obstruction was a prominent feature, type A curves were 
assumed to be caused by tremor of the muscles of the upper airway and poor 
co-ordination of ventilatory system muscles, whilst type B curves were 
postulated to be predominantly due to muscle weakness (Bogaard et al., 1989, 
Hovestadt et al., 1989). 
The effect of Parkinson’s treatment on pulmonary function was considered in a 
10 patient study by De Bruin et al in 1993. They assessed MIP, MEP, 
spirometry and maximal inspiratory and expiratory flow volume curves, in PD 
patients aged 42 to 60 years old, off treatment and repeated all measurements 
on treatment with apomorphine. Although an unusual study in current times, 
due to the young age of the participants and the dopaminergic medication of 
choice being apomorphine, the study yielded interesting results. Treatment 
improved neurological scores (modified Webster scale) however FVC off 
treatment was 84% predicted and did not change with treatment. Despite the 
relatively normal FEV1/FVC, only 2 of 10 patients had normal flow volume 
curves with the most common abnormality, both on and off treatment, being the 
increased volume expired before PEF achieved and absence of the sharp peak 
and resultant rapid decline in maximum expiratory flow. Off treatment MIP, MEP 
and PEF were all low with percent predicted values of 28.5%, 35.4% and 58.1% 
respectively and PIF was also low at 3.83L/s. On treatment significant 
improvements were seen in MEP (49.9% predicted) and PIF (4.37 L/s) and 
moderate improvements were seen in MIP (37.9% predicted) and PEF (70.0%) 
predicted. The study has to be interpreted with caution as there was no 
exclusion if patients had pre-existing respiratory disease. The authors 
concluded that PD patients have reductions in maximum flows and pressures 
during maximal efforts and these difficulties are improved with dopamine 
agonist treatment (de Bruin et al., 1993).  
In 1994 Izquierdo-Alonso et al, undertook a larger study investigating pulmonary 
function in 63 patients with PD with maximal inspiratory and expiratory flow 
volume curves. There spirometric findings were in contrast to those found in 
previous studies with 54 patients (85%) having a FEV1/FVC ratio equal to or 
higher than 80% suggesting a restrictive element of pulmonary dysfunction. 
They also noted some weak but significant correlations between PD scales 
(UPDRS and Webster scales) and spirographic parameters, noting those with 
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more severe disease had lower FVC%, PIF and PEF and that those with motor 
fluctuations and or dyskinesia had lower FVC% and FEV1%. Thirty one (49.2%) 
had abnormal flow volume curves with 21 type A, 9 type B and 1 obstructive 
and 3 patients had 2 or more spirometric indices (FEV1/PEF, FEV1/FEV0.5, 
FEF50/FIF50) of UAO. Although the authors studied patients in Hoehn and 
Yahr categories I-V, again the results need to be interpreted with caution as 29 
patients were treated with pergolide which is known to cause pleuropulmonary 
fibrosis which could show a restrictive pattern of spirometry. In addition the 
authors used FEV1/FVC to define restriction rather than TLC which would give 
far superior accuracy to results. Upper airway dysfunction and a restrictive 
pattern were heralded as the defining results and it was speculated that the 
restriction may be attributable to poor coordination or muscular rigidity limiting 
forced respiratory movements and also reduction in pulmonary compliance due 
to microatelectasias as a consequence of muscle dysfunction (Izquierdo-Alonso 
et al., 1994).  
In 1996 Sabate et al, published a study of 58 patients that further complicated 
the picture of pulmonary dysfunction in PD by reporting a variety of 
dysfunctions. They undertook spirometry, lung volumes, airway resistance by 
body plethysmography, MIP and MEP in PD patients who had not received any 
dopaminergic medication for 8 hours prior to testing. Based on 3 spirometric 
indices (PIF <3 l/s, FEV1/PEF >8.5 l/min and MEF50/MIF50 >1) they reported 
36 had evidence of UAO. Central obstruction or peripheral obstruction was seen 
in 18 patients and restrictive dysfunction was noted in 16 patients. Restrictive 
dysfunction was described as TLC <85% or FEV1/FVC >80% with FVC <80%, 
however the authors failed to publish the number with TLC <85%. Interestingly, 
they noted 16 patients had evidence of air trapping with RV >120% and RV/TLC 
>40% and 7 patients had a TLC >120% suggesting lung insufflation. Maximal 
inspiratory and expiratory mouth pressures were reduced and whilst FVC, FEV1 
and FEV1/FVC% were all reported to be significantly below normal values the 
group means for these spirometric indices were all above 81% of predicted. An 
increase in the passive resistance to airflow (RAW) was also found, 
bradykinesia was higher in those with UAO, rigidity higher in those with 
obstruction and those with evidence of pulmonary dysfunction had evidence of 
impact on scores of activities of daily living. In summary evidence was reported 
that PD patients have a reduction in MIP and MEP and a high incidence of 
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restrictive and upper, central and peripheral obstructive patterns (Sabate et al., 
1996a, Sabate et al., 1996b).  
Pulmonary rehabilitation is a widely accepted and successful therapy for 
individuals with COPD with origins dating back to the middle of the 20th century 
(Casaburi, 2008). With this in mind it is somewhat surprising that there has 
been very little research on the effect of pulmonary rehabilitation in other 
disorders including PD where there has been documented evidence of 
pulmonary dysfunction. Koseoglu et al, 1997, with the knowledge that 
ventilatory and upper extremity exercise programs enhance maximal ventilatory 
capability and improve the effectiveness of ventilation during exercise, 
assessed 9 PD patients’ pulmonary function and six-minute walk test (6MWT) 
before and after a 5 week exercise training programme as part of a 
comprehensive pulmonary rehabilitation programme (Koseoglu et al., 1997, 
Ries, 1994, Celli, 1994). Nine normal age matched control subjects also 
participated. The program comprised 60 minute sessions, 3 times per week for 
5 weeks and included diaphragmatic breathing exercise, air-shifting techniques, 
voluntary isocapnoeic hyperpnea and unsupported upper extremity exercise. At 
baseline a spirometric restrictive defect was seen in 1 patient, obstructive defect 
in 1 patient (who was also a smoker) and 4 patients had evidence of UAO as 
judged by 2 spirometric indices (PEF and FEF50/FIF50). As may be expected, 
statistically significant differences were seen between the PD group and the 
control group on FVC, FEV1, FEF50, FEF25-75, MVV, PEF, PIF, IC, VC, 
FEF50/FIF50 and 6MWT with all values being lower in the PD group. When 
compared to baseline, a slight increase was seen at follow up in FVC, FEV1, 
FEF50, FEF25-75, PEF, PIF, VC, ERV, TV and MVV and a slight reduction 
seen in IC and respiratory rate, however these changes failed to reach 
statistical significance. A statistically significant increase was seen however in 
minute ventilation and 6MWT. Although the authors concluded this study 
suggested that exercise training in PD could decrease ventilatory requirements 
for a given workload, increase ventilatory muscle force and exercise tolerance 
and improve the effort dependent spirometry variables and ventilatory pattern 
during exercise, these results and conclusions should be interpreted with 
caution given the small number of participants, 2 of whom did not complete the 
study, and importantly the high use of anticholinergic medications which have a 
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large amount of systemic effects including on the respiratory system that can 
result in bronchodilation (Koseoglu et al., 1997).    
Following Koseoglu et al’s interest in the effect of upper extremity exercise on 
pulmonary function, Canning et al, 1997, sought to determine if abnormalities in 
respiratory function and gait affect exercise capacity. As part of this study they 
undertook spirometry, flow volume loops, lung volumes and mouth pressures in 
16 participants with PD, Hoehn and Yahr stages I – III. Individual 
measurements of FEV1, FVC and FEV1/FVC were all normal and lung volumes 
did not indicate any obstructive or restrictive patterns. In contrast to previous 
studies, mean MIP and MEP were not significantly different to predicted values. 
In support of previous studies, PIF was significantly reduced and every subject’s 
flow volume loop had at least one abnormal characteristic of a rounded off PEF, 
low PIF, high MEF50/MIF50 >1 and tremor. Ten patients fulfilled the criteria for 
UAO with FEV1/PEF <8.5ml/L/min, MEF50/MIF50 >1 and a PIF <80% predicted 
normal value. In this study the authors chose to use PIF<80% predicted normal 
value rather than the more commonly used PIF <3L/sec in the identification of 
UAO because they felt the latter failed to take into account variation in predicted 
normal values caused by height and gender. Interestingly they noted that while 
presence of UAO did not significantly correlate with percent predicted peak 
oxygen consumption achieved on maximal exercise testing, percent predicted 
PIF achieved did correlate with peak oxygen consumption. Noting the reduced 
flow rates, notably PIF, respiratory muscle weakness is often thought to 
contribute, however mouth pressures which were normal in this study provide 
only a global indication of respiratory muscle strength and may be altered by 
coordination of individual muscles. The authors concluded rather than weak 
inspiratory muscles in particular, it was more likely that flow rates and MIP 
would decrease because of poor coordination of respiratory muscles for a fast 
forceful manoeuver (Canning et al., 1997).    
In 1999, identifying that little research had looked at breathing patterns at rest in 
PD, rather than forced manoeuvers, Vercueil et al undertook a small study, of 
11 patients with IPD, focused on breathing patterns at rest both in the off state 
and then in the on state after administration of levodopa. The study had a 
number of limitations including size, akinetic rigid type patients only included 
and a number of patients exhibiting dyskinesia in the on state. The amount of 
ventilatory changes induced by levodopa varied massively among the patients, 
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however the most prominent effect on the pattern of breathing seemed to be an 
increase in the inspiratory duration. All patients reported levodopa alleviated 
any breathing discomfort. The authors concluded the larger change observed in 
the inspiratory rather than the expiratory duration was due to levodopa 
administration having more effect on those muscles with a high degree of 
postural function for example the external intercostals (Vercueil et al., 1999). 
These conclusions were reached based on the results of previous studies. 
Electromyography (EMG) of respiratory muscles in PD showed that the 
diaphragm exhibited a close to normal activity and other muscle showed a 
continuous activity that could be related to parkinsonian rigidity thus arguing in 
favour of unimpaired central respiratory rhythm generation (Petit and Delhez, 
1961, Estenne et al., 1984). Findings by Rimmer et al, also supported this 
conclusion that when activated by postural movements the internal intercostals 
were strongly inhibited during inspiration but the external intercostals showed 
increases in inspiratory activity above and beyond that for postural muscular 
activity thus suggesting the internal intercostals (mainly active during expiration) 
provide a more ventilatory than postural role but vice versa for the external 
intercostals which have a more postural than ventilatory role (Rimmer et al., 
1995).  
As recently as the last decade, Pergolide with the potential to cause pulmonary 
fibrosis was still commonly used in the treatment of PD. In 2001 a study of 
pulmonary function in 21 PD patients was published by Polati et al, however in 
this study it has to be acknowledged that 15 of the 21 included were on 
Pergolide and 6 were also ex-smokers. They hypothesized that spirometric 
studies may serve as an indicator of patient’s neurophysiological conditions. 
Spirometry was performed in 21 PD patients (Hoehn and Yahr I-III) and 16 
healthy, age matched, non-smoker volunteers. Results showed 3 of 6 ex-
smokers and 2 of 15 non-smokers had obstructive ventilatory defects however 
they defined this as FEV1/VC <89% predicted. They noted FEV1 and MEF25 
were unsurprisingly decreased in the ex-smokers, however more noteworthy 
that MVV, PEF and MEF75 were significantly lower in the non-smoker PD group 
than the controls. There was a trend across the pulmonary function tests to 
deteriorate with advancing disease state, as defined by Hoehn and Yahr, with 
MVV best correlating with disease severity. Typically reduced in obstructive 
disease, MVV is usually preserved in restrictive disease and can be used as an 
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indicator in neuromuscular disorders that impair the strength and endurance of 
ventilatory muscles. Impairment of MVV in PD is likely as a result of 
bradykinesia and rigidity of respiratory muscles impairing repetitive motor tasks 
(Polatli et al., 2001).  
With previous studies reporting a range in prevalence of UAO in PD and 
conflicting reports from Obenour et al and De Bruin et al with regards to the 
effect of dopaminergic medication on pulmonary function, Herer et al, 2001, 
published a study investigating the effects of levodopa on pulmonary function 
and specifically UAO. Spirometry and maximal inspiratory and expiratory flow 
volume curves were performed in 21 PD patients, Hoehn and Yahr II-IV, age 
range 52-89 years, 12 hours after withdrawal from anti parkinsonian drugs, then 
repeated after administration of placebo or weight dependent Co-beneldopa. 
The study was then repeated in all patients at 24 hours. The authors considered 
UAO to be present if at least 4 of the following 6 criteria were present; curve 
had a characteristic UAO saw-tooth sign, PIF <3L/s, FEV1/PEF >8.5mL/L/min, 
FEV1/FEV0.5 >1.5, FEF50/FIF50 >1 and a PEF/FEF50 <2. At baseline UAO 
was observed in 5 patients and after levodopa therapy 3 of these 5 no longer 
met the authors’ criteria for UAO. Levodopa administration induced significant 
variations in PEF and the UAO ratios of FEV1/PEF and FEV1/FEV0.5. This 
study supported the hypothesis that levodopa improves lung function however 
the study was small, used levodopa doses that may have been insufficient in 
some patients and acknowledging that PEF measurements are subject to 
variability they failed to specify reproducibility criteria (Herer et al., 2001). 
A brief paper published in 2002 by De Pandis et al further supported the finding 
of a restrictive pattern of pulmonary function in advanced PD. They performed 
spirometry and arterial blood gases (ABG) in the on and off states of 12 
individuals with PD staged at least Hoehn and Yahr III. The authors concluded 
the spirometry results revealed a restrictive pattern in both the on and off states 
and that ABG analysis revealed normal values for PaO2, PaCO2 and pH in both 
the on and off states but a significant increase in PaCO2 was seen in the off 
state (De Pandis et al., 2002). Although interesting, these results need to be 
interpreted with caution for a number of reasons; TLC was not measured and 
the presentation of the results in the publication in tabulated form did not include 
any units and by postulating the units it could be interpreted that PaO2 was at 
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the lower end of normal and more importantly that the authors misinterpreted 
their on state spirometry results and it did not truly show restriction.   
A further publication in 2002 by Weiner et al, reported spirometry, respiratory 
muscle strength and perception of dyspnoea in the on and off state of 20 
individuals with PD, Hoehn and Yahr stages II-III and compared their results to 
20 healthy, age and sex matched controls. They reported that predominantly 
patients had spirometry data indicating a mild restrictive pattern and that the 
mean FEV1 and FVC were not significantly different in the on and off states. 
Similar to previous studies the MIP and MEP in the off state were significantly 
reduced at 45% and 57% of predicted values respectively and although these 
values tended to improve in the on state the results were not statistically 
significant. Although using an uncommon technique to assess perception of 
dyspnoea, this was increased in the off state and improved in the on state, but 
despite this improvement those with PD reported more dyspnoea than controls. 
Close correlation was noted only between MIP and perception of dyspnoea in 
the off state. Although limited by size and technique, including no measurement 
of TLC, this study highlights dyspnoea, the pathophysiology of which is poorly 
understood. Weiner et al speculate that dyspnoea may be caused by a 
mismatch between incoming afferent information from airways, lungs, 
respiratory muscles and chest wall structure receptors and central respiratory 
motor activity, which may be similar to the sensory-motor disparity in limb 
muscles in PD (Weiner et al., 2002). 
2002 brought a further publication of Brazilian data by Cardoso and Pereira. 
They reported spirometry and respiratory muscle strength tests of 40 PD 
patients, age 50 – 80, Hoehn and Yahr I-III, compared to 40 matched healthy 
controls. In support of studies in the same year a predominantly restrictive 
picture was reported noting a reduction in VC and FVC in the PD group, 
however in contrast to other studies there was no difference in MIP and MEP 
between the PD group and control group (Cardoso and Pereira, 2002). The 
breakdown in numbers for each Hoehn and Yahr group were not stated thus if 
predominantly early disease no difference in mouth pressures may have been 
observed. Basing a diagnosis of restriction on FEV1 and FVC measurements 
without measuring TLC, raises questions about the validity of data as poor 
technique by the investigator or patient, or submaximal effort, can produce 
results with FEV1 and FVC readings consistent with false positive restriction. 
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As part of a wider study into sleep breathing disorders in PD, Maria et al, 2003, 
reported basic spirometry, MIP and MEP in 15 PD patients and 15 matched 
healthy controls. FEV1, FVC and FEV1/FVC were normal in both groups, 
however median values for MIP and MEP were significantly reduced, 55% 
predicted and 45% predicted respectively, in the PD group (Maria et al., 2003). 
The study did not exclude ex-smokers and also predominantly included those 
with mild disease severity which the authors based on UPDRS scores, rather 
than Hoehn and Yahr stage, which makes the study difficult to compare with 
others.             
Whilst not publishing exact figures, Haas et al’s 2004 study focussed on 
respiratory muscle strength tests yielded interesting results. Respiratory mouth 
pressures, activities of daily living, activity levels and quality of life 
questionnaires, peak heart rate, peak oxygen consumption, lactate thresholds 
and stages completed on a cycle ergometer test were recorded in 66 
participants with PD and 32 age-matched healthy controls. Whilst MIP and MEP 
were found to be significantly lower in the PD group this did not affect the 
results of the questionnaires but did correlate with lactate thresholds and 
ergometer stages completed. With an average Hoehn and Yahr stage of 2, this 
study supported a weakness of respiratory muscles in mild to moderate PD, 
which seemed to affect individuals during exercise but not during tasks that 
required a smaller effort, for example activities of daily living (Haas et al., 2004). 
The strength of skeletal muscles was not measured during this study and given 
the positive findings at ergometer stages and lactate threshold, a contribution by 
limb weakness cannot be excluded. Nonetheless, the results remain relevant as 
previous studies have shown that whole body exercise training has the potential 
to improve respiratory muscles, improving inspiratory muscle strength has 
benefited other patient groups and athletes and can be safely done in patients 
with neuromuscular disorders (Enright et al., Rutchik et al., 1998, Sánchez 
Riera et al., 2001, Cahalin et al., 1997, McCool and Tzelepis, 1995, Koessler et 
al., 2001, Powers and Criswell, 1996).  
With this interest in inspiratory muscle training Inzelberg et al, 2005, measured 
respiratory muscle strength and endurance, perception of dyspnoea and quality 
of life in 20 PD patients, Hoehn and Yahr stages II-III. The patients were then 
divided into 2 groups of 10, 1 group received 12 weeks of ½ hour, 6 times per 
week specific inspiratory muscle training and the other group received sham 
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training. Significant improvements in inspiratory muscle strength, endurance 
and perception of dyspnoea were seen only in the intervention group, MIP 
increased from a mean of 62.0 to 78.0 cmH2O (Inzelberg et al., 2005). Despite 
the small size of the study this highlights a potential role for inspiratory muscle 
training in PD.  
With the afore lack of clarity and conflicting reports on the effect of 
dopaminergic medication on pulmonary function, Sathyaprabha et al, 
researched this further in a study published in 2005. Spirometry, respiratory 
muscle strength and MVV were performed in the off and on states (after 
levodopa therapy) on 35 PD patients and 35 healthy age-matched controls. At 
baseline they reported the PD group had significantly lower FEV1, FVC, PEF, 
MVV, MIP and MEP compared to the controls and 33 of 35 PD patients showed 
restrictive spirometry and 2 obstructive. Following administration of levodopa all 
the above indices significantly improved (Sathyaprabha et al., 2005). The 
results of this study, although supporting studies in the same era that the 
predominant pattern of spirometric dysfunction was restrictive, need to be 
interpreted with caution; lung volumes with TLC were not measured and hence 
not contributory to a diagnosis of restriction, the mean age in the PD group was 
only 53 and 32 patients were Hoehn and Yahr stage II and 3 stage I, thus 
earlier disease than other studies. Although the authors felt the restrictive 
pattern of pulmonary dysfunction demonstrated was probably due to abnormally 
low chest wall compliance secondary to rigidity, I suspect that given the patient 
demographics these results more likely represent a false positive finding of 
restriction due to poor spirometry technique.  
Previous studies had predominantly used spirometry alone rather than including 
body plethysmography for assessment of lung volumes. A small study based in 
Iran, Mikaelee et al 2006, undertook lung function testing including body 
plethysmographic measurements of lung volumes in 25 PD patients, Hoehn and 
Yahr I-V, mean age 63.8 ± 11.1 and compared to 20 control subjects. In the PD 
group an obstructive pattern of respiratory dysfunction was found in 13 (52%) 
and evidence of air trapping in 56% with a markedly raised RV. In contrast to 
previous studies no evidence of restrictive spirometry was found and only 1 in 
the PD group had evidence of UAO (based on abnormal PIF and FEV1/PEF). 
Although there was a trend towards a correlation between increasing Hoehn 
and Yahr scores and abnormal pulmonary function, this was not statistically 
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significant (Mikaelee et al., 2006). Despite use of this methodology, the small 
numbers in the study and attempts to further sub analyse data based on each 
Hoehn and Yahr group led to results lacking statistical significance.  
An eminent American group in the field of speech and language therapy, 
including authors Erin Silverman and Christine Sapienza, published a study on 
mouth pressures in 2006 in 28 PD patients, mean age 64, Hoehn and Yahr 
stages II-III. MIP was less impaired than MEP when compared to controls, 
69.2% of MIP measurements were within or above normal as opposed to only 
28.6% of MEP measurements being within normal range. Whilst their MEP 
findings supported previous studies, their MIP findings contrasted. The authors 
acknowledged potential difficulties in comparing studies including clinician 
measurement technique and pharmacological differences, however 
hypothesized interesting possible reasons for the apparent difference in the 
responses of the inspiratory and expiratory muscles (Silverman et al., 2006). 
The inspiratory and expiratory muscles assume different roles within the 
breathing cycle; during tidal volume breathing the inspiratory muscles have 
constant activation (e.g. the scalenes and parasternal intercostals are always 
active during quiet breathing), however abdominal/expiratory muscles play less 
of a role because expiration during tidal volume breathing is due to passive 
recoil (De Troyer and Estenne, 1984). It is feasible that in the presence of 
disease the inspiratory muscles may lose less strength than the expiratory 
muscles due to baseline EMG activity of inspiratory muscles always being 
greater than that of expiratory muscles during quiet breathing (Silverman et al., 
2006).  
Members of the same group from the National Institute of Mental Health and 
Neurosciences in Bangalore who published a 35 patient study in 2005, reported 
a further study in 53 patients in 2007. Pal et al, assessed spirometry, MIP and 
MEP in the off state and the on state (after levodopa administration) in PD 
patients Hoehn and Yahr II-IV (predominantly stage II) with a mean duration of 
PD of 3.1 years, as compared to 53 healthy age matched controls. They did not 
publish if these participants included those from the previous study. Nineteen of 
the PD group were smokers and 5 of the control group, with all smokers being 
male. Whilst spirometry was measured with standardised commercially 
available equipment, the pressure monitor used to measure MIP and MEP was 
fabricated. They concluded the pattern of pulmonary dysfunction in the PD 
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group was restrictive however did not publish exact numbers and they noted a 
significant impairment in FEV1, FVC, PEF, MVV, MEP and MIP in both the off 
and on state in the PD group compared to the controls. All PFT parameters 
improved with levodopa but remained worse than the control group. 
Interestingly they recorded the percent predicted values of FVC, FEV1, MVV, 
MIP and MEP to be significantly lower in women than men in the PD group only. 
Although there were several correlations between PFT parameters and UPDRS 
motor subscores these did not reach statistical significance likely due to the low 
numbers in the study (Pal et al., 2007). Whilst an interesting study it was limited 
by use of fabricated rather than standardised equipment, low numbers, lack of 
lung volumes assessed by body plethysmography and over 35% of the group 
being smokers.  
A further 2 years passed without any significant publications pertaining to 
pulmonary function in IPD. In 2009, Shaheen et al published a basic spirometry 
study of 30 patients with IPD, mean age 67.7 years, mean disease duration 3 
years, with 77% tremor dominant disease and 23% presenting mainly with 
akinesia. Pulmonary function tests comprised FEV1 and FVC in the off and on 
states (after levodopa) compared to a 15 participant age and sex matched 
control group. They concluded, similar to Pal et al above, the pattern of 
dysfunction was predominantly restrictive, with a restrictive defect observed in 
19 (63.3%) and an obstructive defect observed in 5 (16.7%) of PD patients. 
Thus 80% had abnormal spirometry and whilst they noted pulmonary function 
parameters improved with levodopa treatment, the improvement did not reach 
statistical significance (Shaheen H.A., 2009). Although supporting the findings 
of studies conducted in proximity, the small numbers and simplicity of the study 
unfortunately lessen its impact.  
Identifying that respiratory involvement in PD could potentially occur through 
more than one mechanism, i.e. peripheral or central, Seccombe et al undertook 
a 19 patient study, published in 2011, to identify further evidence of abnormal 
ventilatory control in PD. With the Braak hypothesis suggesting the earliest 
evidence of the disease is in the medulla, enteric nervous system and olfactory 
bulb then slowly spreading to the mid-brain and finally to the cortex, this raises 
the question that medullary (brain stem) ventilatory control could be affected in 
PD (Braak et al., 2004). Predominantly lung function studies have looked at 
peripheral motor manifestations such as tremor or rigidity affecting lung function 
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rather than the effect brain stem involvement has on respiratory control.  
Seccombe et al, measured spirometry, lung volumes (body plethysmography), 
respiratory muscle strength, response to hypoxic gas inhalation and 
hypercapnic ventilatory response and occlusion pressure in 19 patients with PD 
in the on state. Normal lung function was observed in 16, mild airflow limitation 
in 1 and 2 were restrictive based on TLC. No flow volume loops were consistent 
with upper airway obstruction. MIP and MEP were reduced in 68% and 78% of 
patients respectively. Four patients were unable to maintain an adequate seal to 
complete the hypercapnic ventilatory response (which was abnormal in 47%) 
and occlusion pressure (which was abnormal in 73%). Most subjects had 
normal ABGs before and following the altitude simulation test. The authors 
demonstrated impaired respiratory drive in response to hypercapnia and the 
abnormal occlusion pressure response indicated central drive impairment, 
however it has to be remembered that respiratory muscle myopathy may have 
an inhibitory effect on this central measure and it is possible that reduced 
respiratory muscle strength contributed in some way to the abnormal response 
observed (Seccombe et al., 2011). While a comprehensive battery of tests were 
undertaken in this study, the Hoehn and Yahr stages were I-III with 3 
participants unclassified and the medication usage was very varied with 19 
taking levodopa/carbidopa, 11 on dopamine agonists (9 pramipexole, 2 
cabergoline, 1 overnight apomorphine), 10 on entacapone (COMT inhibitor), 2 
on amantadine and 1 had undergone deep brain stimulation. With all these 
variables and a small number of participants, the results are difficult to interpret.  
In 2012 Guedes et el, published a limited study focussed on MIP and MEP in 26 
patients with PD, age range 50 – 75, Hoehn and Yahr II-III compared to 26 
gender age matched controls. The PD group had measurements in the on and 
off states. In support of previous studies MIP and MEP in PD in both the on and 
off states were lower than the control group. This failed to reach significance in 
the female PD MIP results. In contrast to previous studies, with the exception of 
PD female MEP results, any change in respiratory muscle strength in the on 
and off states failed to reach statistical significance. Given their results that 
dopamine replacement had little impact on the measured respiratory 
parameters, the authors proposed that respiratory dysfunction in PD may be 
unrelated to dopaminergic dysfunction (Guedes et al., 2012). I suspect this may 
prove to be inaccurate with the original small number in the study and the 
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dichotomising of results in already small numbers leading to a lack of statistical 
significance.  
Finally, identifying the limited pulmonary function comparative data in PD and 
healthy subjects, and even more limited data between different parkinsonian 
disorders, Wang et al, 2014, compared spirometry, lung volumes (body 
plethysmography), DLCO, MIP and MEP in PD, MSA and healthy subjects. 
They tested 30 PD (mean age 61.8, mean disease duration 4.9 years), 27 MSA 
(mean age 59.85, mean disease duration 3.63 years) and 20 healthy elderly 
controls (mean age 60.85). Hoehn and Yahr stage was II-V for the PD group 
and the MSA group comprised 20 probable and 7 possible MSA. Spirometry 
showed a restrictive pattern in 56.7% of PD patients (63% MSA), central 
obstructive in 3.3% PD (0% MSA) and peripheric obstructive pattern in 43.3% of 
PD (29.6% MSA). Compared to controls, both PD and MSA groups had lower 
VC and higher RV, while there were no significant differences in TLC between 
the groups. In both the PD and MSA groups, VC, FEV1 and FVC decreased 
and MIP and MEP decreased markedly. Interestingly DLCO was only notably 
reduced in the MSA group. In PD patients, VC, FVC, FEV1, PEF, MIP and MEP 
all negatively correlated with UPDRS-III motor section, concluding the more 
seriously the patient is affected by motor symptoms, rather than the disease 
duration, has the greater influence on pulmonary function (Wang et al., 2014). 
When reviewing this study, the authors based the conclusion of restrictive 
dysfunction in this Chinese PD population on the results of spirometric tests and 
not TLC. From the graphical representation of TLC it would appear that the 
mean percentage predicted TLC was above 80% in all groups which would 
indicate an alternative conclusion. This study highlights the need for further 
research into pulmonary function in all parkinsonian syndromes. 
This comprehensive literature review of pulmonary function in PD, highlights the 
small number of studies, with small numbers of participants and the disparity in 
results and conclusions. Aside from the numbers involved, the reviewed studies 
have a number of factors that must be taken into account; varying age groups, 
different Hoehn and Yahr stages and varying definitions of PD. The selection of 
antiparkinsonian medication used across the studies is vast, including a number 
of drug groups, or individual drugs, that are no longer commonly used 
predominantly due to their side effects. The studies reviewed did not 
consistently use standardised equipment and definitions in pulmonary function 
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testing and presumably due to availability, the majority lacked measurement of 
lung volumes by body plethysmography resulting in patterns of dysfunction 
being determined by spirometry alone which can lead to interpretive errors 
particularly in restrictive dysfunction. These findings highlight the need for 
significant further research using gold standard techniques to assess pulmonary 
function in PD and the parkinsonian syndromes.       
2.4 Cardiorespiratory fitness 
Cardiorespiratory fitness describes the ability of the circulatory and respiratory 
systems to supply oxygen to muscles during sustained physical activity. The 
system needs to be able to adapt and respond when demand increases, such 
as during exercise. Exercise induces short term and long term effects on the 
cardiorespiratory system. When exercise commences the pulmonary ventilation 
needs to increase and the cardiovascular system is required to predictably 
respond proportional to the skeletal muscle oxygen demands.  
Pulmonary ventilation primarily increases due to stimulation of the respiratory 
centres in the brain stem from the motor cortex and feedback from the 
proprioceptors in the active muscles and joints. In normal untrained adults this 
can range from 10L/min at rest to over 100L/min on maximal exercise and in 
highly trained, large, male athletes over 200L/min at maximum (Manley, 1996). 
Cardiac output (QT) is the volume of blood the heart pumps out in one minute 
and is the product of the stroke volume (SV) ,which is the amount of blood 
pumped out per beat, and the number of heart beats per minute (heart rate 
(HR)) (Vincent, 2008). The arterial-venous oxygen difference (a-vO2 diff) is the 
difference between the oxygen concentration of the arterial and mixed venous 
blood (Manley, 1996). An individual’s aerobic capacity or maximum oxygen 
uptake (VO2max) is a function of, and thus limited by, the ability of the 
cardiovascular system to supply (QT) and/or the skeletal muscles to use (a-vO2 
diff) oxygen (Manley, 1996, Jakovljevic et al., 2012b).  
As work increases the QT increases in an almost linear pattern up to a 
maximum. This occurs due to increases in HR and SV (Manley, 1996). Although 
both HR and SV increase with exertion, the contribution to the increase QT is 
much greater from the increase in HR particularly at high exertion 
(Higginbotham et al., 1986). Maximal achievable heart rate  
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(HRmax) is related to age and although there are numerous prediction 
equations, HRmax = 220-age is commonly accepted and used (Robergs and 
Landwher, 2002). During exercise, blood flow changes with more blood being 
sent to skeletal muscles, and as temperature rises to the skin. Mean arterial 
pressure increases in response to exercise, predominantly due to a rise in 
systolic blood pressure while diastolic blood pressure remains near resting 
levels. In normotensive individuals systolic blood pressure rises linearly peaking 
at maximum between 200 to 240 mmHg (Manley, 1996). After exercise, blood 
pressure drops below pre-exercise resting levels in an aptly named 
phenomenon called post-exercise hypotension. Whilst this mechanism is 
caused largely by decreased vascular resistance many aspects remain 
misunderstood (Halliwill et al., 2013). During increasing work the a-vO2 diff 
increases as a result of increased oxygen extraction from arterial blood as it 
passes through exercising muscle. Coronary blood flow increases during 
exercise due to an increase in perfusion pressure of the coronary artery and 
from coronary vasodilation (Manley, 1996).  
While exercise produces short term responses to meet immediate demand, 
exercise training produces long term adaptations. These adaptations are not 
purely limited to cardiovascular, respiratory and skeletal muscles but also 
include bone, metabolic and hormonal adaptations. The magnitude of these 
adaptations depends on a number of factors including pre-exercise fitness level, 
type of exercise programme, intensity and duration for example. After 
endurance training, SV is increased at rest and during submaximal and maximal 
exercise, whilst HR is decreased at rest and during submaximal exercise and 
unchanged at maximal work rates. Training increases plasma volume and end 
diastolic volume and results in more elastic recoil. Long term responses also 
include hypertrophy of cardiac muscle fibres and reduction in blood pressure. 
Respiratory adaptations with training are predominantly an increase in 
pulmonary ventilation and an increase in pulmonary diffusion during maximal 
exertion. Dependent on training modality, skeletal muscles undergo fiber 
hypertrophy and hyperplasia and increased recruitment (Manley, 1996). 
Endurance training also facilitates a greater capacity for blood flow in skeletal 
muscles by increasing the numbers of capillaries (Prior et al., 2004).  
The most widely accepted measure of cardiorespiratory fitness or aerobic 
capacity is peak oxygen consumption (VO2peak). As alluded to above, although 
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VO2peak and VO2max are often used interchangeably there is an important 
distinction in that VO2peak is the highest value achieved on a particular test 
where as VO2max refers to the highest value that is considered to be attainable 
by an individual.  
2.4.1 Quantification of cardiorespiratory fitness 
There are a number of commonly used surrogate measures of cardiorespiratory 
fitness for example; the six minute walk test (6MWT), which is the distance an 
individual covers when walking for 6 minutes on a measured track, the multi-
stage fitness test (also known as the beep test or pacer test) and motion 
sensors. The gold standard measure of cardiorespiratory fitness is peak oxygen 
uptake (VO2peak), usually measured during large muscle dynamic activity such 
as running or cycling. Although the gold standard, this technique is not always 
readily available as it requires trained operators and relatively expensive 
equipment. The most common modalities for clinical testing are the treadmill or 
cycle ergometer. Stationary cycle ergometers are particularly useful in groups 
where use of the treadmill may be hazardous. Individuals with significant gait 
abnormalities, including PD where problems can occur with freezing of gait, are 
safer using a cycle ergometer. It has to be remembered that stationary cycling 
may be an unfamiliar activity to some individuals and the exercise test may end 
prematurely, usually due to localised leg fatigue, with resultant lower values in 
VO2peak as compared to treadmill testing (Hambrecht et al., 1992, Myers et al., 
1991).  
VO2peak is the most accurate measurement of functional capacity and an 
indicator of overall cardiopulmonary health (ATS/ACCP, 2003). During an 
exercise test, blood pressure and continuous electrocardiogram (ECG) and 
expired gas composition, oxygen (O2) and carbon dioxide (CO2), are measured. 
VO2max is achieved when oxygen consumption remains plateaued at a steady 
state despite increasing workload. The exercise test protocol selected should 
consider the purpose, outcomes desired, and characteristics of the group or 
individual being tested, e.g. age, disease and symptomology (ACSM, 2010). 
The most familiar and common protocol is the Bruce protocol for treadmill 
testing which uses relatively large increments (metabolic equivalents (METS) or 
watts) every 3 minutes. The Ellestad protocol also uses large increments, where 
the Naughton or Balke-Ware protocols use smaller increments. With larger 
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increments changes in physiological response tend to be less uniform and 
these protocols tend to be better suited to younger or more physically active 
individuals. Protocols with smaller increments or alternative ramp protocols are 
preferable for those who are older, deconditioned or with chronic diseases 
(ACSM, 2010). Rather than incremental increases, in ramp protocols the work 
rate increases in a constant and continuous manner (Kaminsky and Whaley, 
1998, Myers et al., 1992, Myers et al., 1991). The increasingly popular ramp 
protocols are advantageous as they avoid large unequal increments in 
workload, there is uniform increase in haemodynamic and physiologic 
responses, the protocol can be individualised and most importantly they offer 
more accurate estimates of ventilatory thresholds and exercise capacity (Myers 
et al., 1991). When an exercise test is completed, and the individual is in the 
post exercise period, monitoring must continue for at least 5 minutes or until any 
ECG changes return to baseline and any symptoms resolve and heart rate and 
blood pressure return to near baseline (ACSM, 2010).  
As discussed, whilst dependent on a number of factors, absolute VO2max 
levels are typically higher in males than females. As a guide, an untrained 
healthy male may have a VO2max of 35-40 ml/kg/min (Guyton and Hall, 2011). 
The highest VO2max results tend to be seen in elite endurance sportspersons, 
for example runners, rowers and cyclists, with values in the most elite 
approaching 100ml/kg/min. To highlight these exceptional VO2max results in 
the top elite athletes, thoroughbred racehorses exercising on an inclined 
treadmill were recorded as demonstrating VO2max results of 131-153 ml/kg/min 
(Rose et al., 1988).  
While predominantly discussing VO2max, it is important to mention, as above, 
the concept of metabolic equivalents or METS. One MET is the amount of 
oxygen consumed sitting at rest and is equal to 3.5ml O2 per kg body weight 
and as such, the energy cost of an activity can be calculated by dividing the 
relative O2 cost of the activity in ml/kg/min by 3.5. The MET concept provides a 
simple technique to describe functional capacity and with known energy 
expenditure values, in METS and watt units, for household task and recreational 
activities allows simple visual imagery of energy expenditure (Jette et al., 1990).  
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2.4.2 Cardiorespiratory fitness and ageing 
Ageing, including in the absence of disease, is associated with a progressive 
decline in cardiorespiratory fitness, or VO2max, and a resultant reduction in 
capacity for physical activity. As an individual’s aerobic capacity or VO2max is a 
function of, and thus limited by, the ability of the cardiovascular system to 
supply (QT) and/or the skeletal muscles to use (a-vO2 diff) oxygen, it stands to 
reason that ageing’s effects on these factors are causative in the decline. Until 
late middle age, reduced cardiac output and possible maldistribution of cardiac 
output play a dominant role in reductions in oxygen delivery (Betik and Hepple, 
2008). As demonstrated by maximal heart rate prediction equations, maximal 
heart rate achievable declines with age which contributes to decreased cardiac 
output. Sarcopenia, a degenerative loss of skeletal muscle mass and strength, 
is associated with ageing. Ageing, particularly extreme old age, is also 
associated with a decline in skeletal muscle oxidative capacity, due in part to 
mitochondrial dysfunction, but interestingly the structure of the capillary bed 
does not appear to decline in a way that would affect the capacity for oxygen 
diffusion (Betik and Hepple, 2008). Although a small study, and older subjects 
having an average age of 58, Kim et al concluded muscle mass is associated 
with VO2max however it appeared that VO2max was less influenced by muscle 
mass in older subjects than in younger subjects (Kim et al., 2016).   
Despite the effects of ageing, in older persons aerobic exercise training can 
improve VO2max. This was demonstrated in a 41 trial meta-analysis of studies 
including 2012 older subjects (within-group mean age of 60 years and older), 
reporting greater improvement in VO2max to be associated with training length 
greater than 20 weeks and intensity between 60-70% of VO2max (Huang et al., 
2005). With cardiorespiratory fitness associated with cardiovascular and all 
cause mortality this highlights the protective benefits available by improving 
aerobic capacity in older adults. 
2.4.3 Cardiorespiratory fitness and neurodegenerative disease 
Neurodegenerative disease is a somewhat umbrella term for a range of 
diseases that affect the neurons. These include diseases such as PD, 
Parkinson’s plus syndromes, Alzheimer’s, Amyotrophic Lateral Sclerosis (ALS), 
Huntington’s, spinal muscular atrophy, spinocerebellar ataxias and prion 
disease. Despite being grouped together, these disorders are markedly different 
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and affect cellular, physiological and cognitive function in different ways that all 
may affect cardiorespiratory fitness. There is a body of evidence that suggests 
physical activity and higher cardiorespiratory fitness levels can delay the onset 
and reduce the morbidity associated with neurodegenerative diseases 
(Scarmeas et al., 2011, Ahlskog, 2011, Archer et al., 2011).  
Even in early stage ALS, with skeletal muscle mass similar to normal, research 
demonstrates a reduction in VO2peak (Mezzani et al., 2012). In Alzheimer’s 
type dementia (AD) cardiorespiratory fitness is lower than normal subjects, 
including in early disease. Lower cardiorespiratory fitness in AD is associated 
with progression of dementia severity and brain atrophy, indicating a link 
between progression of dementia severity and cardiopulmonary health. In non- 
demented subjects there is also a trend for lower aerobic capacity to be related 
to cognitive decline (Vidoni et al., 2012).   
The evidence, although vast, highlighting impaired cardiorespiratory fitness in 
neurodegenerative disorders, also highlights the potential morbidity and 
mortality benefits from improving cardiorespiratory fitness, particularly in 
cognitive function which supports the neuroplasticity effects of exercise.     
2.4.4 Cardiorespiratory fitness and Parkinson’s disease 
Advancing PD and increased severity of disease are associated with reduced 
physical activity and a more sedentary lifestyle. A recent review of exercise and 
parkinsonism underlined the improvements pertaining to both the functional 
deficits and neurological biomarker manifestations of the disorder and 
concluded that physical exercise co-administered with antiparkinsonian 
medication ought to contribute to an enrichment of aspects of functioning and 
the quality of life of PD patients (Archer et al., 2011). The review however 
mentioned little evidence of the effect of exercise on aerobic capacity in PD and 
literature review has found this area to be lacking in high quality studies. A 
number of studies used estimates of V02max, for example based on heart rate, 
rather than actually measuring it, or used surrogate markers of aerobic capacity.  
For a measure to be valid it needs to be reliable and repeatable in the proposed 
subject population, thus a “gold standard” measure must be highly reproducible 
in repeated measurements obtained from the same subject under the same 
circumstances and must show little within-subject variation. Katzel et al, 
measured VO2peak in 70 individuals with PD (Hoehn and Yahr stages 1.5 to 3) 
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on a maximal effort treadmill test. A second test was performed a week later in 
all 70, and a further week later a third test was performed in 21. Their results 
demonstrated measurement of VO2peak in PD was reliable and repeatable with 
an intraclass correlation coefficient (ICC) of 0.90 for VO2 peak in ml/kg/min. 
Maximum heart rate and final speed achieved were also highly reliable with 
ICCs of 0.91 and 0.94 respectively. In their study population VO2peak values 
were generally 20% lower than age-matched controls without PD tested in the 
same laboratory (Katzel et al., 2011).  
Given the pathophysiology of PD it would be reasonable to assume that aerobic 
capacity would be lower in individuals with PD than in those without, however 
the limited number of studies reporting VO2peak in PD have been mixed with 
some reporting values similar to healthy matched controls (Canning et al., 1997, 
Protas et al., 1996, Saltin and Landin, 1975, Stanley et al., 1999). Directly 
comparing all studies is difficult due not only to the study population 
demographics, but also that some studies used treadmill testing and others a 
cycle ergometer. Protas et al, identified that aerobic capacity in PD had not 
been characterised and undertook cycle ergometer and arm-cranking 
ergometer tests in 8 men with PD (Hoehn and Yahr II-III) and 7 controls. They 
reported no difference between the groups for VO2peak, and in both groups 
VO2peak was lower for the arm-cranking test when compared to the lower 
extremity test. Interestingly they commented that peakVO2 values for both 
groups were comparable to maximal published values for cycle ergometer tests 
in older men (Protas et al., 1996). 
In 1997, Canning et al published exercise results of 16 patients with mild to 
moderate PD. Thirteen men and 3 women, Hoehn and Yahr I-III, performed an 
incremental exercise test to peak work capacity on an electronically braked 
cycle ergometer. Similar to the results of Protas et al, they found VO2peak 
values in subjects with PD were not significantly different to normal values. 
While sedentary subjects produced lower VO2peak scores than exercising 
subjects, there was no significant correlation between percent predicted 
VO2peak and PD disease severity (Canning et al., 1997). When interpreting the 
results of these studies, the small number of participants has to be 
acknowledged. In contrast to the findings of Canning et al, an abstract 
published in 2013, in a larger participant group, reported aerobic capacity in PD 
was affected by rigidity, gait and posture (Sacheli et al., 2013). However very 
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little detail was included in the abstract about aerobic capacity and 
measurements and it would appear the abstract has not further been expanded 
and published as a paper. 
In agreement with the afore mentioned studies, Stanley et al found no 
significant differences in VO2max between those with PD and healthy controls 
in their study population. They performed cycle ergometry on 20 individuals with 
PD and 23 healthy controls. Interestingly however they did report that in 
comparison of time those with PD were unable to exercise for as long before 
reaching VO2max which may indicate that those with PD may be less efficient 
during exercise and thus unable to exercise for as long (Stanley et al., 1999).  
With a plethora of evidence focussed on the effect of exercise in PD on 
outcomes such as cognition, quality of life and gait and balance, there is a 
distinct paucity of research looking at the effect of exercise interventions on 
aerobic capacity or VO2peak in PD. Bergen et al 2002, investigated the effect of 
a 16 week aerobic exercise intervention on aerobic capacity and movement 
initiation time for PD patients finding peak V02 scores significantly improved 
post intervention, by 26%, as compared to the control group, but only 4 patients 
(Hoehn and Yahr 2) completed the intervention (Bergen et al., 2002). Though 
obviously a very small study, this does suggest that aerobic capacity in PD may 
benefit from exercise interventions.   
While investigating the safety and feasibility of a 3 month progressive treadmill 
aerobic exercise programme for individuals with PD with gait impairment, 5 
individuals underwent pre and post programme graded treadmill exercise 
testing. The study subjects were a limited group with Hoehn and Yahr stage II 
or above and presence of gait impairment (dragging a leg, freezing or 
festination), and no change was found in VO2peak post intervention (Skidmore 
et al., 2008). Similar to previous studies participant numbers were small. 
Limitations to this study also include; the dependency of the participant group, 
gait impairment and the exercise test modality. It should also be noted that a 
number of falls or near misses were observed.  
Shulman et al, compared the effects of 3 types of physical exercise on 
VO2peak in individuals with PD. A total of 67 participants (Hoehn and Yahr I-III) 
were recruited and randomised to 3 month interventions of one of; higher 
intensity treadmill training, lower intensity treadmill training or stretching and 
resistance exercise programmes. Pre and post intervention VO2peak was 
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measured via treadmill test. Despite a drop-out rate from the study of 19%, both 
treadmill exercises improved VO2peak (7-8% increase, p<0.05) significantly 
more than the stretching and resistance exercise group (Shulman et al., 2013). 
Despite the limitations of this study, it does support the findings by Bergen et al 
that aerobic exercise interventions can improve cardiorespiratory fitness in 
individuals with PD.  
This comprehensive review of aerobic capacity in PD highlights the paucity of 
research of baseline aerobic capacity and also the effect of exercise 
interventions to improve cardiorespiratory fitness in PD. Given the significance 
of impaired aerobic capacity and the potential benefits of improvement, this 
area warrants significant further research. 
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Chapter 3. Methods: Cross-sectional study; the pattern of 
pulmonary dysfunction in idiopathic Parkinson’s disease 
This project consisted of 2 distinct studies; a cross-sectional study focusing on 
the pattern of pulmonary dysfunction in IPD, and a randomised control trial 
(RCT) evaluating the effect of an exercise intervention on pulmonary function, 
cardiorespiratory fitness and exercise capacity in idiopathic Parkinson’s 
disease. These studies will be described separately. The studies were funded 
by an innovation grant from Parkinson’s UK and a British Geriatrics Society SpR 
start-up grant. The Newcastle and North Tyneside 1 Research Ethics 
Committee reviewed the study application on 8th May 2012. Following minor 
amendments, ethical approval was granted on 30th May 2012.  
3.1 Participant recruitment 
Participant recruitment commenced in August 2012. Individuals with IPD were 
recruited from the Northumbria Healthcare NHS Foundation Trust Parkinson’s 
Service, where over 700 patients are on the Northumbria database (though 
some of these will not meet the Brain Bank Criteria for IPD, and will have other 
causes of parkinsonism). The service covers a large geographical, mixed rural 
and urban area in North-East England. Patients were approached in both 
medical and specialist nurse clinics, and given verbal information and written 
information sheets to take away (see appendices 9.1). The target recruitment 
for the study was 100, larger than any previous studies of pulmonary function in 
PD. Patients who were willing to participate, fulfilled all inclusion criteria and 
with an absence of exclusion criteria were recruited to the study and asked to 
sign a consent form (see appendices 9.2). The study consisted of 2 visits.   
3.2 Inclusion criteria 
Inclusion criteria for the study were: 
 Idiopathic Parkinson’s Disease by the UK PD Society Brain Bank 
Criteria. 
 Hoehn and Yahr Stage I-IV. 
 Ability to provide written informed consent. 
 Aged 18 years or over. 
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3.3 Exclusion criteria 
Exclusion criteria for the study were: 
 Other forms of Parkinsonism e.g. drug induced. 
 Significant medical conditions which would preclude lung function testing. 
 Pregnancy. 
 Recent diagnosis of a blood clot, deep vein thrombosis, pulmonary 
embolism or myocardial infarction. 
 Unstable cardiac status, haemoptysis, pneumothorax, thoracic, 
abdominal or cerebral aneurysm.  
 Recent eye, thoracic or abdominal surgery. 
3.4 Study journey, assessments, questionnaires and outcome measures 
After recruitment participants were booked to attend 2 visits at North Tyneside 
General Hospital. Visit 1 took place in the Education Centre at North Tyneside 
General Hospital and Visit 2, approximately 1 week later, in the Pulmonary 
Function Department at North Tyneside General Hospital, Rake Lane, North 
Shields, NE29 8NH. Transport was arranged if required and travel expenses 
were reimbursed. Participants received no payment for participation in the 
study. 
At visit 1, consent was confirmed and an assessment document was completed. 
The assessment included patient demographics, details of the patient’s PD, PD 
medication, PD symptoms, respiratory symptoms, past medical history (PMH), 
family history (FH), social history (SH), exercise history and general 
examination. The Movement Disorders Society Unified Parkinson's Disease 
Rating Scale (MDS-UPDRS), the Parkinson’s Disease Questionnaire (PDQ-39), 
SCOPA-SLEEP questionnaire, Hospital Anxiety and Depression Scale (HADS), 
Montreal Cognitive Assessment (MoCA) and an electrocardiogram (ECG) were 
completed. Permissions were granted for use of all rating scales. At visit 2, full 
pulmonary function tests were undertaken, with spirometry, lung volumes 
(plethysmography), diffusion and respiratory muscle strength tests, Mouth 
Pressures and Sniff Nasal Inspiratory Pressure (SNIP). Figure 12, below, 
illustrates the patient journey.  
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Figure 12: Cross-sectional study patient journey  
3.4.1 Assessment document 
The assessment document (see appendices 9.3), was created by myself to 
ensure all relevant information was obtained, particularly focusing on history 
and examination findings to ensure suitability for safe pulmonary function 
testing. I undertook the physical examination of all participants. The answers on 
the assessment document were recorded by one of the Northumbria Healthcare 
NHS Foundation Trust Parkinson’s disease specialist nurses or by myself. 
Participant recruitment 
Northumbria Healthcare NHS 
Foundation Trust PD service 
Visit 1 
Education Centre 
North Tyneside 
General Hospital 
Duration: 2 hours 
Demographics 
Medical questionnaire 
Medical assessment 
MDS-UPDRS 
PDQ-39 
SCOPA-SLEEP 
HADS 
MoCA 
ECG 
 
Visit 2 
Pulmonary Function 
Department 
North Tyneside 
General Hospital 
Duration: 35 minutes 
Pulmonary Function Tests: 
Spirometry 
Lung volumes 
(plethysmography) 
Diffusion 
Respiratory muscle strength 
(MIP, MEP, SNIP) 
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Each participant was allocated a unique identification number and visit number 
date, age, height and weight were recorded. Details about their PD were 
obtained; disease duration since diagnosis, symptoms present at onset of PD 
(bradykinesia, rigidity, tremor, postural instability), laterality of symptoms at 
onset of PD, current anti-parkinsonian medication, dosage and date 
commenced and any previous anti-parkinsonian medication used and when 
discontinued. Accurate medication history was important to identify any 
individuals who had been exposed to ergot derived dopamine agonists, for 
example pergolide or cabergoline, due to the potential for these to cause 
cardiac and pulmonary fibrosis and hence influence pulmonary function test 
results. Participants were asked about the presence of symptoms that can be 
associated with PD or PD treatment; hallucinations, REM sleep behaviour 
disorder, anosmia and history of impulse control disorders. If participants had 
undergone structural imaging (magnetic resonance imaging (MRI) or computed 
tomography (CT)) or functional imaging (e.g. DaTSCAN) during their diagnostic 
work up, the results of these were recorded.    
Complete past medical and surgical history was documented and participants 
were specifically asked regarding any history of cardiovascular disease, stroke, 
transient ischaemic attacks, peripheral vascular disease, hypertension, 
dyslipidaemia, diabetes, pulmonary disease, pneumothorax, haemoptysis, joint 
problems, aneurysms, recent surgery, venous thromboembolism and any 
chance of current pregnancy. Full medication history and allergy history was 
documented. Family history was recorded, particularly focussed on 
parkinsonism, PD, PD plus syndromes, tremor, neurological disorders, stroke, 
malignancy and cardiac or pulmonary disorders.    
Smokers were not excluded from the study, thus not restricting potential 
numbers of participants, however the results were dichotomised to analyse 
smokers and non-smokers separately. In view of this, smoking history was 
careful documented, identifying if individuals were current, ex or never smokers, 
and pack year history (which can also be calculated for tobacco rather than just 
cigarette smokers). Social history (SH) was completed by recording of 
occupations, exposure to pets and alcohol history. Detailed SH was important to 
identify any factors which may increase risk of pulmonary disease such as 
exposure to asbestos or birds (which can cause bird fancier’s lung, a type of 
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hypersensitivity pneumonitis). Exercise history was recorded including weekly 
frequency, duration and type of exercise.  
Finally participants were examined; cardiovascular, respiratory and 
gastrointestinal systems, blood pressure, pulse and oxygen saturations were 
recorded, and an ECG was performed.   
3.4.2 MDS-UPDRS 
The Movement Disorders Society Unified Parkinson's Disease Rating Scale 
(MDS-UPDRS) is a validated PD rating scale that is used very commonly in PD 
research and clinical practice. The MDS sponsored new version of the UPDRS 
was developed in response to critique of the weaknesses and ambiguities of the 
original UPDRS. The MDS-UPDRS is divided into four sections; Part I non-
motor experiences of daily living, Part II motor experiences of daily living, Part 
III motor examination and Part IV motor complications. Part III is the only part 
that is solely completed by the rater, at the end of which an assessment of 
Hoehn and Yahr stage is made. The Hoehn and Yahr score from 0-V describes 
the stage of PD objectively rated, where 0 is asymptomatic and V is wheelchair 
bound or bedridden. Throughout the MDS-UPDRS, higher scores reflect worse 
signs and symptoms (see appendices 9.4). Use of the MDS-UPDRS also 
facilitates categorisation of patients into tremor dominant (TD) or postural 
instability gait difficulty (PIGD) subtypes, based on formulas developed from 
MDS-UPDRS scores (Stebbins et al., 2013). The MDS-UPDRS raters were 
either myself or one of the Northumbria Healthcare NHS Foundation Trust 
Parkinson’s specialist nurses, all of whom are trained in performing the rating 
scale. 
3.4.3 PDQ-39 
The Parkinson’s Disease Questionnaire (PDQ-39) is a subjectively completed 
quality of life questionnaire (Peto et al., 1995). A short form of the questionnaire, 
the PDQ-8, is also validated for use (Jenkinson et al., 1997). The PDQ-39 
provides a summary index score for the entire questionnaire and separate 
scores across 8 domains or scales; mobility, activities of daily living (ADL), 
emotional well-being, stigma, social support, cognitions, communication and 
bodily discomfort (see appendices 9.4). In similarity to the MDS-UPDRS, higher 
scores reflect worse symptoms. The PDQ-39 was selected for use in this study 
for a number of reasons; it is validated; it is a MDS recommended scale for use 
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in PD; it is very commonly used in PD research thus allowing comparisons; it is 
comprehensive and data exists on sensitivity to change of the PDQ-39 and 
minimally important difference.   
3.4.4 SCOPA-SLEEP 
The SCOPA-SLEEP scale is a valid and reliable scale to quantify sleep issues 
in PD. The SCOPA–SLEEP consists of two sections (night –time sleep 
problems and daytime sleepiness) and an additional 7-point question as a 
global measure of night time sleep quality. The night-time sleep problems 
subscale includes; sleep initiation, duration, fragmentation, efficiency and early 
wakening. The daytime sleepiness subscale includes frequency of falling asleep 
unexpectedly in particular situations, having difficulty staying awake and 
daytime sleepiness. As previously, higher scores reflect worse symptoms 
(Marinus et al., 2003). The SCOPA-SLEEP scale was selected for use in this 
study over other sleep scales due to it assessing both nocturnal sleep disorders 
and daytime somnolence to a similar extent. For example the Parkinson's 
Disease Sleep Scale (PDSS) can be used to obtain a profile about potential 
causes of bad sleep, but is barely useful in the assessment of daytime 
sleepiness (Martinez-Martin et al., 2008). The SCOPA-SLEEP is a subjectively 
completed rating scale which is recommended by the MDS (see appendices 
9.4).  
3.4.5 HADS 
Although prevalence rates of anxiety and depression in PD vary across studies, 
it is widely acknowledged that rates are substantial (Pontone et al., 2009, 
Reijnders et al., 2008). No PD specific rating scales of anxiety and depression 
are commonly used. The Hospital Anxiety and Depression Scale (HADS) is a 
14 item scale - 7 items relate to anxiety and 7 to depression. This outcome 
measure was specifically developed to differentiate anxiety and depression from 
common somatic symptoms of illness, for example fatigue or insomnia, thus 
creating a tool for the detection of anxiety and depression in individuals with 
physical health problems. Each item on the questionnaire is scored from 0-3, 
thus a person can score up to 21 for either anxiety or depression (Snaith and 
Zigmond, 2000). A systematic review of a large number of studies concluded a 
cut-off point of 8/21 for diagnosis of anxiety or depression (Bjelland et al., 2002). 
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The HADS is a MDS recommended rating scale for use in individuals with PD 
(see appendices 9.4).  
3.5 Pulmonary function measurement 
Participants attended the Pulmonary Function Department at North Tyneside 
General Hospital. All testing was performed by qualified, experienced 
respiratory physiologists accredited to the Association for Respiratory 
Technology and Physiology (ARTP). The ARTP are the professional guardians 
of physiological measurement in respiratory medicine in the UK and provide the 
only national, professionally recognised, qualifications in respiratory function 
testing and spirometry. They achieve this through standards of training and 
quality assurance (ARTP, 2017). The variability in lung function measurements 
can be very high, unless high-quality measurements, expertly trained staff and 
high-quality assurance processes are in place, thus the decision to perform all 
testing with respiratory physiologists to ensure gold standard testing. All 
equipment used was regularly calibrated according to guidelines.  
Before testing commenced all patients had height and weight recorded, to 
enable calculation of Body Mass Index (BMI). If standing height could not be 
measured easily, for example due to severe kyphoscoliosis, arm span was 
measured instead, which is normal practice in these circumstances. Smoking 
history and use of inhalers the same day was also documented.  
When performing PFTs, dynamic studies (spirometry, flow volume loops, peak 
expiratory flow rates) are performed first followed by lung volumes and diffusion 
capacity (Ranu et al., 2011). Respiratory muscle strength testing is performed 
subsequently. Interpretation of PFTs is based on comparisons of data with 
reference (predicted) values. The European Community for Coal and Steel 
(ECCS) have published comprehensive listings of reference equations which 
were used in this study (Quanjer et al., 1993). Medisoft’s BodyBox 5500 was 
used for measurement of spirometry, lung volumes and diffusion. Micro 
Medical’s MicroRPMTM respiratory pressure meter was used for respiratory 
muscle strength testing. In association with the BodyBox 5500, the computer 
software used was Medisoft Expair 2010, 1.29, 13. All equipment met the 
specification standards of the ATS and ERS.  
All procedures were explained before and during the testing and 
encouragement during testing is important to achieve optimal accurate results. 
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Test procedures followed the recommendations of the BTS and the ARTP 
publication on guidelines for the measurement or respiratory function 
(ARTP/BTS, 1994).  
3.5.1 Spirometry 
Participants were tested in an upright sitting position and wearing a nose clip. 
The spirometer was fitted with a bacterial filter. The participant then sealed their 
mouth around the mouthpiece of the spirometer and breathed in and out 
normally for the measurement of tidal volumes (TV). Relaxed or slow vital 
capacity (VC) was measured next; the patient was instructed to breathe in as 
deeply as possible (to full inspiration), seal the lips tightly around the 
mouthpiece and then breathe out into the spirometer at a sustained, 
comfortable speed to full expiration. For VC the best result was recorded from a 
maximum of 4 tests.  
Forced expiratory volume in 1 second (FEV1), forced vital capacity (FVC) and 
flow volume curves were measured next. The equipment was able to measure 
the maximal flow volume curve, FEV1, FVC and PEF using the same expiratory 
manoeuvre, however to facilitate reader understanding of the technique I shall 
describe these separately starting with FEV1 and FVC measurement. The 
participant was instructed to breathe in to maximal inspiration then form a tight 
seal with the lips around the spirometer mouthpiece and breathe out as hard 
and fast as possible until no further air could be exhaled. A maximum of 8 tests 
were done to achieve 3 reproducible tests. Three valid, or technically 
acceptable tests, should have FEV1 and FVC highest values within 5% or 
100mls. The highest FEV1 and FVC, which did not have to come from the same 
test, were selected for reporting. Potential sources of errors which would lead to 
a test being rejected included; leak at the mouth, not inspiring to TLC, tongue or 
false teeth obstructing mouthpiece, poorly coordinated start to the manoeuvre, 
coughing and sub-maximal effort  (ARTP, 2003).  
Peak expiratory flow (PEF) was measured as part of the forced expiratory 
manoeuvre used to measure FEV1 and FVC, and the highest value which 
correlated with the highest FEV1 was recorded. The maximal flow volume 
curves measurement technique is largely to similar to that described above. A 
nose clip is essential and the participant was asked to breathe in to full 
inspiration and then seal lips tightly around the mouth piece and blow out as 
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hard and fast as possible until the lungs were empty and then breathe in as 
hard and fast as possible until the lungs were completely full again. Criteria for 
test acceptability was as for FEV1 and FVC testing, and the flow volume curve 
was visibly displayed for inspection. Values for maximum expiratory flow (MEF) 
and maximum inspiratory flow (MIF) were recorded from these curves.      
3.5.2 Lung volumes 
Lung volumes were measured using whole body plethysmography in a constant 
volume box. This technique, discussed in section 2.3.4, was described by 
Dubois et al, and later reviewed in an ERS/ATS workshop series (Dubois et al., 
1956, Coates et al., 1997). Boyle’s law (pressure x volume = constant) is the 
fundamental basis for its operation (ARTP, 2003). The patient was enclosed in 
an airtight box, the door was shut and temperature and pressure were allowed 
to stabilise. A pneumotachograph at the mouth allowed measurement of airflow 
and a shutter was used to occlude the airway during the testing when required. 
Pressure was measured in the box and at the mouth by pressure transducers. 
When respiratory efforts continue and the mouthpiece is occluded, changes in 
the box pressure reflect rarefaction and compression of gas within the thorax 
and can be used to calculate thoracic gas volume (TGV) (ARTP, 2003).   
The procedure was clearly explained as breathing against a closed shutter can 
be an unusual feeling for patients. With a nose clip insitu, the patient was 
attached to the mouthpiece and was asked to breathe normally. The shutter 
was closed at the end of a tidal expiration and the patient was asked to 
pant/breathe gently against the shutter (approximately 1 breath per second). 
The shutter was reopened and the patient was asked to breathe fully in to 
maximal inspiration and then fully out (relaxed or slow VC). This recorded 
inspiratory vital capacity (IVC) and expiratory reserve volume (ERV). The 
computer software then applied a line of best fit for calculation of total lung 
capacity (TLC) and residual volume (RV). The procedure was repeated to 
ensure reproducibility and when this was achieved, with 2 functional residual 
capacity (FRC) recordings within a 5% match, the mean of the 2 was calculated 
and recorded.  
Unlike other lung function tests, there is no maximum number criteria for 
attempts as lung volume measurement is less effort dependent. Individuals with 
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severe airflow limitation may tire however. Due to the technique, sources of 
error with whole body plethysmography are very few (ARTP, 2003).  
3.5.3 Diffusion 
The gas exchange characteristics of the lungs were assessed by measuring 
Transfer factor for carbon monoxide (TLCO), by the single breath breath-hold 
technique. This has to be done after measurement of VC as this figure is 
required for the procedure. The apparatus consisted of an industrial gases 
cylinder with the gas mix in, an inspiratory start bag and a bag to collect the 
expired sample. The cylinder (BOC) contents at the start of the test were carbon 
monoxide (CO) 0.28%, helium (He) 14%, oxygen (O2) 18% and nitrogen 
balance. The inspiratory start bag (1.8L) was filled with the test gas and 
composition analysed by the machine. Volumes could be reduced in patients 
with small lung volumes. 
With a nose clip insitu, the patient was connected to the system via a 
mouthpiece. The patient was instructed from RV (having breathed out as far as 
possible), to take a sharp breath in and maximally inhale as far as possible. For 
a valid reading the patient had to inspire >85% of VC. The patient was then 
asked to breath hold for 10 seconds (should not be less than 6 seconds) and 
then breathe out slowly, as far as possible, to maximal expiration into the 
expired sample bag. Of note it is more important to inspire >85% VC than 
breath hold for 10 seconds for valid results. During the exhalation, the initial 
portion (washout) from the anatomical and instrument deadspace was 
discarded to ensure that sample is representative of alveolar gas (ARTP, 2003). 
The gas concentrations in the expired bag were then analysed and compared to 
the inspired bag to calculate TLCO and hence gas exchange characteristics.  
A maximum of 5 attempts (due to carbon monoxide) were performed, with the 
aim to produce 2 reproducible TLCO results within 5% of each other. At least 4 
minutes was left between attempts. The recorded results were a mean of the 2 
best results. If TLCO was not reproducible within 5%, the best was recorded 
and a comment made. Diffusion results were reported for assumed 
haemoglobins and correction equations were done for those participants with 
documented recent haemoglobin results.  
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3.6 Respiratory muscle strength  
Respiratory muscle strength was measured using a hand-held respiratory 
pressure meter, the Micro Medical MicroRPMTM. The MicroRPM was used to 
measure the maximal expiratory pressure at the mouth (MEP), the maximal 
inspiratory pressure at the mouth (MIP) and the sniff nasal inspiratory pressure 
(SNIP). There was no set amount of maximal tests and the tests were repeated 
until 3 were reproducible within 10%. The best result was recorded. Nose clips 
are not used during respiratory muscle strength testing.   
To assess MEP, the expiratory valve, the bacterial filter and the rubber 
mouthpiece were attached. The meter was put in “MIP/MEP” function. The 
patient was requested to inhale maximally (to TLC), put the mouthpiece with the 
bite blocks between the teeth and the lips over the flange and then blow out as 
hard as possible.  
To assess MIP, the inspiratory valve, the bacterial filter and the rubber 
mouthpiece were attached. The meter was put in “MIP/MEP” function. The 
patient was instructed to exhale maximally, until the lungs felt empty (RV), and 
with mouthpiece as before, then take a fast, as hard as possible, breath in.  
To assess SNIP, the nasal plug adaptor and appropriately sized nasal probe 
were attached to the MicroRPM. The meter was put in “SNIP” mode. The nasal 
probe was inserted into one nostril, with the patient supporting the probe. At the 
end of a normal breathing cycle, the patient was asked to perform a short sharp 
sniff with as much effort as possible. The other nostril was not occluded during 
the procedure. Each nostril was tried once and then the nostril that achieved the 
highest result was repeatedly used until 3 results were reproducible within 10%.  
Results for MIP and MEP reflect the highest value maintained over 1 second, as 
opposed to SNIP which records the highest value.  
Respiratory muscle strength testing concluded the pulmonary function tests. 
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Chapter 4. Results, Discussions and Conclusions: Cross-
sectional study; The pattern of pulmonary dysfunction in 
idiopathic Parkinson’s disease 
With the distinction between the 2 sections of the study, this chapter concerns 
the results, discussion and conclusion of the cross-sectional study. Having been 
approached by the Northumbria PD team, 103 patients volunteered to take part 
in the study.  
Three participants failed to complete the study, by inability to attend visit 2. Two 
participants completed visit 1 and due to time pressures and other commitments 
were unable to attend visit 2. The other participant, during visit 1, gave a history 
consistent with pulmonary embolism and was admitted to hospital for 
investigations and excluded from visit 2. Thus of the 3 who discontinued the 
study, 2 were withdrawals by the participants and 1 had participation terminated 
by the investigator. Figure 13, below, summarises the recruitment, drop out and 
completion. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13: Cross-sectional study recruitment, drop-out and completion 
103 Participants  
Recruited and consented 
Visit 1 
Questionnaires/assessments/ 
ECG 
n = 103 
 
Visit 2 
Pulmonary Function Testing 
n = 100 
Discontinued = 3 
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Results were inputted by a research assistant and second checked by myself. 
Only very few data points were missing from the entire dataset of the cross-
sectional study (3 participants had some answers missing from the PDQ-39, 2 
had answers missing from the HADS and 1 had answers missing from the 
SCOPA-SLEEP). As a consequence no attempt was made to impute the 
missing values and the data are presented as collected. Where data are 
missing they have been listed. As such missing data have been assumed to be 
missing completely at random and so non-informative.  The data from both 
groups were not normally distributed, on review of histograms, as such medians 
and interquartile ranges are quoted and non-parametric tests (Mann-Whitney U 
tests) were used to analyse the unpaired data. Visual inspection of the data 
distribution using histograms was used for assessing normality. The statistical 
normality tests are auxiliary to the graphical assessment. Statistical tests have 
the advantage of making an objective normality assessment, but are 
disadvantaged by sometimes lacking sensitivity at low sample sizes (having  
little power to reject the null hypothesis and thus passing normality tests)  or 
being overly sensitive to large sample sizes (significant results derived even in 
the case of a small deviation from normality) (Ghasemi and Zahediasl, 2012). In 
cases where there was any discrepancy in the distribution on visual inspection, 
the statistical Kolmogorov-Smirnov test of normality was used. For categorical 
data, e.g. male or female, Chi-square test was used. Alpha was set at 0.05.   
4.1 Demographic features 
Smokers and those with known obstructive lung disease, for example asthma or 
COPD, were not excluded from the study. However the results were 
dichotomised and analysed as 2 separate groups. One group was termed 
“smokers” and included any individual with a known history of obstructive lung 
disease and those who had a 10 pack year or greater smoking history. The 
other group were termed “non-smokers” and included any participant without 
known lung disease, lifelong non-smokers and those with a smoking history of 
less than 10 pack years. The term “pack year” is a widely used quantification of 
a person’s smoking history to measure tobacco exposure. One pack year is 
equivalent to smoking 20 cigarettes per day for 1 year, thus if an individual 
smoked 40 cigarettes a day for 10 years they would have a 20 pack year 
smoking history.  
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The results were dichotomised to avoid any false positive results as the 
prevalence of obstructive pulmonary function test results would be expected to 
be higher in the “smokers”. Table 4, below, illustrates a comparison of the basic 
demographics between the 2 groups (non-smokers and smokers). There were 
64 in the non-smokers group and 36 in the smokers group. The smokers and 
those with known obstructive lung disease group comprised 20 smokers with a 
history of 10 or more pack years (but without a known diagnosis of obstructive 
lung disease), 13 with a diagnosis of asthma and 3 with a diagnosis of COPD. 
The 3 with COPD all had pack year histories over 10 years. Of the 13 with a 
past medical history of asthma, 3 had pack year histories over 10 years also, 3 
had smoking histories of less than 10 years and 3 were not prescribed any 
inhalers at all. The participants were asked if they had ever been given a 
diagnosis of asthma but were not asked how the diagnosis was made, thus it 
has to be remembered that there is a possibility of historically incorrect 
diagnoses of asthma particularly if spirometry with reversibility testing has not 
been accurately performed by trained individuals. Thus 26 of the 36 in the 
smokers group had a smoking history of 10 or more pack years.  
Particularly in a research setting it is difficult to interpret results and make 
comparisons when patients are on a number of different medications and at 
different doses. To address this issue, Tomlinson et al calculated conversion 
factors for different antiparkinsonian drugs to give a total daily levodopa 
equivalent dose (LED). They undertook a systematic review of studies 
identifying 56 primary reports of LED estimates, extracted data, calculated 
modal and mean LEDs and derived a standardised LED for each 
antiparkinsonian drug. The conversion factor for each drug was to have the 
same antiparkinsonian effect as 100mg of levodopa. Thus for immediate 
release levodopa the conversion factor was x1, controlled release levodopa 
x0.75, Duodopa x1.11, Pramipexole (as salt) x100, Ropinirole x20, Rotigotine 
x30, Selegiline (oral) x10, Rasagiline x100, Amantadine x1, Apomorphine x10 
and Entacapone was levodopa x0.33 (Tomlinson et al., 2010). This formula was 
used to calculate LEDs in this study making it comparable to other large studies 
including PD MED and PD SURG.  
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 Non-smokers 
N=64 
Median (IQR) 
Smokers 
N=36 
Median (IQR) 
Significance 
 
Age (years) 68.0 
(63.0 – 76.8) 
71.5 
(66.0 – 76.8) 
Z = -0.755 
P = 0.450 
Male (%) 
 
N = 44 (68.8%) N = 27 (75.00%)  
P = 0.509 
BMI (kg/m2) 
 
26.6 
(23.9 – 30.0) 
28.2 
(24.9 – 32.0) 
Z = -1.339 
P = 0.180 
Disease duration 
(months) 
48.0 
(21.0 – 83.8) 
52.0 
(14.3 - 108.0) 
Z = -0.305 
P = 0.760 
Levodopa equivalent 
dose (mg) 
490.0 
(270.0 – 655.0) 
500.0 
(300.0 – 862.3) 
Z = -0.640 
P = 0.522 
Table 4: Comparison of the basic demographics between non-smokers and 
smokers   
(Significance tests Mann-Whitney U in all except Male. Male Chi-square test.)  
 
No statistically significant difference was observed between the non-smokers 
and smokers with respect to age, sex, BMI, disease duration and levodopa 
equivalent dose. 
4.2 UPDRS Results 
The results of the four sections of the MDS-UPDRS (Part I non-motor 
experiences of daily living, Part II motor experiences of daily living, Part III 
motor examination and Part IV motor complications) are reported in table 5, 
below, comparing smokers to non-smokers. Part III is the only part that is solely 
objective and completed by the rater. Table 5 also illustrates the Hoehn and 
Yahr scores and motor phenotype as derived from the MDS-UPDRS using 
widely adopted formulas (Stebbins et al., 2013). Motor phenotype is reported as 
tremor dominant (TD), postural instability gait difficulty (PIGD) subtype or 
indeterminate. As for the demographics, the data from both groups were not 
normally distributed and as such medians and interquartile ranges are quoted 
and non-parametric tests (Mann-Whitney U tests) were used to analyse the 
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unpaired data. For categorical data Chi-square test was used. Alpha was set at 
0.05. 
No statistically significant difference was seen between the groups in the 
objectively assessed UPDRS part 3 scores, however a statistically significant 
difference was seen between the groups for the subjectively assessed UPDRS 
part 1 and 2 scores. Median Hoehn and Yahr score was the same in both 
groups. Figures 14 and 15, below, illustrate the derived motor phenotypes in 
each group. The smokers group had a statistically significant higher percentage 
of individuals with PIGD motor phenotype. 
 
 Non smokers 
N=64 
Median (IQR) 
Smokers 
N=36 
Median (IQR) 
Significance 
UPDRS Part 1 
 
7.0  
(4.0 – 13.0) 
11.0  
(9.0 – 15.5) 
Z = -3.206 
P = 0.001 
UPDRS Part 2 
 
9.0  
(5.3 – 15.0) 
13.5 
(9.3 – 19.0) 
Z = -2.809 
P = 0.005 
UPDRS Part 3 
 
27.5 
(20.0 – 35.0) 
25.5 
(20.0 – 41.5) 
Z = -0.765 
P = 0.444 
UPDRS Part 4 
 
0.0 
(0.0 – 3.0) 
0.0 
(0.0 – 3.0) 
Z = -0.300 
P = 0.764 
Hoehn and Yahr  
 
2.0 
(2.0 – 2.0) 
2.0 
(2.0 – 3.0) 
Z = -1.292 
P = 0.196 
Motor phenotype 
PIGD (%) 
N = 37 
(57.8%) 
N = 28 
(77.8%) 
 
P = 0.045 
Motor phenotype 
TD (%) 
N = 21 
(32.8%) 
N = 6 
(16.7%) 
 
P = 0.081 
Motor phenotype 
Indeterminate (%)  
N = 6 
(9.4%) 
N = 2  
(5.6%) 
 
P = 0.499 
Table 5: Comparison of UPDRS, Hoehn and Yahr and motor phenotype 
between non-smokers and smokers 
(Significance tests Mann-Whitney U in all except Motor phenotype. Motor 
phenotype Chi-square test.) 
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Figure 14: Motor phenotype of smokers group 
 
Figure 15: Motor phenotype of non-smokers group 
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4.2.1 Discussion 
The demographic, UPDRS and motor phenotype data, compared between non-
smokers and smokers, yielded interesting results. While the groups were 
comparable with no significant difference between the groups on age, sex, BMI, 
disease duration and levodopa equivalent dose, differences were apparent in 
UPDRS scores and motor phenotype. The objective UPDRS section 3 scores 
were not significantly different between the 2 groups, with the non-smokers 
median score being 2 points higher than the smokers indicating a trend towards 
the non-smokers having worse motor scores. Similarly there was no difference 
in the objective Hoehn and Yahr scores between the groups. However the 
subjective UPDRS part 1 and 2 scores were significantly different between the 
groups with the smoker’s median scores being significantly higher than the non-
smokers indicating that the smokers rated themselves worse for non-motor and 
motor experiences of daily living.   
There are a number of potential reasons for these findings. One of the 
symptoms of lung disease is shortness of breath on exertion and this may limit 
an individual’s ability and increase the time it takes to perform tasks. Section 3 
of the UPDRS does not require significant physical exertion by the patient 
where as some of the subjective assessments of sections 1 and 2, including 
eating, dressing, hobbies, walking and getting out of bed, a car or a deep chair 
require more physical exertion and may thus be scored higher with individuals 
with lung disease. Lung disease may also impact on fatigue and sleep leading 
to higher subjective ratings on these questions in UPDRS sections 1 and 2. 
Thus an individual may appear objectively better on short, non-exertional 
assessments. UPDRS sections 1 and 2 also include questions pertaining to 
anxiety and depression which may also be affected by lung disease but also 
may be affected by smoking in the absence of lung disease (Munafo and Araya, 
2010, Moussavi et al., 2007). Anxiety and depression and their impacts on 
perception of health and abilities are important considerations also. 
Focussing on motor phenotype there was a statistically significantly higher 
prevalence of PIGD phenotype in the smokers group, and although it did not 
reach statistical significance there was a higher prevalence of TD phenotype in 
the non-smokers group. Remembering this group included both smokers and 
those without a smoking history but with a diagnosis of obstructive lung disease, 
these are interesting findings. Smoking and PD has long been of interest, 
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particularly in the research setting, dating back nearly half a century, 
prospective and retrospective studies have demonstrated an inverse correlation 
between PD and smoking concluding a reduced risk of developing PD in 
smokers and a recent large study concluded smoking duration was more 
associated with lower PD risk than smoking intensity (Baumann et al., 1980, 
Marttila and Rinne, 1980, Checkoway et al., 2002, Chen et al., 2010).  Thus 
considering smokers alone, do one or more of the 600 ingredients in cigarettes, 
creating more than 7000 chemicals when burnt, have cellular influences that 
affect the expressed phenotype of PD to give a higher prevalence of the PIGD 
phenotype? This question remains unanswered in current published research.  
Depression, apathy and hallucinations are more prominent in the PIGD 
phenotype which may have contributed to the UPDRS part 1 and 2 scores 
being higher in the smokers group (Reijnders et al., 2009). The PIGD 
phenotype usually presents a more severe pattern of non-motor features, faster 
motor deterioration, faster rate of cognitive decline and is associated with 
progression of disability and a negative impact on survival (Burn et al., 2006, 
Post et al., 2007, Auyeung et al., 2012, Poletti et al., 2012, Vu et al., 2012, 
Moustafa and Poletti, 2013). With these facts in mind, considering the patients 
included in the smokers group that do not have a smoking history but have a 
historical diagnosis of obstructive lung disease caused by asthma, the question 
arises about the potential of a misdiagnosis of asthma. It is a feasible 
suggestion that their obstructive spirometry could be caused by PD rather than 
asthma and given the pathophysiology would be more likely to be present in the 
PIGD than TD phenotype. Including these participants in the smokers group 
may give the impression of a higher prevalence of PIGD in this group. This 
theory is further discussed with the pulmonary function results.  
4.3 PDQ-39, SCOPA-SLEEP, HADS Results 
The results of the patient reported questionnaires are reported in table 6, below.  
The Parkinson’s Disease Questionnaire (PDQ-39), subjectively completed 
quality of life questionnaire, summary index score for the entire questionnaire is 
quoted. The SCOPA-SLEEP scale to quantify sleep issues is described as 
SCOPA B (sleep at night), SCOPA C (global measure of night time sleep 
quality) and SCOPA D (sleep during the day and evening). The Hospital Anxiety 
and Depression Scale (HADS) is separately documented as HADS A (anxiety) 
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and HADS D (depression). For all 3 rating scales (PDQ-39, HADS and SCOPA-
SLEEP) higher scores reflect worse symptoms.  
 
 Non smokers 
N=64 
Median (IQR) 
Smokers 
N=36 
Median (IQR) 
Significance 
PDQ 39 summary 
index 
12.7 
(7.1 – 29.3) 
23.1 
(14.3 – 36.4) 
Z = -2.573 
P = 0.010 
SCOPA B 
 
4.0 
(2.0 – 7.0) 
5.0 
(1.0 – 8.0) 
Z = -0.195 
P = 0.846 
SCOPA C 
 
3.0 
(2.0 – 4.0) 
3.0 
(1.0 – 4.0) 
Z = -0.067 
P = 0.946 
SCOPA D 
 
3.5  
(2.0 – 5.8) 
4.0 
(3.0 – 6.8) 
Z = -1.504 
P = 0.133 
HADS A 
 
4.0 
(2.0 – 6.3) 
3.5 
(2.0 – 8.8) 
Z = -0.645 
P = 0.519 
HADS D 
 
3.0 
(2.0 – 6.0) 
7.0 
(3.0 – 8.0) 
Z = -2.765 
P = 0.006  
Table 6: Comparison of PDQ-39 summary index, SCOPA-SLEEP and HADS 
between non-smokers and smokers 
(Significance tests Mann-Whitney U.) 
Statistically significant differences between the groups were observed in quality 
of life, as reported by the PDQ-39 summary index, and in depression, as 
reported by the HADS. These results indicated worse symptoms in the smokers 
group. 
4.3.1 Discussion  
The self-reported questionnaires; PDQ-39, SCOPA-SLEEP and HADS 
reflecting quality of life, day time sleepiness, night time sleep quality and anxiety 
and depression provided very interesting results. There was a trend for the 
smokers group (including those with known obstructive lung disease history), to 
rate themselves worse for quality of life, sleeping during the night, sleeping 
during the day and evening, and depression. The only subjective outcome 
where the smokers group rated themselves better than the non-smokers was 
anxiety. Statistically significant differences between the 2 groups were in the 
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PDQ-39 summary index and in the depression scores, with the smokers 
reporting significantly worse symptoms reflected by higher scores. There was a 
large difference in the median PDQ-39 scores between the 2 groups with the 
smokers’ median of 23.1 and the non-smokers’ median of 12.7. These scores 
mirror the subjective UPDRS part 1 and 2 scores, reported in section 4.2, with 
the smokers’ median scores being significantly higher than the non-smokers. 
However it must be remembered that the objectively assessed UPDRS part 3 
scores (see section 4.2) and Hoehn and Yahr scores were not significantly 
different between the 2 groups. Thus despite no objective difference in motor 
scores and PD disease severity, the smokers reported worse quality of life and 
higher depression scores.   
The PDQ-39 asks participants questions with the prefix “due to having 
Parkinson’s disease, how often in the last month have you……” with a variety of 
questions to follow such as “had difficulty walking half a mile?”. A large number 
of the questions require significant activity such as; had difficulty with leisure 
activities, looking after your home, difficulty washing and dressing or have you 
been confined to the house. Smokers or those with lung disease may suffer 
symptoms such as breathlessness on exertion that limit their activities and 
although the questionnaire asks the effect of having PD on their activities, it is 
feasible that individuals may have answered describing the effect of respiratory 
symptoms on their activities in addition to their PD symptoms resulting in higher 
scores in the smoker’s group.  With the breadth of potential PD symptoms, it 
can be difficult for both patients and clinicians to ascertain which symptoms are 
attributable to PD and which are caused by other conditions. There is significant 
crossover of questions in the PDQ-39 and the HADS, with the PDQ-39 
enquiring about feelings of being frightened, worried, angry, bitter, depressed, 
isolated, lonely, weepy, tearful and anxious. Thus using the PDQ-39 summary 
index score, which includes all domains, those individuals with higher anxiety 
and depression (particularly depression) scores will record worse quality of life 
scores reflected in higher PDQ-39 scores.  
The smokers group includes those with a known diagnosis of a chronic 
obstructive lung disease and those with a significant smoking history. Thus 
there are two distinct areas to consider within this group; the effect of chronic 
respiratory disease on quality of life, anxiety, depression and sleep and 
separately the effect of smoking on these outcomes. Quality of life is a 
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multifaceted, complex concept and most studies in individuals with chronic 
diseases refer to health related quality of life (Megari, 2013). The World Health 
Organization defines quality of life as “an individual's perception of their position 
in life in the context of the culture and value systems in which they live and in 
relation to their goals, expectations, standards and concerns” (WHOQOLGroup, 
1993). Health related quality of life is multidimensional and comprises at least 
three broad domains, physical, psychological and social functioning, that are 
affected by an individual’s disease and/or treatment (Sprangers, 2002).  As 
individuals are living longer and the management of chronic diseases improves, 
the prevalence of those living with a chronic disease that can adversely affect 
their quality of life has increased. Although there are cultural differences in 
results, depression is frequently found to have a greater impact on health 
related quality of life than other chronic diseases (Megari, 2013). If individuals 
have the comorbid state of depression this incrementally worsens health 
compared with depression alone, with another chronic disease alone and with 
combinations of chronic diseases without depression (Moussavi et al., 2007).  
Both Asthma and COPD are known to have a negative impact on quality of life 
and this further deteriorates with increasing disease severity (Stahl et al., 2005, 
Gonzalez-Barcala et al., 2012). Anxiety and depression are particularly common 
in patients with COPD. Whilst the prevalence varies considerably among 
studies it is probably higher than is currently reported. Significant symptoms of 
depression have been reported in up to 74% of those with COPD (Rubio et al., 
2009, Yellowlees et al., 1987, Karajgi et al., 1990, Light et al., 1985, Yohannes 
et al., 2000). Similarly to COPD, asthma is associated with increased 
prevalence of anxiety and depression and the presence of an anxiety or 
depression is highly associated with increased asthma symptom burden 
(Moussas et al., 2008, Richardson et al., 2006). With 16 of the 36 participants in 
the smokers group having a diagnosis of COPD or asthma it is likely that their 
chronic respiratory disease contributed to the higher and thus significantly 
worse scores for quality of life as assessed by the PDQ-39 and depression as 
rated by the HADS. 
The causal direction between smoking and anxiety and depression remains a 
debated one and for obvious ethical reasons, randomised control trials cannot 
be conducted to unequivocally answer this question. Smokers often describe 
the anxiolytic and antidepressant effects of smoking, but evidence exists to 
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suggest that smoking may increase negative affect suggesting the association 
is in the opposite direction and that smoking leads to depression (Boden et al., 
2010, Munafo and Araya, 2010). Many questions remain; does depression 
cause people to smoke to self-medicate symptoms? Does smoking cause 
increased depression risk via neurotransmitter pathway alterations in chronic 
exposure? Is the relationship bidirectional in that acute or infrequent smoking 
reduces negative affect, but chronic smoking exacerbates it (Munafo and Araya, 
2010)? Depression and lower quality of life are associated with higher 
probabilities of smoking initiation and lower likelihoods of successful cessation 
of smoking. There is a negative relationship between smoking and quality of life, 
with the degree related to the number of cigarettes smoked. Interestingly 
passive smoking is also negatively associated with quality of life, whilst 
cessation of smoking improves quality of life (Goldenberg et al., 2014). 
Whichever the direction of the causal association, with 26 out of 36 in the 
smokers group having a significant smoking history, this provides an 
explanation to the observed statistically significantly worse subjective 
assessments of quality of life and depression in the smokers group.  
4.4 Pulmonary Function Results 
The pulmonary function testing provided both quantitative and qualitative results 
for each participant. The pulmonary function and respiratory muscle strength 
tests reported in excess of 25 variables for each participant thus appropriate 
selection of quantitative variables is vital to ensure the results can be easily 
interpreted and compared to previous studies. The flow volume loops also 
provided visual qualitative information pertaining to upper airway obstruction.  
Initially the PFT results were reviewed to ascertain in the lung function is 
normal, if there is evidence of airflow obstruction or if there is any evidence of 
restriction. The PFT data from both groups (smokers and non-smokers) were 
not normally distributed, on review of histograms, as such medians and 
interquartile ranges are quoted where appropriate. Visual inspection of the data 
distribution using histograms was used for assessing normality, as in chapter 4 
in cases where there was any discrepancy in the distribution on visual 
inspection the statistical Kolmogorov-Smirnov test of normality was used.  
Focusing first on the spirometry, lung volumes and flow volume loop results, the 
results are best displayed in 2 ways; with median and interquartile ranges and 
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also the number of individuals with a particular pattern of lung dysfunction. All 
100 participants were able to perform technically acceptable spirometry and all 
but 3 were able to perform the assessments of lung volume. Of the 3 that were 
unable to produce results for lung volume, 2 were from the non-smokers group 
and 1 from the smokers group. The reasons for inability to complete the lung 
volume assessments in the 2 participants in the non-smokers group were; 1 
was unable to comply fully with the instructions given and 1 was too dyskinetic 
to be able to technically measure accurately to an acceptable level. In the 
smokers group, the individual who failed to complete the lung volume 
assessments was too claustrophobic to allow the body plethysmography box 
door to be shut thus precluding lung volume measurement in this way. We 
considered the use of helium dilution as an alternative to body plethysmography 
in this participant however concluded that it was preferable to report all results 
measured in the same way. Table 7 below, illustrates the median and 
interquartile ranges of a number of spirometry and lung volume variables. 
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Non smokers 
N=64 Median (IQR) 
Smokers 
N=36 Median (IQR) 
FEV1 % PREDICTED 
(%) 
108.00 
(94.00 – 115.25) 
107.00 
(88.00 – 118.00) 
FVC % PREDICTED 
(%) 
113.50 
(101.75 – 125.75) 
122.00 
(95.75 – 130.00) 
VC % PREDICTED 
(%) 
109.50 
(97.75 – 123.00) 
116.50 
(98.00 – 131.25) 
FEV1/FVC OBSERVED 
(%) 
74.92 
(69.20 – 77.57) 
69.53 
(63.49 – 76.07) 
FEV1/VC OBSERVED 
(%) 
74.96 
(69.73 – 76.93) 
68.19 
(63.01 – 74.03) 
FEF25-75 % PREDICTED 
(%) 
83.50 
(60.25 – 100.50) 
61.50 
(34.75 – 83.00) 
PEF % PREDICTED 
(%) 
100.50 
(84.00 – 111.25) 
97.50 
(82.00 – 110.25) 
RV % PREDICTED 
(%) 
121.50 
(100.00 – 141.75) 
126.00 
(113.00 – 147.50) 
TLC % PREDICTED 
 
107.50 
(98.00 – 119.75) 
113.00 
(103.50 – 121.00) 
RV/TLC OBSERVED 
(%) 
43.95 
(37.34 – 48.55) 
44.46 
(39.87 – 50.04) 
Table 7: Comparison of group median results of spirometry and lung volumes 
between non-smokers and smokers 
As illustrated in the table above, in both the non-smokers and smokers groups 
the FEV1 % predicted, FVC % predicted and VC % predicted medians were all 
above 100%. The FVC % predicted and the VC % predicted medians were 
higher in the smokers than in the non-smokers group. The FEV1/FVC observed 
and FEV1/VC observed medians were above 70% in the non-smokers group 
and below 70% in the smokers group. The median results indicated obstruction 
in the smokers group. VC may also be referred to as relaxed or slow vital 
capacity (SVC). For completeness it is appropriate to quote FVC and VC as 
although in normal individuals a small difference can be present in VC and FVC, 
this is notably exaggerated, with FVC comparatively lower than VC, in those 
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with airflow obstruction reflecting hyperinflation and air trapping. In addition, as 
VC should be better than FVC, if a large difference is present between the 2 
measurements with VC being lower than FVC, this could indicate an imperfect 
procedure. 
Measurements of FEF25-75% provide information about the small airways and 
a reduction in this measurement can be an early change reflecting airflow 
obstruction in these small airways (Ranu et al., 2011, Pellegrino et al., 2005). 
While a reduction was noted in FEF25-75 % predicted in both groups, the 
median %predicted in the non-smokers was still above 80% whilst the smokers 
however had a median FEF25-75 %predicted of 61.50 indicating more 
involvement in small airways in the smokers group.  Median PEF% predicted in 
both groups was above 97% and indeed exceeded 100% in the non-smokers 
group. 
Focusing on median lung volumes, both RV and TLC % predicted in both the 
smokers and non-smokers groups exceeded 100%. Whilst measurement of RV 
and TLC are essential in the accurate diagnosis of restrictive lung disorders 
characterised by a reduction in TLC, they are also very useful in diagnosing 
obstructive lung diseases where an increase in RV, suggests air trapping, TLC 
or the RV/TLC ratio may suggest the presence of obstruction (Pellegrino et al., 
2005). Both the non-smokers and the smokers had median results which may 
suggest air trapping with RV % predicted >120% and RV/TLC % observed 
>40% in both groups.  
Whilst looking at the medians for variables in each group is important, it is 
arguably more informative to look at the pattern of lung dysfunction to ascertain 
if each individual has a normal, obstructive, restrictive or mixed (obstructive and 
restrictive) pattern of lung function. Obstructive lung function is indicated by a 
FEV1/FVC <70%, restrictive lung function is indicated by a FEV1/FVC >70% 
and FVC <80% predicted, but most importantly a TLC <80% predicted. Mixed 
ventilatory defects are the co-occurrence of both obstruction and restriction with 
reduced FEV1/FVC and reduced TLC. The measurement of TLC is necessary 
to accurately diagnose a mixed defect as VC or FVC can be reduced in both 
restriction and obstruction. Table 8, below, summarises the patterns of lung 
function in the non-smokers and smokers groups. 
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 Non smokers 
N=64 
Number (%) 
Smokers 
N=36 
Number (%) 
Normal lung  
function 
44 
(68.75%) 
17 
(47.22%) 
Obstructive lung  
function 
18 
(28.13%) 
18 
(50.00%) 
Restrictive lung 
function 
2 
(3.13%) 
1 
(2.78%) 
Mixed obstructive and 
restrictive lung function 
0 
(0.00%) 
0 
(0.00%) 
Table 8: Summary of pattern of lung function in non-smokers and smokers 
Those individuals categorised as having normal lung function all had FEV1/FVC 
≥70% and a TLC ≥80% predicted. Those individuals classed as having 
obstructive lung function all had a FEV1/FVC <70% and a TLC ≥80% predicted. 
Two participants in the non-smokers group were classed as having restrictive 
lung function and one in the smokers group was classed as having restrictive 
lung function. These 3 participants warrant further explanation and results 
interpretation, in these 3, with caution. One of these 2 participants in the non-
smokers group had a FEV1/FVC of 79.56%, FEV1/VC of 81.59% and a FVC of 
71% predicted and as such had spirometric evidence of restriction, however this 
was the same participant in which the gold standard to assess restriction, TLC, 
could not be measured as he was too dyskinetic. The other participant in the 
non-smokers group classed as restriction based on TLC had spirometry results 
that were not consistent with restriction or obstruction, with a TLC of 78% 
predicted, FEV1/FVC of 78.88%, FEV1/VC of 78.95% and a FVC of 87% 
predicted. Similarly to the last participant, the individual in the smokers group 
categorised as restriction on TLC, with a TLC of 75% predicted, had a normal 
FEV1/FVC, normal FEV1/VC and a FVC >100% predicted.  
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Figure 16: Pattern of lung function in non-smokers 
  
Figure 17: Pattern of lung function in smokers 
As highlighted in table 8 and figures 16 and 17, 68.75% of the non-smokers 
group and 47.22% of the smokers group had normal lung function, however 
28.13% of the non-smokers group and 50.00% of the smokers group had 
spirometric evidence of obstruction. As discussed in section 2.3.2, when airflow 
obstruction is identified with a FEV1/FVC <0.7, this can be further categorised 
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into severity according to the reduction in FEV1. Categorised based on  FEV1 
%predicted; ≥80% mild or stage 1, 50-79% moderate or stage 2, 30-49% 
severe or stage 3,  <30% very severe or stage 4 whilst noting that symptoms 
should be present to diagnose someone with COPD if FEV1 %predicted is 
≥80% (NICE, 2010). Table 9 below, categorises the severity of the obstruction 
in those with a FEV1/FVC <70% in each group.  
 Non-smokers with 
obstruction  
N = 18 
Number 
(%) 
Smokers with 
obstruction 
N = 18 
Number 
(%) 
FEV1 ≥80% 
Stage 1 
Mild 
16 
(88.89%) 
12 
(66.67%) 
FEV1 50 – 79% 
Stage 2 
Moderate 
2 
(11.11%) 
5 
(27.78%) 
FEV1 30 – 49% 
Stage 3 
Severe 
0 
(0.00%) 
1 
(5.56%) 
 
FEV1 <30% 
Stage 4 
Very severe 
0 
(0.00%) 
0 
(0.00%) 
Table 9: Severity of obstruction in non-smokers and smokers with obstructive 
spirometry 
In both the non-smokers and smokers with obstructive spirometry, the severities 
were mild to moderate (stage 1 to stage 2) predominantly, with the highest 
percentages in both groups being classified as stage 1 or mild. Focusing on the 
severity of the obstruction to airflow there was an interesting finding in our 
patient demographic of a tendency towards supranormal values when the 
variables of FEV1 % predicted and FVC % predicted were looked at in isolation. 
In the non-smokers group, of the 44 with normal lung function, 34 had a FEV1 
of >100% predicted and 34 had a FVC of >100% predicted. In the smokers 
group, of the 17 with normal lung function, 11 had a FEV1 of >100% predicted 
and 12 had a FVC of >100% predicted. In the non-smokers group, of the 18 
with obstructive lung function, 7 had a FEV1 of >100% predicted and 15 had a 
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FVC of >100% predicted. In the smokers group, of the 18 with obstructive lung 
function, 7 had a FEV1 >100% predicted and 13 had a FVC of >100% 
predicted. Thus, particularly thinking about those with obstructive spirometry, 
whilst the individual volumes may have been supranormal in some cases, the 
ratio of the FEV1/FVC still indicates obstruction to airflow in the volume that can 
be forcibly exhaled in the first second.  
Being cautious not to continually dichotomise to increasingly small numbers; 
tables 10 and 11, below, report the demographics, disease phenotype, UPDRS, 
PDQ39 summary index, HADS and SCOPA-SLEEP results for the non-smokers 
with normal and obstructive spirometry and the smokers with normal and 
obstructive spirometry. Although not a recognised score in its own right, a 
“bulbar score” was devised from UPDRS questions. Question 3.1 of the UPDRS 
is an objective assessment of speech and was hence used as an objective 
bulbar score. Questions 2.1, 2.2 and 2.3 of the UPDRS are subjective 
assessments of speech, saliva, drooling, chewing and swallowing, hence were 
used as a subjective bulbar score. An overall bulbar score was calculated by 
adding the objective and subjective bulbar score results. As per the UPDRS, 
worse signs and symptoms are reflected by higher scores. With the exception of 
disease phenotype, where numbers of individuals were reported, the values 
reported are medians and interquartile ranges.  
Due to the numbers when dichotomised the tables were interpreted with 
caution. An interesting finding was the higher percentage of tremor dominant 
motor phenotype in the non-smokers obstructive lung function group, the other 
3 groups all had a higher percentage of PIGD phenotype which was most likely 
a representation that there were simply higher numbers of PIGD phenotype 
patients across the whole study (Of 100 patients; 65 were PIGD phenotype, 27 
were TD phenotype and 8 indeterminate motor phenotype). The smokers with 
obstructive lung function scored highest across all domains in the SCOPA-
SLEEP assessment suggesting poorer sleep at night and increased sleepiness 
during the day and evening. Both smokers groups, normal and obstructive lung 
function, had higher depression ratings than the comparative non- smokers.   
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 Non-Smokers 
Normal lung 
function 
N = 44 
Non-smokers 
Obstructive 
lung function 
N = 18 
Smokers 
Normal lung 
function 
N = 17 
Smokers 
Obstructive 
lung function 
N = 18 
Age 
(years) 
67.00 
(62.75 – 
73.00) 
71.50 
(68.00 – 
77.75) 
68.00 
(63.00 – 75.00) 
72.50 
(67.50 – 
76.75) 
Disease 
duration 
(months) 
58.50 
(23.00 – 
89.50) 
41.50 
(19.00 – 
63.75)  
49.00 
(14.00 – 87.00) 
51.50 
(17.25 – 
108.00) 
PIGD 
phenotype 
27 
(61.36%) 
8 
(44.44%) 
13 
(76.47%) 
14 
(77.78%) 
TD  
Phenotype 
11 
(25.00%) 
10 
(55.56%) 
4 
(23.53%) 
2 
(11.11%) 
Indeterminate 
Phenotype 
6 
(13.64%) 
0 
(0.00%) 
0 
(0.00%) 
2 
(11.11%) 
Bulbar score 
Objective  
1.00 
(0.00 – 1.00) 
1.00 
(1.00 – 1.00) 
1.00 
(1.00 – 2.00) 
1.00 
(0.00 – 1.00) 
Bulbar score 
Subjective   
2.00 
(0.00 – 4.00) 
2.00 
(0.25 – 3.00) 
2.00 
(1.00 – 5.00) 
2.00 
(1.00 – 3.00) 
Total bulbar 
score 
2.50 
(1.00 – 5.00) 
3.00 
(1.25 – 4.00) 
3.00 
(2.00 – 6.00) 
3.00 
(1.00 – 4.00) 
UPDRS  
Part 1 
7.00 
(4.75 – 13.00) 
6.50 
(4.00 – 12.00) 
11.00 
(8.00 – 13.00) 
12.50 
(9.00 – 15.50) 
UPDRS  
Part 2 
9.00 
(5.75 – 15.00) 
9.00 
(5.25 – 14.50) 
15.00 
(12.00 – 19.00) 
11.00 
(8.25 – 18.75) 
UPDRS  
Part 3 
24.50 
(19.75 – 
31.50)   
35.00 
(28.25 – 
37.00) 
37.00 
(27.00 – 40.00) 
23.00 
(20.00 – 
41.75) 
Hoehn and 
Yahr 
2.00 
(2.00 – 2.00) 
2.00 
(2.00 – 2.00) 
2.00 
(2.00 – 2.00) 
2.00 
(2.00 – 3.75) 
UPDRS  
Part 4 
0.50 
(0.00 – 4.00) 
0.00 
(0.00 – 0.75) 
0.00 
(0.00 – 4.00) 
0.00 
(0.00 – 3.00) 
Table 10: Demographics, motor phenotype and UPDRS scores comparison; 
non-smokers and smokers, normal lung function and obstructive lung function 
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 Non-Smokers 
Normal lung 
function 
N = 44 
Non-smokers 
Obstructive lung 
function 
N = 18 
Smokers 
Normal lung 
function 
N = 17 
Smokers 
Obstructive 
lung function 
N = 18 
PDQ 39 SI 12.03 
(7.84 – 29.61)  
13.23 
(6.25 – 25.63) 
22.73 
(14.95 – 34.75) 
23.59 
(14.41 – 
33.93) 
SCOPA B  5.00 
(2.00 – 8.00) 
3.00 
(2.25 – 4.75)  
2.00 
(0.75 – 7.25) 
5.50 
(3.25 – 7.75) 
SCOPA C 3.50 
(2.00 – 4.00) 
2.50 
(2.00 – 3.75) 
2.00 
(1.00 – 4.25) 
3.50 
(1.25 – 4.00) 
SCOPA D 3.00 
(2.00 – 5.25)  
4.00 
(2.00 – 5.75) 
4.00 
(2.00 – 5.00) 
4.00 
(4.00 – 7.00) 
HADS A  4.00 
(2.00 – 6.00) 
3.00 
(1.00 – 5.00) 
4.00 
(2.00 – 8.00) 
3.00 
(2.00 – 7.00) 
HADS D  3.00 
(2.00 – 5.50) 
3.00 
(3.00 – 6.00) 
8.00 
(3.00 – 8.00) 
6.50 
(3.50 – 8.00) 
Table 11: PDQ-39, SCOPA-SLEEP and HADS scores comparison; non-
smokers and smokers, normal lung function and obstructive lung function 
As extensively discussed in section 2.3.3, the shape of maximal flow volume 
loops can be helpful in diagnosing an upper airway obstruction (UAO) and 
differentiating this from lower airway. The shape can help classify the location, 
being extrathoracic or intrathoracic, and the nature, being fixed or variable of 
the obstruction. With variable extrathoracic UAO the obstruction is worse during 
inspiration as the pressure inside the trachea falls on inspiration, thus flattening 
is seen of the inspiratory portion of the flow volume loop. Patterns of UAO can 
also be seen on the flow-volume loops as a respiratory flutter, with regular 
consecutive flow accelerations and decelerations (in a saw tooth pattern), or 
irregular abrupt changes in flow often dropping to zero.  
Whilst the shape of the flow volume loop is most useful in the detection of UAO, 
some numerical indices are also helpful in the indication of UAO. With 
numerical indices there is variation in terminology and values used between 
previous authors, such as the value above which FEV1/PEF indicates UAO. 
There are also not widely accepted numerical criteria to diagnose UAO e.g. an 
individual must have “x” many positive indices for a diagnosis of UAO thus the 
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indices are indicators. As previously discussed, the numerical parameters also 
reflect different types of UAO e.g. fixed extrathoracic UAO presents with 
decreased PEF, decreased MIF50 and MIF50/MEF50 ~1; variable extrathoracic 
UAO normal or decreased PEF, decreased MIF50 and MIF50/MEF50 <1; while 
intrathoracic UAO demonstrated decreased PEF, normal or decreased MIF50 
and MIF50/MEF50 >1 (Pellegrino et al., 2005). Due to the nature of PD, it could 
be postulated that we would be looking for potential variable extrathoracic UAO. 
For this study, numerical indicators of UAO were considered to include 
FEV1/PEF >8ml/l/min, MEF50/MIF50 >1 (i.e. MIF50/MEF50 <1), PIF<3l/sec, 
FEV1/FEV0.5 >1.5, PEF/MEF50 <2 and reduced PEF (<80% predicted).  
As described in section 3.5, all pulmonary function testing was performed by 
qualified, experienced respiratory physiologists accredited to the ARTP. When 
the initial flow volume loop results were reviewed it was evident that all 
respiratory physiologists were aware they had to do maximal expiratory flow 
volume loops but not all were aware they were requested to do maximal 
inspiratory loops also, which has to be born in mind when interpreting the 
inspiratory results of the flow volume loops. The results from any loops that 
were obviously not maximal efforts were not included in the reporting. Table 12 
below, reports the prevalence in numbers and percentages of each afore 
mentioned UAO criteria in the non-smokers and the smokers. All participants in 
both groups had complete results for flow oscillations, flattened inspiratory loop, 
abrupt flow changes, FEV1/PEF, PEF <80% predicted and PEF/MEF50. One 
participant in the non-smokers group did not have a FEV0.5 recorded thus one 
FEV1/FEV0.5 result was missing from the non-smokers group. As highlighted 
above, 11 of the non-smokers and 3 of the smokers inspiratory loops were 
obviously not maximal efforts and were thus not included, thus for these 14 
participants PIF and MIF50 were not recorded. Table 12 details the actual 
numbers in each group demonstrating the particular UAO criteria. The 
percentages reported in table 12 are percentages of individuals with available 
results e.g. for non-smokers with a PIF<3l/s that represents 15 of 53 with 
inspiratory loop results.   
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 Non smokers 
N=64 
Number  
(%) 
Smokers 
N=36 
Number  
(%) 
Flow oscillations 
 
39 
(60.94%) 
19 
(52.78%) 
Flow oscillations 
(marked) 
19 
(29.69%) 
7 
(19.44%) 
Flattened inspiratory loop 24 
(37.50%) 
14 
(38.89%) 
Abrupt flow changes 11 
(17.19%) 
9 
(25.00%) 
FEV1/PEF > 8ml/l/min 7 
(10.94%) 
3 
(8.33%) 
PEF/MEF50 < 2 22 
(34.38%) 
8 
(22.22%) 
PEF < 80% predicted 11 
(17.19% 
9 
(25.00%) 
PIF < 3l/s 15 
(28.30%) 
9 
(27.27%) 
FEV1/FEV0.5 > 1.5 2 
(3.17%) 
3 
(8.33%) 
MEF50/MIF50 > 1 20 
(37.74%) 
6 
(18.18%) 
Table 12: Prevalence of indicators of UAO in non-smokers and smokers 
 The above table illustrates high percentages across both the non-smokers and 
smokers groups of individual visual qualitative and also quantitative indicators of 
UAO. Importantly both groups demonstrated high prevalence of UAO indicators, 
not just smokers. Table 12 reports the prevalence of each UAO criteria, 
however it is important acknowledge that each individual participant may have 
more than 1 of the 9 criteria. It would be expected that increasing numbers of 
UAO criteria per individual makes a clinically significant diagnosis of UAO more 
likely. Table 13 and figure 18 below, illustrate the frequency in the non-smokers 
and smokers groups of those with a total of 0, 1, 2 and 3 or more UAO criteria. 
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With respect to the visual criteria, those with marked rather than more subtle 
flow oscillations were regarded as a positive result. It has to be acknowledged 
also that these results may be under reporting the numbers in each individual 
for 2 reasons; as highlighted above ensuring the flow oscillations were marked 
and as the 14 individuals whose inspiratory results were discounted are also 
included in the below numbers.    
 Non smokers 
N=64 
Number  
(%) 
Smokers 
N=36 
Number  
(%) 
UAO 3 or more criteria 
 
20 
(31.25%) 
9 
(25.00%) 
UAO 2 criteria 18 
(28.13%) 
12 
(33.33%) 
UAO 1 criteria 15 
(23.44%) 
8 
(22.22%) 
UAO 0 criteria 11 
(17.19%) 
7 
(19.44%) 
Table 13: Cumulative numbers of UAO criteria in non-smokers and smokers 
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Figure 18: Cumulative numbers of UAO criteria in non-smokers and smokers 
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Cumulative numbers of UAO criteria in both the non-smokers and smokers are 
high with it being more common to have criteria indicating UAO than no 
indicators of UAO. In the non-smokers and smokers groups, 31.25% and 
25.00% respectively had 3 or more criteria of UAO, which is also a probable 
underestimation. Noting the higher number in the non-smokers and those 
without known obstructive lung disease indicates this result cannot be attributed 
to smoking, COPD or asthma.  
Finally in the pulmonary function test results section, as discussed in section 
2.3.6, respiratory muscle function tests should be performed as part of a more 
comprehensive diagnostic process and respiratory muscle dysfunction is to be 
differentiated from lung function abnormalities (Troosters et al., 2005). In 
generalised neuromuscular disorders it is unusual for the respiratory muscles to 
be unaffected (Polkey et al., 1995). The maximal expiratory pressure and 
maximal inspiratory pressure measured at the mouth are abbreviated to MEP 
and MIP respectively and sniff nasal inspiratory pressure to SNIP. In normal 
subjects maximal expiratory pressures are expected to be higher than 
inspiratory pressures, however SNIP results are generally higher than MIP 
results (Troosters et al., 2005, Fitting, 2006). Table 14 below, illustrates the 
median values and interquartile ranges of the percent predicted MEP, MIP and 
SNIP results for the non-smokers and smokers. 
 Non smokers 
N=64 
Median 
(IQR) 
Smokers 
N=36 
Median 
(IQR) 
MEP % predicted 82.34 
(58.55 – 98.42) 
96.82 
(80.74 – 105.20) 
MIP % predicted 79.02 
(57.80 – 92.53) 
82.21 
(69.70 – 102.08) 
SNIP % predicted 58.53 
(35.89 – 81.50) 
63.96 
(43.30 – 82.81) 
Table 14: Respiratory muscle strength in non-smokers and smokers 
The results of the respiratory muscle strength tests are illustrated as percent 
predicted values and thus take into account that values for expiratory muscle 
tests are usually higher than inspiratory muscle tests. In both the non-smokers 
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and smokers inspiratory muscle function seems to be more affected and 
impaired than expiratory muscle function.  Unlike normal individuals, SNIP 
percent predicted results are worse than MIP results in both the non-smokers 
and smokers. Interestingly the percent predicted MEP, MIP and SNIP median 
values are worse in all 3 domains in the non-smokers compared to the smokers, 
noting that the smoker’s median percent predicted MEP is greater than 96%.   
The pulmonary function and respiratory muscle strength tests have yielded 
some fascinating results in this cross-sectional study and will be discussed in 
detail.   
4.4.1 Discussion 
Pulmonary function and respiratory muscle strength tests should be performed 
as part of a comprehensive diagnostic process and each of the tests 
complement each other to aid in diagnostic accuracy. As such it is appropriate 
to discuss the results together. The PFT and respiratory muscle strength tests 
have yielded very interesting, surprising and novel results.  
Twenty seven studies were reviewed in section 2.3.9, Pulmonary function in 
Parkinson’s disease, however it is difficult to compare these due to the different 
assessments and outcome variables, for example some studies only looked at 
respiratory muscle strength tests and not spirometry. Studies that looked at 
spirometry, with or without body plethysmography, tended to report the 
percentage of or number of participants with either normal, restrictive or 
obstructive lung function. Eight of the studies reported the predominant pattern 
of respiratory dysfunction seen in PD was restriction, these were predominantly 
more recent studies (Izquierdo-Alonso et al., 1994, De Pandis et al., 2002, 
Weiner et al., 2002, Cardoso and Pereira, 2002, Sathyaprabha et al., 2005, Pal 
et al., 2007, Shaheen H.A., 2009, Wang et al., 2014). Of these 8 studies only 1 
performed body plethysmography for measurement of TLC, however they 
reported their findings of restrictive dysfunction based on the spirometry findings 
not TLC (Wang et al., 2014).   
Based on the findings of restrictive lung function in a number of neuromuscular 
diseases, e.g. muscular dystrophy and amyotrophic lateral sclerosis, and 
previous research, particularly in more recent years, of lung function in PD 
pointing towards restrictive spirometry it would not be unreasonable to consider 
this as a likely potential result of PFT testing in PD. The results however have 
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indicated that this is not the case in our patient demographic. Highlighted in 
tables 7 and 8, with reduced TLC being the gold standard for diagnosing 
restriction, both the non-smokers and smokers had median TLCs of over 100% 
predicted and only 3 participants out of 100 were diagnosed as having 
restrictive lung function. One of these diagnoses was based on the results of 
FEV1 and FVC alone, without TLC, as the patient was too dyskinetic to tolerate 
lung volume testing. Thus the prevalence of restrictive lung function in our 
group is very low. As mentioned this is contrary to a number of previous studies 
of lung function in PD. Most previous studies based their diagnoses of 
restriction on spirometry variables, FEV1 and FVC, alone without the benefit of 
lung volumes. Poor instruction, poor technique and insufficient effort can 
produce low FEV1 and FVC values with a ratio diagnostic of restriction and thus 
give false positive results. Given the findings in this study using gold standard 
tests performed by qualified, experienced respiratory physiologists accredited to 
the ARTP, it is likely that in this demographic restriction is rare and that previous 
studies have produced false positive results by not basing the conclusions on 
TLC. Interestingly, of the 27 studies reviewed in section 2.3.9, Pulmonary 
function in Parkinson’s disease, only 5 studies recorded TLC measurements. Of 
these 5 studies, 1 reported the finding of predominantly normal lung function, 2 
predominantly obstructive dysfunction, 1 reported from 58 patients 18 had 
obstructive dysfunction and 16 had restrictive dysfunction and finally 1 reported 
predominantly restrictive dysfunction (Obenour et al., 1972, Sabate et al., 
1996a, Sabate et al., 1996b, Mikaelee et al., 2006, Seccombe et al., 2011, 
Wang et al., 2014). The 1 study that measured TLC and reported a 
predominantly restrictive pattern of pulmonary dysfunction based this on 
spirometry results and not the TLC results. Looking at the graphical 
representation of the TLC results in the afore mentioned paper this was not 
consistent with a finding of restrictive dysfunction (Wang et al., 2014). 
Whilst 44 (68.75%) of the non-smokers and 17 (47.22%) of the smokers had 
normal lung function, 18 (28.13%) of the non-smokers and 18 (50.00%) of the 
smokers had obstructive lung function. No participants had mixed obstructive 
and restrictive pictures. It is an expected finding of a high prevalence of 
obstruction in those with known asthma or COPD and those with a known 
significant smoking history. With only 50% in the smokers group demonstrating 
obstructive spirometry it does however raise the question of previous accurate 
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diagnoses of those labelled with obstructive lung disease. An unexpected 
finding was in the non-smokers that over 25% had obstruction based on 
FEV1/FVC ratio. This result is even more interesting when the severity of the 
obstruction is categorised as highlighted in table 9. Of the 18 non-smokers with 
obstructive spirometry, 16 (88.89%) were categorised as stage 1 or mild with a 
FEV1 ≥80% predicted. Of these, 7 had a FEV1 of >100% predicted. As reported 
in table 7, when looking at FEV1 and FVC in isolation and not as a ratio there is 
a tendency towards supranormal results with the median FEV1 and median 
FVC results, in both the smokers and non-smokers, being more than 100% 
predicted. In the non-smokers with normal lung function, 34 out of 44 had a 
FEV1 and FVC of >100% predicted and in the smokers with normal lung 
function, 11 had a FEV1 of >100% predicted and 12 had a FVC of >100% 
predicted. In addition to questioning the previous diagnoses of some of those 
diagnosed with obstructive lung disease these findings raise questions; why 
does there seem to be a high prevalence of supranormal (>100% predicted) 
values of FEV1 and FVC in this population and why do over 25% of non-
smokers with PD have obstructive spirometry?  
In this study “supranormal” values are described as those >100% predicted, 
and whilst it is unlikely that values less than 120% predicted are clinically 
relevantly “supranormal”, these are interesting findings none the less. These 
supranormal FEV1 and FVC values also further add evidence that restriction is 
not a typical characteristic in this demographic. It could be postulated that the 
reference (predicted) equations used in this study, and routinely in clinical 
practice, of European Community for Coal and Steel (ECCS) published in 1993, 
may be out of date and do not reflect current populations. As described in 
section 2.2.2, dating back over 30 years, prospective and retrospective studies 
have demonstrated an inverse correlation between PD and smoking concluding 
a reduced risk of developing PD in smokers. With this in mind, the individuals 
with PD in this study may represent a large proportion of those with no direct 
smoking or passive smoking history and resultant supranormal FEV1 and FVC 
values.  
Over 25% of the non-smokers group had evidence of obstruction based on the 
ratio of FEV1/FVC. Whilst in this group the individual measurements of FEV1 
and FVC in some participants may have been normal or supranormal, the ratio 
of FEV1/FVC still indicated obstruction to airflow in the volume that could be 
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forcibly exhaled in the first second compared to the FVC. Obstructive lung 
disease is characterised by lower airway obstruction and is caused by any 
disease that obstructs the airflow, for example by narrowing the airways (e.g. 
asthma). An obstructive ventilatory defect is represented by a disproportionate 
reduction in expiratory maximal airflow in relation to maximal volume, i.e. FEV1 
is reduced more than FVC and thus FEV1/FVC is lowered (Ranu et al., 2011, 
Pellegrino et al., 2005). This reduction in the volume of air that can be forcibly 
exhaled in the first second suggests airway narrowing during exhalation 
(Pellegrino et al., 2005). Generating maximal flows during FVC manoeuvres 
requires rapid activation of appropriate driving pressures by respiratory 
muscles, coordinated with stabilisation of extrathoracic airway muscles to 
optimise the dimensions of, and flow through, the extrathoracic airway. With this 
in mind, could upper airway obstruction (UAO) be sufficiently severe to limit 
airflow and demonstrate obstructive spirometry or is the obstruction from, or 
contributed to by, another site. As highlighted in the results there is evidence of 
UAO which will be further discussed in detail, however noting the median 
results of FEF25-75 % predicted of 83.50% and 61.50% in the non-smokers 
and smokers respectively purely attributing obstructive spirometry to UAO may 
not be appropriate. Although the FEF25-75 was above 80% predicted in the 
non-smokers, as reported in table 7, noting the other supranormal values in this 
demographic this may reflect a reduction. Changes in FEF25-75 provide 
information about the small airways and a reduction in this measurement is 
often an early change reflecting airflow obstruction in these small airways. 
Thus other contributors to obstruction need to be considered. The majority of 
PD patients have symptoms or signs of dysautonomia. Dysfunction of 
components of the autonomic nervous system (ANS) can produce characteristic 
clinical signs and symptoms. Cardiovascular dysautonomia is commonly 
reviewed where as other dysautonomias may be overlooked (Goldstein, 2014). 
Dysautonomia of the respiratory system does not appear to be researched in 
PD but could easily be a cause of obstruction. Bronchial smooth muscle and 
mucous glands both affect the diameter of airways and thus resistance to 
airflow, i.e. obstruction. The afore mentioned are also the targets of the ANS 
within the respiratory system with the upper thoracic sympathetic ganglia, and 
the dorsal motor nucleus of the vagus providing the autonomic nerves to the 
airways. The parasympathetic ganglia found in the bronchi and bronchioles 
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innervate airway smooth muscle and glands. The parasympathetic innervation 
of bronchial smooth muscle is greater than that of the sympathetic system and 
stimulation of the vagus causes bronchoconstriction and the vagus also causes 
secretion of mucus. Thus it could be postulated that dysautonomia associated 
with PD causing parasympathetic over activity could be the cause of airway 
narrowing, increased resistance to airflow and the subsequent obstructive 
spirometry.     
Consideration of possible causes of obstruction also need to be reflected back 
to the pathophysiology of PD, particularly alpha-synuclein and Lewy pathology. 
As already discussed Lewy pathology is not restricted to the brain and has also 
been found to affect the autonomic nervous system, including the 
cardiovascular autonomic system. There is increasing research and interest in 
the involvement of the enteric nervous system and early positive biopsies of the 
gastrointestinal system (Braak et al., 2003, Hawkes et al., 2007, Lebouvier et 
al., 2010). Questions do still remain surrounding why not all individuals with PD 
suffer autonomic dysfunction and why presence of pathology does not always 
translate into symptoms (Ferrer, 2011). However despite the interest in Lewy 
body formation in the bowel, there seems to have been little or no research 
looking at potential Lewy body formation and lung and airway parenchyma. 
Previous cellular research reported that in addition to a presynaptic nerve 
terminal protein, alpha-synuclein is also expressed in cultured human 
astrocytes and its levels are increased by stimulation with interleukin-1beta. 
This suggests it has potential involvement in inflammatory processes and 
immune responses. The authors further investigated the effect of inflammatory 
stimuli on alpha-synuclein expression in human macrophages and particularly 
noted that alpha-synuclein immunoreactivity was present in alveolar 
macrophages from human lung tissues (Tanji et al., 2002). This potential 
involvement of alpha-synuclein in inflammatory processes and presence in the 
lung could feasible contribute to airway obstruction. 
Focusing on a more clinical level, the cardinal features and motor symptoms of 
PD; bradykinesia, tremor and rigidity, could be causing obstructive lung 
function. Bradykinesia being slowness of movement and hypokinesia meaning 
movements are small in addition to being slow. Rigidity is frequently described 
as “lead pipe rigidity” and may be felt in the limbs or more proximally, termed 
axial rigidity, in the neck and trunk. Tremor can be frequently evident in the legs, 
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lips, chin and jaw and patients often describe a sensation of internal tremor, a 
feeling of tremor inside the chest, abdomen, arms, or legs that cannot be seen 
on the outside (Shulman et al., 1996). Pulmonary function testing tests many 
effort dependent variables and also those over a timed period. Focusing on 
FEV1 and the ratio of FEV1/FVC that represents obstruction, is represented by 
a comparatively lower (more affected) FEV1 than FVC. The slowness of 
movement of bradykinesia and potential start hesitation may affect the 
recording of FEV1, as this is a measurement over the first 1 second of the 
procedure, more markedly than it affects FVC resulting in lower FEV1 than 
would be expected and thus resultant obstruction. Air flow, particularly when 
considering the upper airways, requires considerable coordination to achieve 
maximal flow and no restriction to the flow. Tremor, rigidity and bradykinesia 
could contribute to disorganised movements of respiratory muscles that become 
important variables in inducing obstruction. It is important to acknowledge when 
considering FEV1 and PEF measurements, the initial 25-33% of FVC exhaled 
depends   primarily on muscular effort rather than the mechanical 
characteristics of the lungs and hence these measurements also reflect the 
calibre of the central airways and force exerted by expiratory muscles and this 
initial activation could be impaired by the clinical features of PD. It also has to 
be considered that disorganised movements of the respiratory muscles could be 
caused by dyskinesia, dystonia and medication and also affect lung function.  
Upper airways obstruction warrants a significant amount of discussion and 
consideration if involvement of the upper airway musculature is significantly 
severe enough to limit air flow.  
The upper airway can be considered to extend from the mouth to the carina, 
subdivided into extrathoracic and intrathoracic portions. During inspiration, the 
intrathoracic airways expand with the expanding lungs and the calibre of 
extrathoracic airways diminishes in caliber due to their intraluminal pressure 
being lower than the atmospheric pressure. During expiration this pattern is 
reversed. Large airway flow is turbulent and this turbulence increases if the 
diameter of the airway reduces. As extensively discussed in section 2.3.3, the 
most useful indicator of UAO is visual inspection of the flow volume loop. 
Numeric indices can be indicators of UAO and those highlighted in table 12 
represent different aspects of UAO however no “formula” as such exists to 
define UAO from a combination of numerical indices, they are however 
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indicators. It would stand to reason that the more numeric indicators of UAO an 
individual demonstrates the more likely that this is clinically significant.  
Focusing on tables 12 and 13 and on figure 18, the most striking feature is the 
prevalence of visual and numeric indicators of UAO and the cumulative 
numbers of indicators in each individual. Each numeric indicator of UAO is seen 
in between 3.17% and 37.74% of non-smokers and 8.33% and 27.27% of 
smokers. In the non-smokers the most commonly seen numeric indicator is 
MEF50/MIF50 >1 and in the smokers is PIF <3l/s. Reflecting back to flow 
volume loops, these 2 indicators suggest the inspiratory portion is more affected 
which would be seen in variable extrathoracic UAO. This finding is supported by 
visual inspection for flattened inspiratory loop which was seen in 37.50% and 
38.89% of non-smokers and smokers respectively. Other visual indicators of 
UAO were even more commonly seen, with flow oscillations “saw tooth” seen in 
60.94% (marked in 29.69%) and 52.78% (marked in 19.44%) of non-smokers 
and smokers respectively. Abrupt flow changes were seen in 17.19% of non-
smokers and 25.00% of smokers. Cumulative numbers of UAO criteria were 
high in both groups with it being more common to have criteria indicating UAO 
than no indicators of UAO. Given the highlighted prevalence of UAO in this 
group it is entirely feasible that involvement of the upper airway musculature is 
significantly severe enough to limit air flow and demonstrate obstructive 
spirometry.  
Thus it has to be considered why and what causes UAO and turbulent airflow to 
be so prevalent in this patient demographic. The intrathoracic airway has the 
relative protection of the thoracic cage, however the extrathoracic airway is 
surrounded closely by muscles required for respiration and the accessory 
muscles in the neck. It is known that PD demonstrates axial involvement and 
thus it is more than feasible that these muscles are affected. Bradykinesia and 
rigidity of these muscles could lead to UAO and given that muscle dysfunction 
in PD is often asymmetrical, this may lead to laterality of muscles and different 
muscles affected in asymmetrical ways which may cause distortion of the upper 
airway and disorganised movements subsequently causing UAO. Abrupt 
changes, at times down to baseline on the flow volume loops, suggest 
intermittent airway closure which again may be caused  by disorganised upper 
airway musculature movement. Dyskinesia seen in some individuals with PD 
may also potential involve the upper airway musculature and cause abrupt 
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changes and distortions. Given the pathophysiology of PD and clinical signs of 
tremor, it is likely that regular “saw tooth” oscillations causing UAO are caused 
by tremor of the upper airway musculature. It has to be born in mind, particularly 
when considering symptoms and future research, this finding was historically 
believed to be predominantly characteristic of the upper-airway narrowing seen 
in obstructive sleep apnoea (OSA). The intermittent nocturnal hypopharyngeal 
obstruction in OSA is probably the commonest form of UAO and flow volume 
loops in these patients may have this “saw tooth” sign of regular oscillations 
(Krieger et al., 1985). 
Finally respiratory muscle function tests are to be considered, importantly as it 
is very unusual for respiratory muscles to be spared in neuromuscular 
disorders. In normal individuals, expiratory pressures are higher than inspiratory 
pressures and SNIP results are generally higher than MIP results. As detailed in 
table 14 the respiratory muscle strength tests in this demographic revealed very 
interesting results. The smokers group demonstrated higher percent predicted 
values than the non-smokers in all the expiratory and inspiratory strength tests. 
This is in itself an interesting finding with various potential causes for this; it may 
be that the severity of axial disease involvement in this group was less or even 
chronic respiratory symptoms have conditioned these muscles for example for 
stronger cough. In both the non-smokers and smokers, inspiratory results were 
worse than expiratory results; with median MEP percent predicted of 82.34 and 
96.82, MIP of 79.02 and 82.21 and SNIP of 58.53 and 63.96 in non-smokers 
and smokers respectively. As discussed in section 2.3.6 severe generalised 
respiratory muscle weakness manifests as breathlessness and tachypnoea and 
nocturnal hypoventilation disturbs sleep, cognitive function and causes daytime 
somnolence, finally resulting in ventilatory failure and cor pulmonale. Inspiratory 
muscle weakness tends to cause dyspnoea and poor exercise tolerance, while 
expiratory muscle and bulbar weakness leads to speech problems, impaired 
cough and predisposes to mucus retention, pneumonia and aspiration.  
Two interesting features warrant further discussion; why is SNIP worse than 
MIP and why are inspiratory muscles seemingly more affected than expiratory 
muscles? It would be expected that SNIP results would be higher than MIP but 
the opposite was true in our population. Considering the Braak hypothesis and 
olfactory bulb involvement in PD it may be postulated that these patients 
struggle to perform the SNIP manoeuvre. Another possibility is the effect of start 
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hesitation and bradykinesia; SNIP is a ballistic manoeuvre requiring immediate 
activation and force with the highest value recorded, where as MIP is a 
sustained over 1 second measurement. Given the pathophysiology of PD it is 
possible that the ballistic nature of a SNIP manoeuvre is more difficult for this 
group. Inspiratory muscles being more affected than expiratory muscles is a 
fascinating finding as it has previously been suggested that in the presence of 
disease the inspiratory muscles may lose less strength than the expiratory 
muscles due to baseline EMG activity of inspiratory muscles always being 
greater than that of expiratory muscles during quiet breathing with the 
inspiratory and expiratory muscles assuming different roles within the breathing 
cycle; during tidal volume breathing the inspiratory muscles have constant 
activation, whilst abdominal/expiratory muscles assume less of a role because 
expiration during tidal breathing is due to passive recoil (De Troyer and 
Estenne, 1984, Silverman et al., 2006). The worse inspiratory results in this 
demographic may be due to the asymmetric nature of PD and a tendency to not 
affect all muscles equally and could also be due to difficulty coordinating 
muscular manoeuvres, particularly unfamiliar ones, with MIP being a less 
intuitive and automatic procedure than MEP.      
The results of the cross-sectional study have shown a notable prevalence of 
obstruction, upper airways obstruction and inspiratory muscle weakness in this 
population. This pattern of dysfunction of the respiratory system could lead to 
increased morbidity and mortality. With inspiratory muscle weakness individuals 
could suffer dyspnoea, hypoxia, tachypnoea, increased respiratory infections 
reduced exercise tolerance and impaired functional capacity. Speaking and 
swallowing require coordinated, precise upper airway movements; UAO could 
contribute to speech and swallowing difficulties, hypophonia, sleep disordered 
breathing, excessive daytime somnolence, acute respiratory failure and difficulty 
in extubation. Given these significant findings, further research is warranted to 
assess the benefit of rehabilitation of the pulmonary system, both 
pharmacologically and non-pharmacologically. The effect of dopaminergic 
treatment on pulmonary function needs to be assessed in detail and 
rehabilitation, by general and specific inspiratory muscle training, warrants 
significant further study.     
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4.5 Strengths and limitations 
The cross-sectional study had both strengths and limitations. The study had a 
significant amount of strengths which most notably included; the largest study to 
date in pulmonary function in PD, dichotomising but including both smokers and 
non-smokers, testing performed to gold standards by experienced respiratory 
physiologists accredited to ARTP and body plethysmography assessment of 
lung volumes to determine TLC. There were also some limitations to the study; 
in retrospect with the results we have obtained it would have been useful to also 
assess peak cough flow (PCF) and airway resistance (RAW), as described in 
the results a number of inspiratory flow volume loops were excluded, it would 
have been interesting to perform more comprehensive bulbar function 
assessments and including more participants with higher Hoehn and Yahr 
scores would also have been very informative. As detailed in the patient 
information sheet, capillary blood gas sampling was attempted, this was chosen 
above arterial blood gas sampling to be less invasive and painful however the 
sampling technique was not successful in this study population and was 
abandoned after a number of attempts. Although a commonly used technique in 
neonates and paediatrics, in adults the blood would not advance successfully 
down the glass sampling tube and as such the analyser could not produce a 
result. Given the broad ranging nature of the variables studied it was decided 
not to apply corrections for multiple comparisons. Since the study was largely 
observational and exploratory, on balance it was felt that each variable 
considered was sufficiently unique and so no two variables were from the same 
family, to make correction for multiple comparisons unnecessary.  This is 
however acknowledged as a limitation as it is important to recognise that in 
some cases significance may have been over estimated for this reason.      
4.6 Conclusion 
Reflecting back to the hypothesis that pulmonary function is impaired in PD and 
the aim and objective of the cross-sectional part of the study; to establish 
whether pulmonary function is impaired in IPD and to define the pattern of 
respiratory dysfunction in IPD, the hypothesis is accepted and the aim and 
objective have been achieved. The results of the cross-sectional study have 
shown a notable prevalence of obstructive spirometry, upper airways 
obstruction and inspiratory muscle weakness in this population. This pattern 
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was observed in both non-smokers and smokers or those with known 
obstructive lung disease. This pattern of dysfunction of the respiratory system 
could lead to increased morbidity and mortality. Given these significant findings, 
further research is warranted to assess the benefit of rehabilitation of the 
pulmonary system, both pharmacologically and non-pharmacologically. The 
effect of dopaminergic treatment on pulmonary function needs to be assessed 
in detail and rehabilitation, by general and specific inspiratory muscle training, 
warrants significant further study.     
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Chapter 5. Methods: Randomised control trial; the effect of an 
exercise intervention on pulmonary function, 
cardiorespiratory fitness and exercise capacity in idiopathic 
Parkinson’s disease 
The second part of the study was a RCT looking at the effect of an exercise 
intervention on pulmonary function, cardiorespiratory fitness and exercise 
capacity in IPD. 
5.1 Participant recruitment 
As per the cross-sectional study, participant recruitment commenced in August 
2012. Individuals with IPD were recruited from the Northumbria Healthcare NHS 
Foundation Trust Parkinson’s Service. Patients were approached in both 
medical and specialist nurse clinics, and given verbal information and written 
information sheets to take away (see appendices 9.5). The target recruitment 
for the study was 30. These 30 were included in the 100 in the cross-sectional 
study as the baseline demographics, assessments and lung function testing 
were the same. Patients who were willing to participate, fulfilled all inclusion 
criteria and with an absence of exclusion criteria, were recruited to the study 
and asked to sign a consent form (see appendices 9.6). The study consisted of 
6 visits. At Visit 1 the participants were randomised 1:1 to a control or an 
intervention group. The baseline assessments took place over 3 visits during a 
2 week period. The control group then received normal care for 12 weeks and 
the intervention group took part in a 12 week exercise intervention. After the 12 
week period, all baseline assessments were repeated over the 3 visits during a 
2 week period.     
5.2 Inclusion criteria 
Inclusion criteria for the study were: 
 Idiopathic Parkinson’s Disease by the UK PD Society Brain Bank 
Criteria. 
 Hoehn and Yahr Stage I-III. 
 Ability to provide written informed consent. 
 Aged 18 years or over. 
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5.3 Exclusion criteria 
Exclusion criteria for the study were: 
 Other forms of Parkinsonism e.g. drug induced. 
 Significant medical conditions which would preclude lung function testing. 
 Significant medical conditions which would preclude exercise. 
 Pregnancy. 
 Recent diagnosis of a blood clot, deep vein thrombosis, pulmonary 
embolism or myocardial infarction. 
 Unstable cardiac status, haemoptysis, pneumothorax, thoracic, 
abdominal or cerebral aneurysm.  
 Recent eye, thoracic or abdominal surgery 
5.4 Study journey, assessments, questionnaires and outcome measures 
After recruitment participants were booked to attend 6 visits. Visits 1 and 4 took 
place in the Education Centre at North Tyneside General Hospital. Visits 2 and 
5 took place in the Pulmonary Function Department at North Tyneside General 
Hospital. Visits 3 and 6 took place at the MoveLab, Clinical Research Facility, 
Royal Victoria Infirmary, Queen Victoria Road, Newcastle upon Tyne, NE1 4LP. 
Transport was arranged if required and travel expenses were reimbursed. 
Participants received no payment for participation in the study. 
At visit 1, consent was confirmed and an assessment document was completed. 
The assessment included patient demographics, details of the patient’s PD, PD 
medication, PD symptoms, respiratory symptoms, past medical history (PMH), 
family history (FH), social history (SH), exercise history, speech assessment 
and general examination. The Movement Disorders Society Unified Parkinson's 
Disease Rating Scale (MDS-UPDRS), the Parkinson’s Disease Questionnaire 
(PDQ-39), SCOPA-SLEEP questionnaire, Hospital Anxiety and Depression 
Scale (HADS), Mini Mental State Examination (MMSE), Trail Making Test and 
an electrocardiogram (ECG) were completed. Clinical Research Facility 
Standard Operating Procedures documentation was completed. Blood tests 
were taken for full blood count (FBC) and brain derived neurotrophic factor 
(BDNF). Permissions were granted for use of all rating scales. At the end of visit 
1 the participants were randomised to either the control group or the 
intervention group. The randomisation process involved the participants blindly 
drawing out of a bag a piece of paper. The piece of paper had either 1 or 0 on it, 
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1 denoted randomisation to the intervention group, 0 denoted randomisation to 
the control group.  
At visit 2, full pulmonary function tests were undertaken, with spirometry, lung 
volumes (plethysmography), diffusion and respiratory muscle strength tests 
Mouth Pressures and Sniff Nasal Inspiratory Pressure (SNIP).  
At visit 3, cardiorespiratory fitness (aerobic capacity) was assessed with a 
Cardiopulmonary Exercise Test (CPET), measuring VO2peak. A Montreal 
Cognitive assessment (MoCA) was performed and exercise capacity was 
measured by the Six Minute Walk Test (6MWT). 
After the first 3 visits, the control group received normal care for 12 weeks and 
the intervention group participated in a 12 week exercise intervention at Moor 
Park Healthy Living Centre, Drury Lane, North Shields, NE29 8SR. After the 12 
week period, all baseline assessments were repeated in both the control and 
intervention groups. Visits 4, 5 and 6 followed the same format as visits 1, 2 and 
3 respectively. Figure 19, below, illustrates the patient journey.  
There was a minor change in the order of the assessments detailed in the 
patient information sheet and the patient journey above. The MoCA and 6MWT 
were performed at visits 3 and 6 instead of 1 and 4. The change was made in 
the 6MWT location due to the Clinical Research Facility having a more suitable 
and quiet location than the Jubilee Day Hospital for setting out the length of 
course required for the 6MWT. The MoCA was changed so that it was not 
performed on the same day as the MMSE and in addition was performed 
between the CPET and the 6MWT to allow the patients a period of physical rest 
between the two physically demanding assessments.  
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Figure 19: Randomised control trial patient journey 
Participant recruitment 
Northumbria Healthcare NHS 
Foundation Trust PD service 
Visit 1 
North Tyneside General Hospital 
Duration: 210 minutes  
Demographics 
Medical questionnaire/ assessment 
MDS-UPDRS, PDQ-39 
SCOPA-SLEEP, HADS 
MMSE, TMT, Blood tests, ECG 
Visit 2 
Pulmonary Function Department 
North Tyneside General Hospital 
Duration: 35 minutes 
Pulmonary Function Tests: 
Spirometry 
Lung volumes, Diffusion 
Respiratory muscle strength 
Visit 3 
Clinical Research Facility 
Royal Victoria Infirmary 
Duration: 75 minutes  
CPET (Aerobic capacity/ VO2peak) 
MoCA 
6MWT 
Control group: Normal care 
Intervention group: 3 x weekly exercise intervention 
Moor Park Health Living Centre, 12 weeks 
Visit 4 
As per visit 1 
As per visit 1 
Visit 5 
As per visit 2 
As per visit 2 
Visit 6 
As per visit 3 
As per visit 3  
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5.4.1 Assessment document 
The assessment document (see appendices 9.7), was created by myself to 
ensure all relevant information was obtained, particularly focusing on history 
and examination findings to ensure suitability for safe pulmonary function 
testing, cardiopulmonary exercise and exercise capacity testing. I undertook the 
physical examination of all participants. The patient assessments were all 
completed by myself.  
Each participant was allocated a unique identification number and the visit 
number was documented. The assessment document for the randomised 
control trial contained all the same questions and examinations as the cross-
sectional study assessment document (see section 3.4.1), with some additional 
assessments. The additional assessments, as noted in the document, were 
related to speech and swallowing and blood tests. These additional results were 
analysed outwith the scope of this thesis. 
5.4.2  MDS-UPDRS 
As per section 3.4.2 in the cross-sectional study methods, the MDS-UPDRS 
was performed in all participants (see appendices 9.4). This was performed at 
visits 1 and 4. The MDS-UPDRS raters for the RCT were either myself or one of 
the Northumbria Healthcare NHS Foundation Trust Parkinson’s specialist 
nurses, all of whom are trained in performing the rating scale. 
5.4.3 PDQ-39 
As per section 3.4.3 in the cross-sectional study methods, the patients 
completed the PDQ-39 (see appendices 9.4). This was completed at visits 1 
and 4. 
5.4.4 SCOPA-SLEEP 
As per section 3.4.4 in the cross-sectional study methods, the patients 
completed the SCOPA-SLEEP scale (see appendices 9.4). This was completed 
at visits 1 and 4. 
5.4.5 HADS 
As per section 3.4.5 in the cross-sectional study methods, the patients 
completed the HADS (see appendices 9.4). This was completed at visits 1 and 
4.  
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5.4.6 ECG 
A 12 lead ECG was performed at visits 1 and 4, firstly to look for any 
abnormalities that would be a contraindication, or require review by a 
cardiologist prior, to cardiopulmonary exercise testing (CPET) or an exercise 
intervention. Abnormalities to prompt further investigation include; ST segment 
changes (e.g. excessive ST depression, down sloping ST depression, abnormal 
ST elevation), bradyarrhythmias (e.g. heartblocks, slow atrial fibrillation) and 
tachyarrhythmias (e.g. ventricular tachycardia, supraventricular tachycardia). 
A baseline ECG and ECG monitoring is vital during CPET to differentiate 
normal and abnormal ECG responses to exercise. Certain ECG changes during 
exercise are absolute indications to terminate a CPET. 
During exercise, normal ECG responses include; minor insignificant changes in 
P-wave morphology, increases in septal Q-wave amplitude, superimposition of 
the P and T-waves of successive beats, slight decreases in R-wave amplitude, 
increases in T-wave amplitude, depression of the J point, minimal shortening of 
QRS duration and rate-related shortening of the QT interval (ACSM, 2010).   
5.5 Pulmonary function measurement 
At visits 2 and 5, full pulmonary function tests were performed as detailed in 
sections 3.5, 3.5.1, 3.5.2, 3.5.3 and 3.6. All participants had spirometry, flow 
volume curves, lung volumes (whole body plethysmography), diffusion and 
respiratory muscle strength measurements.  
5.6 Cardiorespiratory fitness measurement 
For visits 3 and 6, participants attended the Clinical Research Facility at the 
Royal Victoria Infirmary for CPET. Cardiopulmonary exercise testing was 
completed in compliance with local standard operating procedures for exercise 
testing within Newcastle University and Newcastle Hospitals NHS Trust. 
Aerobic capacity was assessed using a maximal progressive exercise test 
(ramp protocol) exercise test on an electro-magnetically controlled recumbent 
bicycle ergometer (Corival, Lode, Groningen, Netherlands, see figure 20). 
Expired gases were collected at rest for 5 minutes and continuously during the 
CPET. Online gas analysis was conducted using a Metalyzer 3B (Cortex, 
Leipzig, Germany, see figure 21). The Metalyzer works on the principle of a 
mixing chamber and expired gases were recorded and analysed, then averaged 
every 10 seconds.  As per the manufacturer’s guidelines, the system was 
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routinely calibrated for pressure, gas and volume (using a 3 litre Hans Rudolf 
syringe) prior to exercise tests.  A 12-lead ECG (Custo, CustoMed GmbH, 
Ottobrunn, Germany) was continuously monitored and systolic blood pressure 
(SBP) and diastolic blood pressure (DBP) (Tango, SunTech Medical, 
Morrisville, NS, USA) were recorded twice at rest, then every 3 minutes during 
exercise, at VO2peak and during recovery. During the test the patient wore a 
Hans Rudolf facemask. The test was supervised by myself and either a 
physiotherapist or an exercise physiologist with certification from the American 
College of Sports Medicine. The physiotherapist and exercise physiologist were 
blinded as to whether the participants were in the control or intervention group. 
The test procedure was explained to the patient, they were instructed not to talk 
during the test but to indicate via hand gestures (thumb up or down) and by 
indicating their rating of perceived exertion by pointing at the Borg Rating of 
Perceived Exertion (RPE) scale (Borg, 1998 ).     
As previously discussed a ramp protocol was chosen, due to this being more 
suitable for use in the elderly and those with PD, rather than a Bruce protocol 
for example which increases in steps of large increments which patients can 
find difficult to cope with and tire quickly. The ramp procedure CPET began with 
a seated rest period for 5 minutes, then a warm up period cycling at 20 watts for 
3 minutes and from then on there was a progressive increase of 10 watts per 
minute. The participant was asked to keep the revolutions per minute (rpm) at 
60 and continue until volitional exhaustion. Patients were asked to give 
approximately 1 minute warning before they felt they would need to end the 
test, to facilitate a final blood pressure measurement at the peak of exercise. 
The test was terminated when the patient was unable to pedal at a cadence of 
at least 50 rpm or they voluntarily terminated the test at exhaustion. The test 
was terminated by the supervisors if any of the standard criteria to terminate 
tests occurred; chest pain, arrhythmias, ischaemic changes on ECG or 
abnormal blood pressure response (>220 systolic, >115 diastolic, drop in 
systolic blood pressure (SBP) below resting pressure or drop in SBP with 
increasing workload accompanied by signs or symptoms). Peak oxygen 
consumption was defined as the average oxygen uptake during the last 30 
seconds of exercise and expressed as ml per kg of body weight per min.  Peak 
work rate was recorded and defined as the peak wattage when the test was 
terminated. Peak metabolic equivalents were calculated, by a standardised 
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method, as peak oxygen consumption/3.5 (Kaminsky et al., 2006). Monitoring 
continued during recovery. 
 
Figure 20: The electromagnetically controlled recumbent bicycle ergometer 
(Corival, Lode, Groningen, Netherlands) 
 
Figure 21: The Metalyzer (Cortex, Leipzig, Germany) 
5.7 Exercise capacity, six minute walk testing 
At visits 3 and 6, exercise capacity was assessed with the six minute walk test 
(6MWT), the distance a participant can walk in 6 minutes. The 6MWT is easier 
to administer, safer, better tolerated and more supremely reflects activities of 
daily living than other walk tests (e.g. shuttle walk test) (Enright, 2003). Validity 
and high test-retest reliability of the 6MWT has been found in patients with PD 
(Steffen and Seney, 2008). The 6MWT which is recognised for use to measure 
functional status, as a predictor for morbidity and mortality and as a pre-
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treatment and post-treatment comparison, was performed in line with ATS 
guidelines (ATS, 2002).  
The 6MWT was performed in a quiet flat corridor, with 30 metres marked by a 
tape measure and orange traffic cones. The participant was asked to walk 
clockwise around the cones and to cover as greater distance as possible. The 
participant was instructed not to jog or run and they were allowed to stop or take 
breaks if needed. The participant was informed when they had 3 minutes, 1 
minute and 10 seconds remaining. The total distance walked (six minute walk 
distance (6MWD)) was recorded. 
5.8 The structured exercise therapy intervention 
The intervention group underwent a structured exercise programme designed to 
improve cardiorespiratory fitness and exercise capacity. As reviewed in section 
2.4.4, there is a distinct paucity of research looking at the effect of exercise 
interventions on aerobic capacity or VO2peak in PD. Therefore a programme 
was designed by myself, in conjunction with a physiotherapist. A patient 
volunteer (Hoehn and Yahr III) was involved in the design and testing of the 
programme to ensure the programme was suitable, manageable and enjoyable 
for differing stages of PD including those with more advanced disease.  
With aerobic capacity, or VO2max, being a function of, and thus limited by, the 
ability of the cardiovascular system to supply (QT) and/or the skeletal muscles to 
use (a-vO2 diff) oxygen, the programme was designed to include both aerobic 
and resistance exercise. Despite exercise training being a cost effective, 
clinically proven, primary intervention that can reduce mortality, and even delay 
the onset of chronic diseases, there is no consensus of the type and dose of 
exercise required to accrue the required benefit (Gibala et al., 2012). It was 
traditionally acknowledged that within each level of exercise duration, 
frequency, programme length or initial fitness level, the greatest improvements 
in VO2max occurred when the participants exercised at higher intensities (e.g. 
from 90 to 100% of V̇O2max) with maximal gains at a frequency of 4 times per 
week and exercise duration of 35-45 minutes. Lower intensities still produced 
effective changes and reduced injury risk. As fitness improved, the change in 
VO2max decreased regardless of the intensity, frequency or duration of 
exercise, or to put it another way, the more unfit had the most to gain (Wenger 
and Bell, 1986).  In recent years there has been a growing interest in high 
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intensity interval training (HIT) which is considered able to serve as an effective 
alternative to traditional endurance-based training and although less well 
studied, low-volume HIT is acknowledged to stimulate physiological remodelling 
comparable to moderate intensity continuous training (Gibala et al., 2012). Thus 
no consensus remains on exercise programmes in health and disease.  
With the paucity of research in this area in PD, the exercise programme was 
designed to improve cardiorespiratory fitness, be manageable and safe for 
those with PD and use simple readily available equipment and thus make the 
study reproducible. The 12 week, 3 times per week, exercise intervention took 
place at Moor Park Healthy Living Centre (HLC), which is a gym with specially 
trained staff and resuscitation equipment that accepts public and NHS referrals. 
The HLC is a site for cardiac and pulmonary rehabilitation and all staff are 
trained to British Association of Cardiac Rehabilitation level 4 and GP referral 
qualification level 3. The participants were exercised in groups of 5, to facilitate 
a circuit training approach and the appropriate level of supervision (at least 2 
qualified staff per session). The HLC was closed to the public and other users 
during the exercise intervention. Pulse and oxygen saturations were measured 
before and after each session and heart rate monitors (RS400, Polar, Finland) 
were worn throughout. All sessions were in the afternoons and participants 
were exercised in the on state. 
The participants started and finished each session with a gentle 10 minute 
warm up and cool down respectively, including stretches. Each participant 
commenced at an aerobic station and moved around the 12 stations in a circuit. 
The stations alternated between aerobic and resistance. The aerobic stations 
were 4 minutes in duration and the resistance stations were 2 minutes in 
duration. Over the course of the 12 weeks the aerobic stations were increased 
to 5 minutes in duration as tolerated and time was allowed within the protocol 
for movement between equipment. To increase intensity over the 12 weeks, on 
relevant stations and within individual capabilities, speed, level, incline, step 
height and rating of perceived exertion were increased and weights and bands 
were added. Thus at the start of the study, aerobic stations comprised 6 x 4 
minutes (24 minutes) and resistance stations comprised 6 x 2 minutes (12 
minutes) totalling 36 minutes, with the addition of the warm up and cool down. 
This allowed for an increase on the aerobic stations of 1 minute per station later 
in the programme thus a total of 42 minutes and to allow for moving between 
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stations each session was approximately 45 minutes plus warm up and cool 
down. Table 15, below, summarises the exercise intervention. 
Station 
 
Exercise Progression 
1. Aerobic   
4 mins 
Treadmill  Increase speed  
 Increase incline 
 Increase to 5 mins 
2. Resistance 
2 mins 
 
Upright 
rowing 
 Add weights/band 
3. Aerobic  
4 mins 
Sit to stand 
From chair 
 
 Use a chair without arms 
 Increase to 5 mins 
 
4. Resistance 
2 mins 
 
Lateral 
raises 
 Add a band/weights 
5. Aerobic 
4 mins 
Marching/ 
Step ups 
 Add a step 
 Increase step height 
 Increase speed 
 Increase to 5 mins 
6. Resistance  
2 mins 
 
Triceps 
kick backs 
 Add weight 
7. Aerobic  
4 mins 
Hand bike  Increase Speed 
 Increase level 
 Increase to 5 mins 
8. Resistance 
2 mins 
 
Rotator 
cuff 
 Add a band/weights 
 Increase band difficulty 
9. Aerobic 
4 mins 
Recumbent 
Bike 
 Increase speed 
 Increase level 
 Increase to 5 mins 
10. Resistance 
2 mins 
 
Bicep curl  Add weights 
11. Aerobic 
4 mins 
 
 
Boxing  Increase exertion 
 Increase to 5 mins 
12. Resistance 
2 mins 
 
Chest 
stretch at 
90 degrees 
 
 Add band/ use wall 
Table 15: The exercise intervention 
At the end of each exercise session, in addition to the cool down, pulse and 
oxygen saturations check, all participants were observed for recovery prior to 
leaving the HLC.  
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5.9 Follow up 12 week assessments 
All assessments were repeated at 12 weeks, for the control group after normal 
care and for the intervention group after the exercise intervention. Visits 1, 2 
and 3 corresponded to visits 4, 5 and 6 respectively for repeat testing. After visit 
6, the control group were offered the opportunity to participate in a 12 week 
exercise programme at Moor Park Healthy Living Centre (HLC), if they wished 
to do so.  
5.10 Sample size calculations 
Based on previous stroke data (unpublished data and personal communication 
from a study based at the Clinical Research Facility) and the reported 
statistically significant improvement in VO2max in the Bergen et al 2002 study 
of 5ml/kg/min or 26%,  assuming a clinically significant improvement in VO2max 
to be 5 and assuming the standard deviation for the change in scores from 
baseline to post-intervention in VO2max to be no greater than 4 and setting 
alpha =0.05 and power at 0.9 and using a t-test for 2 related samples gives 
desired sample size of 6.7, rounding this up to 7 to achieve statistical 
significance (Bergen et al., 2002). 
Increase in 6MWT is likely to be the outcome of most relevance to the patients. 
Based on the work of Koseoglu et al who observed a mean increase in 6MWT 
distance of 108.1 (SD 31.954), setting alpha =0.05 and power at 80% and using 
a t-test for 2 related samples gives a sample size of 5 to achieve statistical 
significance (Koseoglu et al., 1997). Thus a RCT sample of 30 (15 intervention, 
15 control) allows for significant dropout to still achieve statistical significance in 
primary outcomes. A larger sample size was chosen to endeavour to have 
enough participants to achieve statistical significance as the increase in 6MWT 
observed in the Koseoglu study was large however their sample size was small 
and it was the only prior study that focused on PD, lung function and 6MWT. 
Quoted values for minimal clinically significant difference in 6MWT vary widely 
between different chronic diseases, in older adults small meaningful change of 
20 m and substantial change of 50 m for 6MWT has been quoted (Perera et al., 
2006). 
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Chapter 6. Results: Randomised control trial; The effect of an 
exercise intervention on pulmonary function, 
cardiorespiratory fitness and exercise capacity in idiopathic 
Parkinson’s disease 
With the distinction between the 2 sections of the study, this chapter concerns 
the results, discussion and conclusion of the RCT. Having been approached by 
the Northumbria PD team, 32 patients volunteered to take part in the RCT arm 
of the study. These 32 were randomised 1:1 intervention to control thus 16 in 
each group. A total of 27 participants completed the RCT. Two participants from 
the control group failed to complete the study. The first due to inability to 
perform the CPET, he was unable to pedal at a cadence of 50 rpm (this seemed 
to be due to failure to understand the instructions despite repeated attempts), 
thus the exercise test was abandoned. The second participant from the control 
group who failed to complete the study was admitted to hospital during the 12 
week normal care period, with an unrelated illness, but due to her ongoing 
investigations she was excluded from follow up testing. Thus of the 2 
participants who discontinued the study from the control group both had 
participation terminated by the investigator. Thus 14 participants completed the 
control group. In the intervention group 13 participants completed the study, 
thus 3 failed to complete. The first participant to withdraw underwent all 
baseline testing then subsequently declined the exercise intervention as she 
was concerned she would struggle to complete. The second and third 
withdrawals occurred during the intervention (1 participant’s relative became 
unwell and he withdrew to assume a carer’s role and 1 participant had a viral 
illness and decided to withdraw).Thus of the 3 who discontinued the study in the 
intervention group all 3 were withdrawals by the participants. Figure 22, below 
summarises the recruitment, drop out and completion. 
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The exercise intervention comprised 36 sessions. The 13 participants who 
completed the exercise intervention had a median session attendance of 32, 
Interquartile Range (IQR) 28 – 35, range 27 – 36. Thus all participants who 
completed the intervention attended at least 75% of structured exercise 
sessions. 
Results were inputted by a research assistant and second checked by myself. 
There was no missing data in the RCT. The data was not normally distributed, 
on review of histograms, as such medians and interquartile ranges are quoted 
and non-parametric tests (Wilcoxon signed-rank) were used to analyse the 
paired data. Visual inspection of the data distribution using histograms was 
32 patients 
Recruited and consented 
Visit 1 and  
Randomisation  
Intervention group 
n = 16 
Control group 
n = 16  
Visits 2 and 3 
Discontinued = 1 
Visits 2 and 3 
Discontinued = 1 
12 weeks  
exercise intervention 
Discontinued = 2 
 
12 weeks 
normal care 
Discontinued = 1 
Visits 4, 5 and 6 
Completed = 13  
Visits 4, 5 and 6 
Completed = 14  
Figure 22: Randomised control trial; recruitment, drop out and completion 
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used for assessing normality, as in chapter 4 in cases where there was any 
discrepancy in the distribution on visual inspection the statistical Kolmogorov-
Smirnov test of normality was used. Alpha was set at 0.05. The study produced 
interesting results in two distinct ways; the effect of a 12 week exercise 
intervention and the physiological response to an acute episode of maximal 
exercise in PD. The following tables detail the group median and interquartile 
ranges for the variables pre and post the exercise intervention in the control and 
intervention groups. The final 2 columns of the tables detail the median change 
from baseline scores, and interquartile ranges, in the individuals in the control 
group and intervention group with the associated z scores and p scores from 
the Wilcoxon signed-rank test results.     
Table 16 below, details the demographics of the control and intervention groups 
pre and post the exercise intervention. The median ages of the control and 
intervention groups were comparable at 67.5 and 68 years respectively, while 
the duration of disease since diagnosis was lower in the intervention group than 
the control group. Both before and after the intervention, the group median BMI 
and levodopa equivalent dose were lower in the intervention group than the 
control group. In either group BMI was not significantly changed after the 12 
week exercise intervention or 12 weeks of normal care. As described in section 
4.1 of the cross-sectional study, levodopa equivalent dose (LED) was calculated 
using the conversion formulae developed by Tomlinson et al (Tomlinson et al., 
2010). 
The UPDRS section scores and Hoehn and Yahr scores pre and post the 
intervention are reported in table 17. It was notable that both before and after, 
the control group subjectively reported their parkinsonian symptoms, as 
reported in UPDRS sections 1 and 2, to be worse than those of the intervention 
group noting also that the control group had longer median disease duration 
than the intervention group. At baseline the UPDRS 3 objective median score 
was higher in the intervention group. Statistically significant changes from 
baseline after the 12 weeks of exercise or normal care were only seen in the 
intervention group as improvements in UPDRS 1 and 2 section scores. 
Although UPDRS section 3 in the intervention group changed from baseline by 
a median improvement of 2 points, this did not reach statistical significance. 
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Resting cardiovascular parameters and peak heart rate pre and post the 
intervention or normal care are reported in table 18. Cardiorespiratory fitness 
and exercise capacity pre and post intervention or normal care are reported in 
table 19. Both the control group and the intervention group had median normal 
resting systolic and diastolic blood pressure at baseline and follow up, with no 
statistically significant changes in these parameters. At follow up, resting heart 
rate showed a statistically significant drop in both the control and the 
intervention groups. At follow up, peak heart rate achieved during the maximal 
cardiopulmonary exercise test also fell in both the control and intervention 
groups. 
The primary outcomes in the RCT were those of cardiorespiratory fitness 
(aerobic capacity), as measured by VO2peak and exercise capacity, as 
measured by six minute walk distance (6MWD). In the control group there were 
no significant changes after 12 weeks in anaerobic threshold at percent of 
VO2max predicted, VO2peak, peak metabolic equivalents, peak work rate and 
6MWD. In contrast, in the intervention group after 12 weeks structured exercise 
therapy statistically significant improvements were seen in all these outcomes. 
In the intervention group the median individual change from baseline was 9.7% 
for anaerobic threshold at percent of VO2max predicted, 2.0ml/kg/min for 
VO2peak, 0.7METS for peak metabolic equivalents, 8.0watts for peak work rate 
and 39.8m for 6MWD. The relevance of anaerobic threshold at percentage of 
VO2max predicted is that the better an individual’s cardiorespiratory fitness is, 
the closer the anaerobic threshold should be to the VO2max. In our study 
population this anaerobic threshold at percent of VO2max predicted improved 
by almost 10%. Figure 23 illustrates the effects of the exercise intervention or 
normal care on median change from baseline for anaerobic threshold 
percentage of VO2max predicted. Figure 24 illustrates the effects of the 
exercise intervention or normal care on median change from baseline for 
VO2peak, thus cardiorespiratory fitness.
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Figure 23: Effects of exercise intervention on median change from baseline 
anaerobic threshold percentage of VO2max predicted 
 
 
Figure 24: Effects of exercise intervention on median change from baseline on 
VO2peak, cardiorespiratory fitness  
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Having reported the objective outcomes of aerobic capacity and exercise 
capacity it is important to consider the effects of the exercise intervention on 
self-rated reports of quality of life, sleep, anxiety and depression. Table 20 
below, reports the effect of the exercise intervention or 12 weeks normal care 
on the PDQ 39 single index, SCOPA-SLEEP scores and the Hospital Anxiety 
and Depression Scale (HADS) scores. Following the exercise intervention in the 
intervention group or 12 weeks normal care in the control group, statistically 
significant results were only seen in the intervention group and these were as 
improvements in the PDQ 39 single index, SCOPA C, SCOPA D, HADS A and 
HADS D scores. The median change from baseline in the intervention group for 
these parameters was -2.2 for the PDQ 39 single index, -1.0 for overall quality 
of night time sleep, -1.0 for sleepiness in the daytime and evenings, -1.0 for 
anxiety and -1.0 for depression. For the PDQ-39, SCOPA-SLEEP and HADS, 
lower score reflect an improvement in symptoms.  
Table 21 below, reports the pulmonary function and respiratory muscle strength 
test results pre and post either the exercise intervention or 12 weeks normal 
care. As noted in the cross-sectional study of pulmonary function, in both the 
control and intervention groups, the inspiratory muscle strength tests (MIP and 
SNIP) were worse than the expiratory muscle strength test (MEP) and in 
addition to this, SNIP was again worse than MIP. The pulmonary function and 
respiratory muscle strength tests focused on in the RCT were predominantly the 
effort dependent variables to look at the effect of exercise. In both the control 
and the intervention groups, no statistically significant changes were seen in 
percent predicted values of FEV1, FVC, PEF, MEP, MIP and SNIP. Of note the 
median FEV1/FVC of both the control and intervention groups, pre and post, 
exceeded 70%. Whilst there was a trend in the intervention group of an 
improvement post exercise intervention in percent predicted MIP, this did not 
reach statistical significance and was also not reflected in the SNIP results.   
 
 
1
4
3
 
  
C
o
n
tr
o
l 
 
B
a
s
e
lin
e
  
N
=
1
4
 
M
e
d
ia
n
 (
IQ
R
) 
In
te
rv
e
n
ti
o
n
 
B
a
s
e
lin
e
  
N
=
1
3
 
M
e
d
ia
n
 (
IQ
R
) 
C
o
n
tr
o
l 
F
o
llo
w
 u
p
  
 
N
=
1
4
 
M
e
d
ia
n
 (
IQ
R
) 
In
te
rv
e
n
ti
o
n
 
F
o
llo
w
 u
p
  
N
=
1
3
 
M
e
d
ia
n
 (
IQ
R
) 
C
o
n
tr
o
l 
c
h
a
n
g
e
  
fr
o
m
 b
a
s
e
lin
e
  
N
=
1
4
 
M
e
d
ia
n
 (
IQ
R
) 
W
ilc
o
x
o
n
 s
ig
n
e
d
-r
a
n
k
 
te
s
t 
In
te
rv
e
n
ti
o
n
 c
h
a
n
g
e
 
fr
o
m
 b
a
s
e
lin
e
  
N
=
1
3
 
M
e
d
ia
n
 (
IQ
R
) 
W
ilc
o
x
o
n
 s
ig
n
e
d
-r
a
n
k
 
te
s
t 
P
D
Q
 3
9
 s
in
g
le
 
in
d
e
x
 
2
2
.1
 
(9
.2
 –
 3
0
.6
) 
9
.4
  
(6
.2
 –
 1
7
.0
) 
1
7
.1
 
(8
.2
 –
 3
0
.4
) 
6
.3
 
(3
.3
 –
 1
2
.6
) 
-0
.7
 (
-6
.6
 –
 1
.0
) 
Z
 =
 -
1
.2
2
4
, 
P
 =
 0
.2
2
1
 
-2
.2
 (
-4
.5
 –
 0
.1
) 
Z
 =
 -
2
.2
0
1
, 
P
 =
 0
.0
2
8
 
S
C
O
P
A
 B
 
4
.5
 
(1
.8
 –
 8
.3
) 
4
.0
 
(2
.5
 –
 6
.0
) 
5
.5
 
(0
.7
5
 –
 8
.3
) 
3
.0
 
(1
.0
 –
 4
.5
) 
0
.0
 (
-1
.2
5
 –
 1
.2
5
) 
Z
 =
 -
0
.1
0
3
, 
P
 =
 0
.9
1
8
 
-1
.0
 (
-3
.5
 –
 0
.0
) 
Z
 =
 -
1
.5
8
6
, 
P
 =
 0
.1
1
3
 
S
C
O
P
A
 C
 
 
3
.5
 
(1
.0
 –
 5
.0
) 
3
.0
 
(2
.0
 –
 4
.0
) 
3
.0
 
(1
.0
 –
 4
.0
) 
2
.0
 
(1
.5
 –
 3
.5
) 
0
.0
 (
-1
.0
 –
 0
.0
) 
Z
 =
 -
1
.1
8
6
, 
P
 =
 0
.2
3
6
 
-1
.0
 (
-1
.0
 –
 0
.0
) 
Z
 =
 -
2
.6
3
6
, 
P
 =
 0
.0
0
8
 
S
C
O
P
A
 D
 
 
3
.5
 
(2
.8
 –
 5
.5
) 
4
.0
 
(1
.5
 –
 6
.0
) 
4
.0
 
(1
.0
 –
 7
.0
) 
2
.0
 
(0
.5
 –
 3
.5
) 
0
.0
 (
-1
.3
 –
 2
.3
) 
Z
 =
 -
0
.3
8
1
, 
P
 =
 0
.7
0
4
 
-1
.0
 (
-2
.5
 –
 0
.0
) 
Z
 =
 -
2
.4
4
6
, 
P
 =
 0
.0
1
4
 
H
A
D
S
 A
 
 
5
.0
 
(2
.8
 –
 8
.3
) 
3
.0
 
(1
.5
 –
 6
.0
) 
4
.0
 
(3
.3
 –
 7
.3
) 
1
.0
 
(0
.0
 –
 3
.5
) 
-1
.0
 (
-2
.0
 –
 0
.0
) 
Z
 =
 -
1
.0
8
5
, 
P
 =
 0
.2
7
8
 
-1
.0
 (
-2
.5
 –
 0
.0
) 
Z
 =
 -
2
.1
5
5
, 
P
 =
 0
.0
3
1
 
H
A
D
S
 D
 
 
6
.0
 
(3
.0
 –
 8
.3
) 
4
.0
 
(2
.0
 –
 5
.0
) 
5
.5
 
(2
.8
 –
 9
.3
) 
2
.0
 
(1
.0
 –
 2
.5
) 
 
0
.5
 (
-1
.3
 –
 1
.0
) 
Z
 =
 -
0
.0
7
2
, 
P
 =
 0
.9
4
3
 
-1
.0
 (
-3
.0
, 
-1
.0
) 
Z
 =
 -
2
.9
6
9
, 
P
 =
 0
.0
0
3
 
T
a
b
le
 2
0
: 
P
D
Q
 3
9
 s
in
g
le
 i
n
d
e
x
, 
S
C
O
P
A
-S
L
E
E
P
 a
n
d
 H
A
D
S
 s
c
o
re
s
 p
re
 a
n
d
 p
o
s
t 
in
te
rv
e
n
ti
o
n
 
 
1
4
4
 
  
C
o
n
tr
o
l 
 
B
a
s
e
lin
e
  
N
=
1
4
 
M
e
d
ia
n
 (
IQ
R
) 
In
te
rv
e
n
ti
o
n
 
B
a
s
e
lin
e
  
N
=
1
3
 
M
e
d
ia
n
 (
IQ
R
) 
C
o
n
tr
o
l 
F
o
llo
w
 u
p
  
 
N
=
1
4
 
M
e
d
ia
n
 (
IQ
R
) 
In
te
rv
e
n
ti
o
n
 
F
o
llo
w
 u
p
  
N
=
1
3
 
M
e
d
ia
n
 (
IQ
R
) 
C
o
n
tr
o
l 
c
h
a
n
g
e
  
fr
o
m
 b
a
s
e
lin
e
  
N
=
1
4
 
M
e
d
ia
n
 (
IQ
R
) 
W
ilc
o
x
o
n
 s
ig
n
e
d
-r
a
n
k
 
te
s
t 
In
te
rv
e
n
ti
o
n
 c
h
a
n
g
e
 
fr
o
m
 b
a
s
e
lin
e
  
N
=
1
3
 
M
e
d
ia
n
 (
IQ
R
) 
W
ilc
o
x
o
n
 s
ig
n
e
d
-r
a
n
k
 
te
s
t 
F
E
V
1
  
%
p
re
d
ic
te
d
 
1
1
0
.0
 
(9
9
.5
 –
 1
1
7
.0
) 
1
1
8
.0
 
(9
7
.0
 –
 1
2
5
.0
) 
1
0
6
.5
 
(9
7
.8
 –
 1
1
7
.5
) 
1
1
5
.0
 
(9
9
.0
 –
 1
2
8
.0
) 
-1
.0
 (
-4
.5
 –
 2
.3
) 
Z
 =
 -
1
.0
2
6
, 
P
 =
 0
.3
0
5
 
0
.0
 (
-2
.0
 –
 6
.0
) 
Z
 =
 -
1
.1
7
5
, 
P
 =
 0
.2
4
0
 
F
V
C
  
%
p
re
d
ic
te
d
 
1
2
2
.5
 
(1
1
0
.0
 –
 1
3
4
.0
) 
1
2
5
.0
 
(1
0
7
.0
 –
 1
3
0
.5
) 
1
2
3
.5
 
(1
1
5
.3
 –
 1
2
7
.0
) 
1
2
6
.0
 
(1
0
7
.0
 –
 1
2
9
.5
) 
1
.5
 (
-6
.3
 –
 5
.3
) 
Z
 =
 -
0
.1
4
0
, 
P
 =
 0
.8
8
9
 
-1
.0
 (
-1
0
.0
 –
 3
.0
) 
Z
 =
 -
0
.8
9
0
, 
P
 =
 0
.3
7
3
 
P
E
F
  
%
p
re
d
ic
te
d
 
1
0
2
.0
 
(8
7
.0
 –
 1
1
1
.0
) 
1
1
0
.0
 
(9
2
.5
 –
 1
2
5
.5
) 
1
0
5
.5
 
(9
4
.0
 –
 1
1
2
.5
) 
1
1
2
.0
 
(1
0
0
.0
 –
 1
2
5
.0
) 
1
.0
 (
-1
.5
 –
 1
2
.3
) 
Z
 =
 -
1
.6
0
1
, 
P
 =
 0
.1
0
9
 
2
.0
 (
-3
.0
 –
 9
.5
) 
Z
 =
 -
1
.2
9
5
, 
P
 =
 0
.1
9
5
 
M
E
P
  
%
p
re
d
ic
te
d
 
9
3
.7
 
(7
8
.8
 –
 1
1
3
.9
) 
9
4
.4
 
(7
7
.8
 –
 1
0
4
.6
) 
9
8
.4
 
(8
4
.6
 –
 1
0
4
.9
) 
9
0
.8
 
(6
4
.5
 –
 1
0
1
.8
) 
3
.2
 (
-1
6
.1
 –
 2
0
.6
) 
Z
 =
 -
0
.3
4
5
, 
P
 =
 0
.7
3
0
 
-1
.1
 (
-2
5
.2
 –
 5
.5
) 
Z
 =
 -
0
.9
4
3
, 
P
 =
 0
.3
4
5
 
M
IP
  
%
p
re
d
ic
te
d
 
8
1
.9
 
(7
4
.0
 –
 9
5
.0
) 
8
1
.3
 
(5
0
.4
 –
 1
2
9
.5
) 
9
2
.4
 
(6
9
.8
 –
 1
1
1
.5
) 
9
3
.6
 
(7
1
.8
 –
 1
1
6
.5
) 
5
.8
 (
-4
.4
 –
 1
8
.8
) 
Z
 =
 -
0
.9
7
3
, 
P
 =
 0
.3
3
1
 
1
5
.2
 (
-5
.5
 –
 2
4
.5
) 
Z
 =
 -
1
.6
4
2
, 
P
 =
 0
.1
0
1
 
S
N
IP
  
%
p
re
d
ic
te
d
 
6
1
.6
 
(3
4
.4
 –
 9
7
.9
) 
6
8
.6
 
(3
7
.3
 –
 9
1
.3
) 
6
2
.5
 
(4
3
.5
 –
 9
0
.1
) 
7
6
.6
 
(5
9
.3
 –
 8
7
.0
) 
7
.8
 (
-7
.9
 –
 1
5
.1
) 
Z
 =
 -
1
.0
9
9
, 
P
 =
 0
.2
7
2
 
2
.8
 (
-1
9
.4
 –
 3
1
.5
) 
Z
 =
 -
0
.6
6
4
, 
P
 =
 0
.5
0
7
 
T
a
b
le
 2
1
: 
P
u
lm
o
n
a
ry
 f
u
n
c
ti
o
n
 a
n
d
 r
e
s
p
ir
a
to
ry
 m
u
s
c
le
 s
tr
e
n
g
th
 p
re
 a
n
d
 p
o
s
t 
in
te
rv
e
n
ti
o
n
 
145 
 
As noted at the beginning of this results section, the study produced interesting 
results in two distinct ways; the effect of a 12 week exercise intervention and 
the physiological response to an acute episode of maximal exercise in PD. The 
results above focused on the effect of a 12 week exercise intervention, the table 
below, table 22, reports the effect of an acute episode of maximal exertion in 
the form of the cardiopulmonary exercise test. 
 
 Control  
Baseline  
N=14 
Median (IQR) 
Intervention 
Baseline  
N=13 
Median (IQR) 
Control 
Follow up   
N=14 
Median (IQR) 
Intervention 
Follow up  
N=13 
Median (IQR) 
Peak heart 
rate  
(bpm) 
122.00 
(113.00 - 
128.75) 
124.00 
(109.00 -  
129.5) 
116.50 
(107.75 
129.25) 
120.00 
(103.50 -  
128.00) 
Heart rate 
%predicted 
75.30 
(67.38 -  
82.35) 
76.69 
(67.59 -  
81.22) 
75.29 
(64.75 - 
82.57) 
75.90 
(68.05 -  
80.06) 
Table 22: Heart rate response to cardiopulmonary exercise test 
As reported also in table 18, it is noted that in both the control and intervention 
groups, pre and post the intervention or normal care 12 weeks, the peak heart 
rate achieved during the maximal cardiopulmonary exercise tests was 
significantly lower than the predicted value. At baseline and follow up, each 
group median peak heart rate was below 77% predicted. This result was not 
reflected in the median VO2peaks achieved, at baseline and follow up, in each 
group which were equal to or exceeded 90% predicted. The only heart rate 
limiting medication that any participant was taking was a beta blocker. Two 
participants in the intervention group and two in the control group were 
prescribed beta blockers. Allowing for this, when the heart rate data was 
analysed not including those on beta blockers, there was not a significant 
difference in the findings and the peak heart rates achieved remained 
significantly lower than would be predicted. There is considerable debate on the 
most appropriate predication equation for maximal heart rate with the most well 
recognised being 220-age, however a vast number of other prediction equations 
exist (Robergs and Landwher, 2002). Using 3 different maximal heart rate 
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prediction equations continued to show the peak heart rate achieved in our 
population remained well below the expected value.   
The effect of a structured exercise intervention and the physiological response 
to an acute episode of maximal exercise in PD warrant further detailed 
discussion.  
6.1.1 Discussion 
The RCT primarily looked at the effect of a structured exercise intervention on 
cardiorespiratory fitness as defined by VO2peak, but also looked at the effect of 
an exercise intervention on markers of cardiovascular health, exercise capacity 
(6MWD), pulmonary function, respiratory muscle strength, parkinsonian 
symptoms, Parkinson’s disease stage, quality of life, sleep, anxiety and 
depression. The above looked at the effect of a period of training on these 
outcomes, and the study also had the benefit of assessing a cardiorespiratory 
response to an acute episode of maximal exercise. With scope of the study 
covering all these areas, the discussion will be divided accordingly. 
Before discussing the effect of the exercise intervention, the differences 
between the control group and intervention group at baseline warrant further 
discussion. The median age between the groups was comparable at 67.5 years 
in the control group and 68.0 years in the intervention group however the 
control group had a longer disease duration (95.5 months versus 33.0 months) 
and higher levodopa equivalent dose (520.0mg versus 400.0mg) than the 
intervention group. With PD being a progressive disease it is unsurprising that 
those with a longer disease duration required higher doses of medication. In the 
patient scored subjective rating scales of UPDRS part 1, UPDRS part 2, PDQ-
39 single index and HADS A and HADS D the control group rated themselves 
worse than the intervention group (UPDRS part 1 10.5 versus 5.0, UPDRS part 
2 11.0 versus 6.0, PDQ-39 single index 22.1 versus 9.4, HADS A 5.0 versus 3.0 
and HADS D 6.0 versus 4.0). Again this may be expected that those with the 
longer disease duration have a greater impact of their PD on their physical 
abilities, quality of life, anxiety and depression. Interestingly on the objective 
ratings of disease stage (Hoehn and Yahr), UPDRS 3, cardiorespiratory fitness 
(VO2peak) and exercise capacity (6MWD) this trend was not continued. Both 
groups had the same median Hoehn and Yahr score of 2.0 and across the other 
outcome measures the control group performed better than the intervention 
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group (UPDRS 3  20.5 versus 23.0, VO2peak 20.0ml/kg/min versus 
16.0ml/kg/min and 6MWD 532.7m  versus 461.1m). This was a very interesting 
finding as it may be expected that those with longer disease duration would 
have more advanced disease stage, worse UPDRS motor scores, worse 
cardiorespiratory fitness and worse exercise capacity however this was not the 
case. A possible reason for this difference in objective and subjective findings 
may be the effect of having a progressive neurodegenerative disorder for a 
longer period of time affects psychology and perceptions of health faster and 
more profoundly than it affects ability.   
6.1.2 Discussion: Effect of an exercise intervention on cardiorespiratory 
fitness and exercise capacity 
In the intervention group only, there were significant changes after 12 weeks in 
anaerobic threshold at percent of VO2max predicted, VO2peak, peak metabolic 
equivalents, peak work rate and 6MWD. In the intervention group the median 
individual change from baseline was 9.7% for anaerobic threshold at percent of 
VO2max predicted, 2.0ml/kg/min for VO2peak, 0.7METS for peak metabolic 
equivalents, 8.0watts for peak work rate and 39.8m for 6MWD. The 
improvement seen in aerobic capacity as measured by VO2peak was 
comparable to that reported in healthy sedentary adults following a period of 
structured exercise of 10 – 30% improvement (Samitz and Bachl, 1991). Thus it 
would appear that individuals with PD can enjoy the same level of benefits in 
terms of aerobic capacity with a period of exercise training as normal, healthy 
individuals. As would be expected with an increase in aerobic capacity, and as 
such fitness, the anaerobic threshold moved closer to the VO2peak, the peak 
metabolic equivalent improved, the peak work rate improved and the 6MWD 
distance improved. With the associated improvement in 6MWD distance, 
considering the availability of equipment for cardiopulmonary exercise testing 
and the skills of the technicians required to undertake CPET tests, 6MWD could 
be considered for use as a surrogate marker for aerobic capacity if the gold 
standard is not available. While predominantly discussing VO2peak, it is 
important to mention the concept of metabolic equivalents or METS. The MET 
concept provides a simple technique to describe functional capacity and with 
known energy expenditure values, in METS and watt units, for household task 
and recreational activities allows simple visual imagery of energy expenditure 
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(Jette et al., 1990). The increase in METS observed in the intervention group 
could represent the increased ability of an individual to be able to perform heavy 
household chores rather than light household chores. 
As discussed in section 2.4, after endurance training, SV is increased at rest 
and during submaximal and maximal exercise, whilst HR is decreased at rest 
and during submaximal exercise and unchanged at maximal work rates. 
Training increases plasma volume and end diastolic volume and results in more 
elastic recoil. Long term responses also include hypertrophy of cardiac muscle 
fibres and reduction in blood pressure. Interestingly both the control and the 
intervention group showed a statistically significant reduction in resting heart 
rate after the 12 week period of normal care or the exercise intervention 
respectively, thus this effect cannot be concluded to be in response to training.   
In both groups there was no statistically significant change in resting systolic or 
diastolic blood pressure in either group. There are potential reasons why these 
abnormal cardiovascular responses to a period of training have occurred, 
despite the observed increase in aerobic capacity, VO2peak. It is reported that 
the dysautonomia in Parkinson’s disease involves neurocardiological 
abnormalities with postganglionic sympathetic noradrenergic lesions which may 
be responsible for this abnormal cardiac response to training (Goldstein, 2003). 
As previously discussed Cardiac output (QT) is the volume of blood the heart 
pumps out in one minute and is the product of the stroke volume (SV) ,which is 
the amount of blood pumped out per beat, and the number of heart beats per 
minute (heart rate (HR)) (Vincent, 2008). The arterial-venous oxygen difference 
(a-vO2 diff) is the difference between the oxygen concentration of the arterial 
and mixed venous blood (Manley, 1996). An individual’s aerobic capacity or 
maximum oxygen uptake (VO2max) is a function of, and thus limited by, the 
ability of the cardiovascular system to supply (QT) and/or the skeletal muscles 
to use (a-vO2 diff) oxygen (Manley, 1996, Jakovljevic et al., 2012a). Thus after 
a period of training, an observed improvement in VO2peak is contributed to by 
improvement in QT and a-vO2diff to varying degrees. Dependent on training 
modality, skeletal muscles undergo fiber hypertrophy and hyperplasia and 
increased recruitment (Manley, 1996). Endurance training also facilitates a 
greater capacity for blood flow in skeletal muscles by increasing the numbers of 
capillaries (Prior et al., 2004). Thus it could be postulated that in our population 
the improvements seen in VO2peak, without significant associated cardiac 
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changes could be due to a greater contribution of improvement in a-vO2diff 
rather than QT. This could be due to the type of exercise training used or the 
physiological response in individuals with PD. 
6.1.3  Discussion: Effect of an exercise intervention on pulmonary 
function and respiratory muscle strength 
Very little research had been done previously looking at the effect of exercise 
on pulmonary function in PD. A small study by Koseoglu et al, looked at the 
effect of pulmonary rehabilitation in PD on pulmonary function test results and 
whilst trends of improvement existed, the results failed to reach statistical 
significance which may have been due to the small number of participants and 
the intervention length of 5 weeks only (Koseoglu et al., 1997). A further small 
study measured respiratory muscle strength and endurance, perception of 
dyspnoea and quality of life in 20 PD patients, Hoehn and Yahr stages II-III. The 
patients were then divided into 2 groups of 10, 1 group received 12 weeks of ½ 
hour, 6 times per week specific inspiratory muscle training and the other group 
received sham training. Significant improvements in inspiratory muscle strength, 
endurance and perception of dyspnoea were seen only in the intervention group 
(Inzelberg et al., 2005).  
 As highlighted in table 21, in both the control and intervention groups, the 
inspiratory muscle strength tests (MIP and SNIP) were worse than the 
expiratory muscle strength test (MEP) and in addition to this, SNIP was again 
worse than MIP. In both the control and the intervention groups, no statistically 
significant changes were seen in percent predicted values of FEV1, FVC, PEF, 
MEP, MIP and SNIP. Whilst there was a trend in the intervention group of an 
improvement post exercise intervention in percent predicted MIP, this 
unfortunately did not reach statistical significance and was also not reflected in 
the SNIP results. 
While exercise produces short term responses to meet immediate demand, 
exercise training produces long term adaptations. These adaptations include 
cardiovascular, respiratory, skeletal muscles, bone, metabolic and hormonal 
adaptations. The magnitude of these adaptations depends on a number of 
factors including pre-exercise fitness level, type of exercise programme, 
intensity and duration. Respiratory adaptations with training are predominantly 
an increase in pulmonary ventilation and an increase in pulmonary diffusion 
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during maximal exertion. With this in mind, this study may have failed to reach 
statistical significance in changes in lung function and respiratory muscle 
strength for a number of reasons. The effort dependent indices selected to 
review as outcome measures may not best reflect pulmonary ventilation and 
would not reflect pulmonary diffusion where the most benefit is likely to occur. 
The modest numbers in the RCT section of study may have impacted on the 
results. The type of exercise intervention and programme designed was not 
specifically targeting respiratory muscles and thus significant improvements in 
MEP, MIP and SNIP were not seen. Noting the trend in the increase in MIP in 
this study in the intervention group, and the significant improvements in 
inspiratory muscle strength, endurance and perception of dyspnoea in response 
to inspiratory muscle training observed by Inzelberg et al, raises the question 
about the potential role of inspiratory muscle training in this group. Further to 
this, potential exists for a role for expiratory muscle training, upper extremity 
exercise and pulmonary rehabilitation style training to assess if these improve 
pulmonary function and respiratory muscle strength in PD. 
6.1.4 Discussion: Effect of an exercise intervention on parkinsonian 
symptoms, Parkinson’s disease stage, quality of life, sleep, anxiety 
and depression 
While Parkinson’s disease stage, as defined by Hoehn and Yahr, remained the 
same after the 12 week exercise intervention, statistically significant changes 
from baseline after the 12 weeks of exercise or normal care were only seen in 
the intervention group as improvements in UPDRS 1 and 2 section scores. The 
intervention group change from baseline UPDRS part 1 score improved by -1.0 
point and the UPDRS part 2 score improved by -2.0 points.  Although not 
reaching statistical significance, the UPDRS section 3 in the intervention group 
changed from baseline by a median improvement of -2.0 points. Following the 
exercise intervention in the intervention group or 12 weeks normal care in the 
control group, statistically significant results were only seen in the intervention 
group and these were as improvements in the PDQ 39 single index, SCOPA C, 
SCOPA D, HADS A and HADS D scores. The median change from baseline in 
the intervention group for these parameters was -2.2 for the PDQ 39 single 
index, -1.0 for overall quality of night time sleep, -1.0 for sleepiness in the 
daytime and evenings, -1.0 for anxiety and -1.0 for depression. Thus structured 
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exercise therapy in PD improves parkinsonian symptoms, quality of life, sleep, 
anxiety and depression and is an important therapy to improve wellbeing and 
health.  
The mechanism for how exercise in healthy individuals and in those with 
diseases, including PD, improves these symptoms is complex and still not fully 
understood with a number of potential philosophies. Neurotrophins most likely 
play a significant role and research interest in them has increased over recent 
years. To date no pharmacological treatments have been shown to be 
unequivocally neuroprotective in PD (Ahlskog, 2011).  Exercise is known to 
provoke a surge of molecular and cellular processes that support brain 
plasticity. Activity dependent neuroplasticity is supported by neurotrophins, 
which have the ability to signal neurons to survive, differentiate and grow 
(Hennigan et al., 2007, Johnston, 2009, Neeper et al., 1995, Neeper et al., 
1996, Vaynman and Gomez-Pinilla, 2005). Brain derived neurotrophic factor 
(BDNF) seems to be the most susceptible neurotrophin to regulation by 
exercise (Johnston, 2009, Neeper et al., 1995, Vaynman and Gomez-Pinilla, 
2005) Studies have shown decreased BDNF expression within the substantia 
nigra of PD brains as compared to controls (Howells et al., 2000, Parain et al., 
1999). A common single nucleotide polymorphism (SNP) in the BDNF gene, 
G196A, results in a methionine- valine substitution at codon 66 (Val66Met). The 
presence of this minor allele leads to reduced depolarisation induced secretion 
of BDNF from neuronal cells (Egan et al., 2003, Chen et al., 2004). With this 
neural plasticity in mind Fox et al, succinctly summarised philosophies of how 
exercise enhances neuroplasticity in PD; intense activities maximise synaptic 
plasticity, complex activities encourage greater structural adaptation, rewarding 
activities increase dopamine levels, dopaminergic neurons are highly 
responsive to exercise and notably that exercise in addition to improving 
symptoms when the disease is already present can also retard the onset of PD 
(Fox et al., 2006, Archer et al., 2011).   
It must also be remembered that the effects may be “knock on” effects, for 
example poor sleep and early morning waking can be associated depression, 
thus improving depression may also improve sleep. Similarly if parkinsonian 
symptoms are disturbing individual’s sleep, if exercise improves the 
parkinsonian symptoms the sleep may also improve. Previous studies, as 
highlighted in a meta-analysis, indicate that regular exercise increases total 
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sleep time and self-reports epidemiological data support that acute and chronic 
exercise promotes sleep (Kubitz et al., 1996, Driver and Taylor, 2000). The 
exact mechanisms of how exercise improves sleep are not fully understood and 
most studies reporting the effects of exercise on sleep have predominantly 
included young sleepers without problematic sleep. As described and discussed 
the pathophysiology of how exercise improves outcomes such as sleep, anxiety 
and depression is not fully understood and remains complex with a significant 
amount of overlap.  
6.1.5 Discussion: Heart rate response to exercise  
The RCT was primarily designed to look at the long term adaptations to 
exercise training, however had the benefit of also being able to assess the short 
term response to exercise to meet immediate demand during a maximal 
cardiopulmonary exercise test.  In both the control and intervention groups, pre 
and post the intervention or normal care 12 weeks, the peak heart rate achieved 
during the maximal cardiopulmonary exercise tests was significantly lower than 
the predicted value. At baseline and follow up, each group median peak heart 
rate was below 77% predicted. This result was not reflected in the median 
VO2peaks achieved, at baseline and follow up, in each group which were equal 
to or exceeded 90% predicted.  This result was not significantly affected when 
individuals on rate limiting medication were excluded.  
As discussed in section 2.4, An individual’s aerobic capacity or maximum 
oxygen uptake (VO2max) is a function of, and thus limited by, the ability of the 
cardiovascular system to supply (QT) and/or the skeletal muscles to use (a-vO2 
diff) oxygen (Manley, 1996, Jakovljevic et al., 2012a). As work increases the QT 
increases in an almost linear pattern up to a maximum, this occurs due to 
increases in heart rate (HR) and stroke volume (SV) (Manley, 1996). Although 
both HR and SV increase with exertion, the contribution to the increase QT is 
much greater from the increase in HR particularly at high exertion 
(Higginbotham et al., 1986). Maximal achievable heart rate (HRmax) is 
considered to be related to age and although there a numerous prediction 
equations, HRmax = 220-age is commonly accepted and used (Robergs and 
Landwher, 2002). 
Given that all participants achieved anaerobic threshold and the median VO2 
peaks achieved exceeded 90% predicted, it is very unlikely that the poor heart 
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rate response to exercise seen was related to effort or the choice of CPET 
modality with the bicycle causing leg fatigue and early termination of an 
exercise test. As such it must be considered that there are other potential 
causes for a poor heart rate response to exercise in PD patients. It is likely that 
chronotropic incompetence, the inability of the heart to increase its rate with 
increased activity or demand is the cause. Chronotropic incompetence, 
common in cardiovascular disease, causes exercise intolerance, deterioration in 
quality-of-life and very importantly is an independent predictor of adverse 
cardiovascular events and overall mortality (Brubaker and Kitzman, 2011). With 
the dysautonomia in PD known to involve the cardiovascular system, involving 
postganglionic sympathetic noradrenergic lesions, norepinephrine loss in the 
sympathetic nervous system of the heart and parasympathetic over activity it 
seems very plausible that this is the cause of chronotropic incompetence in PD 
and the resultant poor heart rate response to exercise.  
These findings need to be explored further to examine the stability of heart rate 
during exercise and the recovery response of the heart rate to stopping exercise 
in PD. This is a notably interesting finding as it raises questions about the heart 
rate response of those with PD in other situations and as clinicians our 
assessment of them. Given these findings it would be important to consider 
implications such as heart rate in response to sepsis, and if blunted we may be 
underestimating the severity of illness in this population with resultant effects on 
morbidity and mortality. This is an area which warrants significant further 
research.    
6.2 Strengths and limitations 
There were limitations to the study; although exceeding or comparable number 
to previous studies, increasing the number of participants in future studies 
would improve power. It would have been beneficial to assess heart rate 
response during the exercise intervention, this was attempted however the 
equipment used proved complex for the participants to use and unreliable, thus 
produced no interpretable data. As described in section 4.5 the capillary blood 
gas sampling was unsuccessful. The patient information sheet detailed the use 
of a swallow assessment device and a device that measures oxygen levels 
(sats) during sleep, unfortunately the swallow assessment devices were not 
available on commencement of the study and the sats devices did not provide 
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meaningful results. The sats devices were patient operated and could not be 
pre-programmed, unfortunately the participants struggled with setting the 
devices to monitor oxygen levels only overnight resulting in devices recording 
no data or continuous data for days making the results uninterpretable. Given 
the broad ranging nature of the variables studied it was decided not to apply 
corrections for multiple comparisons. On balance it was felt that each variable 
considered was sufficiently unique and so no two variables were from the same 
family, to make correction for multiple comparisons unnecessary. A blanket 
adjustment would be too conservative an approach and likely wrongly show lack 
of significance.  This is however acknowledged as a limitation as it is important 
to recognise that in some cases significance may have been over estimated for 
this reason.     
In research when discussing results we refer to statistically significant changes, 
however this is different to clinically significant changes in outcome scores and 
this has to be taken into account as in some cases statistically significant 
change has little clinical significance.  Minimal clinically important differences 
(MCID) are patient derived scores, that generally involve patient perception, that 
reflect changes that are meaningful for the patient. There is considerable 
confusion in the literature with terminology used interchangeably which is 
actually quite different for example MCID, the minimally important difference 
(MID), the minimal clinical difference (MCD) or the minimal clinically significant 
difference (MCSD).  There is little consensus about defining MCID across the 
majority of outcome tools for a variety of reasons. There are a number of 
different methods to formulate a MCID due to different influencing factors. 
Baseline severity of symptoms can influence MCID of an outcome tool as can 
the use of the same tool in different study populations (Cook, 2008). As 
highlighted in section 5.10 when discussing 6MWT, with the same applying to 
VO2peak, SCOPA SLEEP and HADS, when outcome measures are used in 
different populations the MCID will vary for example the MCID for HADS 
following an exercise intervention in chronic heart failure will be different to that 
following an exercise intervention in PD. While the UPDRS and PDQ-39 are 
specific for use in PD, MCID estimates have not been fully established with 
papers quoting different estimates. More recent studies suggest for the UPDRS 
part 3 MCID for improvement was -3.25 and worsening 4.63, the UPDRS part 1 
MCID for improvement was -2.64 and worsening 2.45 and the UPDRS part 2 
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MCID for improvement was -3.05 and worsening 2.51 (Horvath et al., 2015, 
Shulman et al., 2010). A recent large study quoted estimates for MCID 
thresholds for PDQ-39-SI were -4.72 and +4.22 for minimal clinically important 
improvement and worsening respectively however acknowledged MICD 
estimates varied across PD severity. This all has to be taken into account when 
interpreting results (Horvath et al., 2017). 
The RCT benefitted from a number of strengths including gold standard 
pulmonary function and cardiorespiratory fitness testing, the exercise 
intervention was supervised and the study provided the means to assess short 
term and long term responses to exercise. Perhaps most importantly the 
exercise intervention received markedly positive feedback from the participants, 
with a number continuing voluntarily at the same healthy living centre for a 
further 12 weeks and then subsequently joining fitness centres. I feel one quote 
from a patient from the intervention group sums up the most important strength 
of the study “taking part in this has changed my life”. 
6.3 Conclusion  
Reflecting back to the hypothesis, aims and objectives, the RCT has shown that 
a structured exercise intervention in PD improves cardiorespiratory fitness, 
exercise capacity, parkinsonian symptoms, quality of life, sleep, anxiety and 
depression. Further research needs to be done to establish the optimum 
“exercise prescription” to maximise these benefits and also provide benefits in 
pulmonary function and respiratory muscle strength. 
Secondly the fascinating observation on poor heart rate response to exercise 
warrants significant further research.  
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Chapter 7. Conclusion and future studies 
7.1 Overall conclusions 
The cross-sectional study and the RCT both provided fascinating results and 
provoked questions for further research. Both sections of the study fulfilled the 
aims and objectives set out. The results of the cross-sectional study have 
shown a notable prevalence of obstructive spirometry, upper airways 
obstruction and inspiratory muscle weakness in this population. This pattern 
was observed in both non-smokers and smokers or those with known 
obstructive lung disease. This pattern of dysfunction of the respiratory system 
could lead to increased morbidity and mortality. The RCT has shown that a 
structured exercise intervention in PD improves cardiorespiratory fitness, 
exercise capacity, parkinsonian symptoms, quality of life, sleep, anxiety and 
depression. This study provides evidence in support of structured exercise as a 
treatment for PD. A secondary interesting finding in the RCT was the 
observation of poor heart rate response to exercise, this raises questions about 
heart rate response in PD to other stimuli such as sepsis. These significant 
findings warrant further research.  
7.2 Future studies 
The results from both the cross-sectional study and the RCT have proved very 
thought provoking with ideas for future studies. Further research is indicated to 
look at any association between pulmonary dysfunction in IPD and a number of 
issues including; bulbar problems, speech, swallowing, drooling, night time 
sleep, daytime somnolence and sleep disorders. Rehabilitation of pulmonary 
dysfunction warrants further assessment by pulmonary rehabilitation, specific 
respiratory muscle training and alternative exercise interventions. In addition to 
these non-pharmacological therapies, the effect of dopaminergic therapy on 
pulmonary function should be further studied.   
Considering exercise therapy, further research needs to be done to establish 
the optimum “exercise prescription” to maximise benefits and also provide 
benefits in pulmonary function and respiratory muscle strength. Interventions 
such as high-intensity interval training could be considered for research in this 
population as the short bursts of exertion may suit this population who may 
fatigue easily. Finally, the observation on poor heart rate response to exercise 
warrants significant further research. 
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Appendix A. Cross-sectional study; participant information 
sheet, consent form and assessment document 
 
                                                                                  
Professor Richard Walker 
North Tyneside General Hospital 
Rake Lane 
North Shields 
NE29 8NH 
Tel: 0191 293 2709 
 
PARTICIPANT INFORMATION SHEET 
 
EXERCISE AND PULMONARY FUNCTION IN IDIOPATHIC PARKINSON’S DISEASE 
BASELINE PULMONARY FUNCTION GROUP 
 
We would like to invite you to take part in this research study. Please take time to read 
the following information carefully, it explains why the research is being done and 
what it involves. If you have any questions about the information or if there is anything 
you do not understand, you are very welcome to ask for further explanation.  
 
 Part 1 tells you the purpose of the study and what will happen if you decide to 
take part. 
 Part 2 gives you more detailed information about the conduct of the study. 
 
Thank you for reading this. 
  
PART 1 
 
What is the purpose of the research study? 
 
Parkinson’s disease (PD) is the second most common neurodegenerative condition in 
the UK. Many people with PD suffer from respiratory symptoms including shortness of 
breath on exertion, cough and sputum production. Respiratory complications with PD 
are a common reason for hospital admission. Previous research studies looking at lung 
function in PD have produced some conflicting results. 
 
We plan to undertake a large study to look at the lung function and breathing muscle 
strength in PD. By defining the pattern of any lung problems we hope our results can 
be used to improve management, potentially non pharmacologically and 
pharmacologically, and reduce breathing complications and hospital admissions.  
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Why have I been invited to participate? 
 
You have been invited to participate as you are a patient with Idiopathic Parkinson’s 
Disease (IPD) currently under the care of the Northumbria PD service, the team 
organising this study.  
 
Do I have to take part? 
 
No, your participation is purely voluntary. If you do decide to take part, you are still 
free to withdraw at any time without giving reasons. A decision not to take part or to 
withdraw will not affect the standard of care you receive. If you do decide to take part, 
you will be given this information sheet to keep and then be asked to sign a consent 
form. 
 
What will the research study involve? 
 
You will be asked to attend North Tyneside General Hospital (NTGH) twice and we aim 
to recruit 100 participants. 
 
VISIT 1 – NTGH, JUBILEE DAY HOSPITAL  
This visit will involve taking a medical history and brief examination, questionnaires 
about your Parkinson’s Disease, exercise and breathing. You will have an ECG (heart 
tracing). You will have a blood test.  Total visit time: 120 minutes 
 
VISIT 2 – NTGH, PULMONARY FUNCTION 
This visit will involve measurements of how your lungs work, their volume and the 
strength of the breathing muscles. These are painless assessments involving breathing 
in and out of a tube attached to machines that record the measurements. Total visit 
time: 35 minutes 
 
BLOOD TEST 
At visit 1 you will have a blood test. This blood test is a simple pin prick test called a 
Capillary Blood gas that measures the levels of oxygen and carbon dioxide in the blood. 
 
After full completion of the study, all participants will be invited to a formal feedback 
event to share the overall results of the study. 
 
Expenses and payments 
 
Travel costs will be reimbursed by mileage, public transport or taxi as appropriate. 
 
What are the possible risks/ disadvantages of taking part? 
 
Giving up time to participate has to be considered. 
 
 
 
 
 
159 
 
What are the possible benefits of taking part? 
 
You will be contributing valuable information about how the lungs work in PD. 
Appropriate action will be taken for abnormal results if necessary. 
Contact details:  
 
Dr Ailish O’Callaghan or Professor Richard Walker, Department of Medicine, North 
Tyneside General Hospital, Rake Lane, North Shields. NE29 8NH. Tel: 0191 293 2709 
 
This completes Part 1 of the information sheet. Thank you for reading Part 1 and if 
you are interested in participating in the study please continue to Part 2 before 
making a decision. 
 
PART 2 
 
What will happen if I don’t want to carry on with the study? 
 
You can withdraw from the study at any time. The data already collected could still be 
used if you were agreeable to this. 
 
What if there is a problem? 
 
a) Concerns or complaints – If you have a concern or complaint about any aspect of 
this study you should contact Dr O’Callaghan or Professor Walker by phone on 0191 
293 2709 or in writing at the address above. The NHS operated Patient Advice and 
Liaison Service (PALS) can also provide guidance with any complaints or concerns by 
phone on 0800 032 0202, Text/SMS: 01670511098 or by email 
northoftynepals@nhct.nhs.uk 
 
b) In the unlikely event that something does go wrong and you suffer in any way the 
arrangements are as follows. If negligence of staff led to harm, this would be covered 
by the Northumbria Healthcare NHS Foundation Trust clinical negligence scheme. You 
may have to meet legal costs.  
 
Will my taking part in the study be kept confidential? 
 
All information obtained during the course of the study will be kept strictly 
confidential. It is our duty by law to protect your personal information and all of our 
procedures for handling, processing, storing and destroying data are compliant with 
the Data Protection Act (1998). Data collected during the study and your medical 
records may be looked at by regulatory authorities, who check that research is being 
carried out correctly, and the NHS Trust where it is relevant to your participation in the 
research.  
 
Results will be presented at scientific meetings, published in scientific journals and 
presented to participants at a feedback event without any personal identification. 
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Will my General Practitioner (GP) be involved? 
 
Your GP will be informed of your help with this study. This is standard practice. 
 
 
What will happen to blood samples? 
 
The blood sample will be tested for Capillary Blood Gas analysis (measures the gases in 
the blood). Samples will be disposed of once analysed. 
 
What will happen to the results of the research? 
 
The results will be published in scientific journals and presented at scientific meetings. 
All participants will be invited to a formal feedback event at which the results will be 
presented.  
 
Who is organising and funding the research? 
 
The study is being undertaken as part of Dr Ailish O’Callaghan’s MD degree at 
Newcastle University. The funding is from Northumbria Healthcare NHS Foundation 
Trust and via grants from Parkinson’s UK and The British Geriatrics Society. 
 
Who has reviewed the study? 
 
Ethical review of this study has been conducted by the Newcastle North Tyneside 1 
Research Ethics Committee. 
 
Further information and contact details 
 
You can get further information on this study by contacting Dr Ailish O’Callaghan or 
Professor Richard Walker, Department of Medicine, North Tyneside General Hospital, 
Rake Lane, North Shields, NE29 8NH. Tel: 0191 293 2709. 
 
For further independent information about being involved in a research study 
please contact the Patient Advice and Liaison Service (PALS). Freephone 0800 
0320202, email: northoftynepals@nhct.nhs.uk Text/SMS: 01670511098 
 
 
THANK YOU VERY MUCH FOR YOUR TIME AND INTEREST
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Patient Identification number for this trial:  
CONSENT FORM 
 
Title of project:           Exercise and pulmonary function in Idiopathic Parkinson’s 
disease 
               Baseline pulmonary function group 
 
Name of researcher:  Professor Richard Walker, North Tyneside General Hospital,  
Tel:                                 0191 293 2709 
 
        Please initial box 
 
1. I confirm that I have read and understand the information sheet dated 21st May  
    2012(V1.2) for the above study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at  
    any time, without giving any reason, without my medical care or legal rights being  
    affected. 
 
3. If I choose to withdraw from the study or do not continue in the study for other 
    reasons, I consent to the use of the data already collected.    
 
4. I agree to my GP being informed of my participation in the study.      
 
5. I understand that data collected during this study and my medical records may be  
    looked at by individuals from regulatory authorities or from the NHS Trust where it  
    is relevant to my participation in this research. I give permission for those individuals  
    to access my data.       
 
6. I agree to being contacted on the following telephone number: 
    …………………………………………………………………………………………………………………………………  
 
7. I agree to take part in the above study.     
 
........................................                              …………………………            …………………………………… 
Name of participant                                       Date                                  Signature 
 
……………………………………..                              …………………………            …………………………………… 
Name of person taking consent                   Date                                  Signature 
(if different from researcher) 
 
……………………………………..                              ………………………….           …………………………………... 
Researcher                                                       Date                                  Signature                                                                                                       
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ID NUMBER…………            VISIT NUMBER…………..                 DATE…………….. 
 
EXERCISE AND PULMONARY FUNCTION IN IPD ASSESSMENT 
 
AGE ……………YRS                HEIGHT………………M             WEIGHT………………KG 
 
PARKINSON’S DISEASE 
 
1. DISEASE DURATION………………..YRS  
 
SYMPTOMS AT ONSET RIGHT LEFT 
BRADYKINESIA   
RIGIDITY   
TREMOR    
POSTURAL INSTABILITY  
 
2. CURRENT PD MEDS……………..SCHEDULE……………………DATE STARTED 
 
 
 
 
3. PREVIOUS PD MEDS…………………………………………………DATE STOPPED 
 
 
 
4. HALLUCINATIONS IN LAST WEEK?                       YES                           NO 
IF YES FREQUENCY? 
TYPE? VISUAL/ AUDITORY/ OLFACTORY/ GUSTATORY/ TACTILE 
 
5. SYMPTOMS SUGGESTIVE OF RBD?                      YES                           NO 
 
6. HISTORY SENSE OF SMELL LOSS?                         YES                           NO  
 
7. HISTORY OF COMPULSIVE BEHAVIOR?               YES                           NO 
 
8. SCANS?                                                                      YES                          NO 
MRI/ CT/ DAT (FPCIT SPECT) 
RESULT? 
 
 
 
 
163 
 
PAST MEDICAL HISTORY/ PAST SURGICAL HISTORY 
 
 
 
 
 
 
 
9. HISTORY OF CARDIOVASCULAR DISEASE?                       YES              NO 
MI/IHD/ANGINA/CABG/ANGIO 
DETAILS……………………………………………………………………………………………. 
 
10. HISTORY OF STROKE/TIA/PVD                                          YES              NO 
DETAILS…………………………………………………………………………………………… 
 
11. HISTORY OF HYPERTENSION OR DYSLIPIDAEMIA?         YES             NO 
DETAILS……………………………………………………………………………………………. 
 
12. HISTORY OF DIABETES?                                                        YES            NO 
DETAILS…………………………………………………………………………………………… 
 
13. HISTORY OF PULMONARY DISEASE?                                  YES            NO 
DETAILS…………………………………………………………………………………………… 
 
14. HISTORY OF JOINT PROBLEMS?                                          YES            NO 
DETAILS…………………………………………………………………………………………… 
 
15. KNOWN THORACIC/ABDO/AORTIC ANEURYSM?            YES            NO 
DETAILS…………………………………………………………………………………………… 
 
16. HISTORY PNEUMOTHORAX/ HAEMOPTYSIS?                   YES            NO 
DETAILS…………………………………………………………………………………………… 
 
17. RECENT SURGERY (ALL/EYE/THORACIC/ABDO)?              YES            NO 
DETAILS…………………………………………………………………………………………… 
 
18. HISTORY BLOOD CLOT/DVT/PE?                                          YES           NO 
DETAILS…………………………………………………………………………………………… 
 
19. PREGNANT?                                                                              YES          NO 
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MEDICATION OTHER THAN FOR PARKINSON’S DISEASE 
 
 
 
 
ALLERGIES                                                                                 YES              NO 
DETAILS…………………………………………………………………………………………… 
 
FAMILY HISTORY 
PARKINSONISM/ PD/ PD PLUS/ TREMOR/ NEURO/ CARDIAC/ 
STROKE/ 
PULMONARY/ MALIGNANCY 
DETAILS…………………………………………………………………………………………… 
 
SOCIAL HISTORY 
SMOKER                                                             YES                NO              
EX 
PACK 
YEARS……………………………………………………………………………………………. 
COMMENTS (E.G. PIPE ETC)…………………………………………………………… 
 
OCCUPATIONS..……………………………………………………………………………… 
PETS………………………………………………………………………………………………. 
 
ALCOHOL 
(UNITS/WEEK)……………………………………………………………………………….. 
 
EXERCISE HISTORY 
INEXCLUDING WALKING: 
FREQUENCY/ WEEK   0    1    2    3    4    5    6    7    8    9    10 
DURATION (MINS)     10    20    30    40    50    60    70    80    90 
TYPES OF EXERCISE 
DETAILS………………………………………………………………….. 
 
ON EXAMINATION 
 
HEART SOUNDS/JVP                                                     PULSE………………..     
 
LUNGS/ LEGS                                                                  BP……………………… 
 
ABDOMEN                                                                       SATS………………….  
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Appendix B. Rating scales 
Due to copyright and reproduction prohibitions, copies of rating scales cannot 
be reproduced. 
 
The MDS-UPDRS can be accessed via this URL: 
http://www.movementdisorders.org/MDS-Files1/PDFs/Rating-Scales/MDS-
UPDRS_Vol23_Issue15_2008.pdf 
 
The PDQ-39 can be accessed via this URL: 
https://innovation.ox.ac.uk/wp-content/uploads/2014/07/Final_PDQ-
39_English_UK_SAMPLE.pdf 
 
The SCOPA-SLEEP can be accessed via this URL: 
https://www.lumc.nl/sub/7020/att/1288981/SCOPA-SLEEP-EN 
 
The HADS can be accessed via this URL: 
http://www.scalesandmeasures.net/files/files/HADS.pdf 
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Appendix C. Randomised control trial; participant 
information sheet, consent form and assessment document 
                                                             
Professor Richard Walker 
North Tyneside General Hospital 
Rake Lane 
North Shields 
NE29 8NH 
Tel: 0191 293 2709 
 
PARTICIPANT INFORMATION SHEET 
 
EXERCISE AND PULMONARY FUNCTION IN IDIOPATHIC PARKINSON’S DISEASE 
RANDOMISED CONTROL TRIAL GROUP 
 
We would like to invite you to take part in this research study. Please take time to read 
the following information carefully, it explains why the research is being done and 
what it involves. If you have any questions about the information or if there is anything 
you do not understand, you are very welcome to ask for further explanation.  
 
 Part 1 tells you the purpose of the study and what will happen if you decide to 
take part. 
 Part 2 gives you more detailed information about the conduct of the study. 
 
Thank you for reading this. 
  
PART 1 
 
What is the purpose of the research study? 
 
Parkinson’s disease (PD) is the second most common neurodegenerative condition in 
the UK. Many people with PD suffer from respiratory symptoms including shortness of 
breath on exertion, cough and sputum production. Respiratory complications with PD 
are a common reason for hospital admission. Previous research studies looking at lung 
function in PD have produced some conflicting results. 
 
We plan to undertake a large study to look at the lung function and breathing muscle 
strength in PD and to assess the effect of a 12 week exercise programme on the above 
measurements. By defining the pattern of any lung problems in PD and demonstrating 
the effect of exercise on the heart and lung’s function and on quality of life measures, 
we hope our results can be used to improve management and reduce breathing 
complications and hospital admissions.  
 
 
167 
 
Why have I been invited to participate? 
 
You have been invited to participate as you are a patient with Idiopathic Parkinson’s 
Disease (IPD) currently under the care of the Northumbria PD service, the team 
organising this study.  
 
Do I have to take part? 
 
No, your participation is purely voluntary. If you do decide to take part, you are still 
free to withdraw at any time without giving reasons. A decision not to take part or to 
withdraw will not affect the standard of care you receive. If you do decide to take part, 
you will be given this information sheet to keep and then be asked to sign a consent 
form. 
 
What will the research study involve? 
 
You will be asked to attend North Tyneside General Hospital (NTGH) twice and the 
Clinical Research Facility at the Royal Victoria Infirmary (RVI) once at the beginning of 
the study and then NTGH twice and the RVI once again after 12 weeks. If you are 
allocated to the exercise group, during that 12 week period you will also be asked to 
attend 45 minute supervised exercise sessions 3 times per week at Moor Park Healthy 
Living Centre (HLC), approximately 1.5 miles from NTGH.  
 
We aim to recruit 30 participants and you will be divided at random into 2 equal 
groups, 1 group that will receive the 12 week exercise programme and 1 group that 
will continue to receive normal care. If you are placed in the group which does not 
attend the exercise sessions, at the end of the study you will be offered the 
opportunity to participate in a 12 week exercise programme if you would like to. 
 
VISIT 1 – NTGH, JUBILEE DAY HOSPITAL 
This visit will involve taking a medical history and examination, questionnaires about 
your Parkinson’s disease, exercise, breathing, quality of life, sleep, memory, anxiety 
and depression. You will have a speech assessment, involving measuring the maximum 
volume of your voice and recording you reading 5 sentences and a swallow assessment 
involving drinking a glass of water. You will have a 6 minute walking assessment. You 
will have an ECG (heart tracing). The normal care group will have 2 blood tests and the 
exercise group will have 1 blood test. The exercise group will go home wearing an 
accelerometry sensor (wristwatch type device) that measures movement and a small 
earpiece device that measures swallow. These devices can be dropped back at NTGH 
or collected by a member of the research team the following day. Total visit time: 210 
minutes 
 
VISIT 2 – NTGH, PULMONARY FUNCTION 
This visit will involve measurement of how your lungs work, their volume and the 
strength of the breathing muscles. These are painless assessments involving breathing 
in and out of a tube attached to machines that record the measurements. Total visit 
time: 35 minutes 
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VISIT 3 – RVI 
This visit will involve checks of your pulse, blood pressure and strength, a memory test 
and a cycling test. The cycling test will be done on a recliner bike. During this test you 
will cycle at the same pace but how hard you are cycling will steadily increase. You will 
keep on cycling until you decide to stop or pedalling becomes too difficult. Whilst you 
are cycling you will be asked to wear a breathing mask and heart monitor. The exercise 
test will last 10 – 15 minutes. Total visit time: 75 minutes 
 
12 WEEK EXERCISE INTERVENTION – HLC 
If you are allocated to the exercise group we will ask you to attend the Moor Park HLC 
for 45 minute sessions 3 times per week for 12 weeks. You will be in groups of 5 and 
the HLCs will be closed to the general public during your sessions. The sessions are 
individually tailored and supervised by the HLC staff who have extensive experience 
and qualifications in exercise in those with medical problems. Each 45 minute session 
will comprise 30 minutes of aerobic exercise, for example including cycling, and 15 
minutes of resistance exercise, for example including arm weights. Before and after 
your first and last sessions you will have a blood test. During the first and last weeks 
you will go home from one of the sessions with a wristwatch type device that 
measures your oxygen level while you sleep. Each visit time: 45 minutes 
 
VISIT 4 – NTGH 
The same as visit 1. Total visit time: 210 minutes 
 
VISIT 5 – NTGH 
The same as visit 2. Total visit time: 35 minutes 
 
VISIT 6 – RVI  
The same as visit 3. Total visit time: 75 minutes 
 
BLOOD TESTS 
 
At visits 1 and 4 the normal care group will have 2 blood tests; 1 a simple pin prick test 
to measure the levels of the different gases in the blood and 1 to measure the blood 
count and the level and genotype (the genetic makeup) of a protein released in 
response to exercise into the blood. At visit 1 and 4 the exercise group will have 1 
blood test, a simple pin prick test to measure the levels of the gases in the blood. 
 
In the exercise group only, before and after your first and last exercise sessions you will 
have a simple blood test for the blood count and the level and genotype (genetic 
makeup) of a protein in the blood that is affected by exercise. 
 
After full completion of the study, all participants will be invited to a formal feedback 
event to share the overall results of the study. 
 
Expenses and payments 
 
Travel costs will be reimbursed by mileage, public transport or taxi as appropriate. 
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What are the possible risks/ disadvantages of taking part? 
 
Giving up time to participate has to be considered. 
 
What are the possible benefits of taking part? 
 
It is hoped that participants may feel the benefits of becoming physically fitter during 
the study. You will have supervised exercise sessions, like a personal trainer, which will 
teach you about your body and show you how to exercise and use the equipment 
correctly. 
 
Contact details:  
 
Dr Ailish O’Callaghan or Professor Richard Walker, Department of Medicine, North 
Tyneside General Hospital, Rake Lane, North Shields. NE29 8NH 
Tel: 0191 293 2709 
 
This completes Part 1 of the information sheet. Thank you for reading Part 1 and if 
you are interested in participating in the study please continue to read Part 2 before 
making any decision. 
 
PART 2 
 
What will happen if I don’t want to carry on with the study? 
 
You can withdraw from the study at any time. The data already collected could still be 
used if you were agreeable to this. 
 
What if there is a problem? 
 
a) Concerns or complaints – If you have a concern or complaint about any aspect of 
this study you should contact Dr O’Callaghan or Professor Walker by phone on 0191 
293 2709 or in writing at the address above. The NHS operated Patient Advice and 
Liaison Service (PALS) can also provide guidance with any complaints or concerns by 
phone on 0800 032 0202, Text/SMS: 01670511098 or by email 
northoftynepals@nhct.nhs.uk 
 
b) In the unlikely event that something does go wrong and you suffer in any way the 
arrangements are as follows. If negligence of staff led to harm, then dependent on 
hospital site this would be covered by either the Northumbria Healthcare NHS 
Foundation Trust clinical negligence scheme or the Newcastle upon Tyne Hospitals 
NHS Foundation Trust clinical negligence scheme. You may have to meet legal costs.  
 
Will my taking part in the study be kept confidential? 
 
All information obtained during the course of the study will be kept strictly 
confidential. It is our duty by law to protect your personal information and all of our 
procedures for handling, processing, storing and destroying data are compliant with 
the Data Protection Act (1998). Data collected during the study and your medical 
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records may be looked at by regulatory authorities, who check that research is being 
carried out correctly, and the NHS Trust where it is relevant to your participation in the 
research. 
 
As part of your speech assessment you will be recorded reading 5 sentences. We will 
give each recording a code to make it as anonymous as possible. These recordings will 
be analysed by a speech and language therapist and destroyed after analysis. 
 
Results will be presented at scientific meetings, published in scientific journals and 
presented to participants at a feedback event without any personal identification. 
 
Will my General Practitioner (GP) be involved? 
 
Your GP will be informed of your help with this study. This is standard practice. 
 
What will happen to blood samples? 
 
The blood samples will be tested for Full Blood Count (counts the cells in the blood), 
Brain Derived Neurotrophic Factor (a protein released in response to exercise that may 
improve the ability of the brain’s neurons to survive and grow) level and genotype and 
Capillary Blood Gas analysis (measures the gases in the blood). Samples for Full Blood 
Count and Brain Derived Neurotrophic Factor will be stored until it is certain that the 
test results are accurate and then they will be disposed of. Samples for Capillary Blood 
Gas are disposed of after analysis. 
 
 
What will happen to the results of the research? 
 
The results will be published in scientific journals and presented at scientific meetings. 
All participants will be invited to a formal feedback event at which the results will be 
presented.  
 
Who is organising and funding the research? 
 
The study is being undertaken as part of Dr Ailish O’Callaghan’s MD degree at 
Newcastle University. The funding is via Northumbria Healthcare NHS Foundation Trust 
and grants from Parkinson’s UK and The British Geriatrics Society. 
 
Who has reviewed the study? 
 
Ethical review of this study has been conducted by the Newcastle North Tyneside 1 
Research Ethics Committee. 
 
Further information and contact details 
 
You can get further information on this study by contacting Dr Ailish O’Callaghan or 
Professor Richard Walker, Department of Medicine, North Tyneside General Hospital, 
Rake Lane, North Shields, NE29 8NH. Tel: 0191 293 2709. 
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For further independent information about being involved in a research study please 
contact the Patient Advice and Liaison Service (PALS). Freephone 0800 0320202, email: 
northoftynepals@nhct.nhs.uk Text/SMS: 01670511098 
 
 
THANK YOU VERY MUCH FOR YOUR TIME AND INTEREST
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Patient Identification number for this trial:  
 
CONSENT FORM 
 
Title of project:           Exercise and pulmonary function in Idiopathic Parkinson’s 
disease 
               Randomised control trial group 
 
Name of researcher:  Professor Richard Walker, North Tyneside General Hospital,  
Tel:                                 0191 293 2709 
 
Please initial box 
 
1. I confirm that I have read and understand the information sheet dated 21st May  
    2012(V1.2) for the above study and have had the opportunity to ask questions. 
 
2. I understand that my participation is voluntary and that I am free to withdraw at  
    any time, without giving any reason, without my medical care or legal rights being  
    affected.  
 
3. If I choose to withdraw from the study or do not continue in the study for other 
    reasons, I consent to the use of the data already collected.    
 
4. I agree to my GP being informed of my participation in the study.      
 
5. I understand that data collected during this study and my medical records may be  
    looked at by individuals from regulatory authorities or from the NHS Trust where it  
    is relevant to my participation in this research. I give permission for those individuals  
    to access my data.       
 
6. I agree to being contacted on the following telephone number: 
    …………………………………………………………………………………………………………………………………  
 
7. I agree to take part in the above study.     
 
........................................                              …………………………            …………………………………… 
Name of participant                                       Date                                  Signature 
 
……………………………………..                              …………………………            …………………………………… 
Name of person taking consent                   Date                                  Signature 
(if different from researcher) 
 
……………………………………..                              ………………………….           …………………………………... 
Researcher                                                       Date                                  Signature 
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ID NUMBER………………    VISIT NUMBER………………..    DATE………………………. 
 
EXERCISE AND PULMONARY FUNCTION IN IPD ASSESSMENT 
 
AGE ……………YRS               HEIGHT………………M              WEIGHT………………KG 
 
PARKINSON’S DISEASE 
 
1. DISEASE DURATION………………..YRS  
 
SYMPTOMS AT ONSET RIGHT LEFT 
BRADYKINESIA   
RIGIDITY   
TREMOR    
POSTURAL INSTABILITY  
 
2. CURRENT PD MEDS……………………SCHEDULE…………………...DATE 
STARTED 
 
 
 
 
3. PREVIOUS PD MEDS…………………………………………………………DATE 
STOPPED 
 
 
 
4. HALLUCINATIONS IN LAST WEEK?                       YES                           NO 
IF YES FREQUENCY? 
TYPE? VISUAL/ AUDITORY/ OLFACTORY/ GUSTATORY/ TACTILE 
 
5. SYMPTOMS SUGGESTIVE OF RBD?                      YES                           NO 
 
6. HISTORY SENSE OF SMELL LOSS?                         YES                           NO  
 
7. HISTORY OF COMPULSIVE BEHAVIOR?               YES                           NO 
 
8. SCANS?                                                                      YES                          NO 
MRI/ CT/ DAT (FPCIT SPECT) 
RESULT? 
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PAST MEDICAL HISTORY/ PAST SURGICAL HISTORY 
 
 
 
 
 
 
 
9. HISTORY OF CARDIOVASCULAR DISEASE?                         YES           NO 
MI/IHD/ANGINA/CABG/ANGIO 
DETAILS…………………………………………………………………………………………… 
 
10. HISTORY OF STROKE/TIA/PVD                                            YES            NO 
DETAILS…………………………………………………………………………………………… 
 
11. HISTORY OF HYPERTENSION OR DYSLIPIDAEMIA?          YES            NO 
DETAILS…………………………………………………………………………………………… 
 
12. HISTORY OF DIABETES?                                                        YES            NO 
DETAILS…………………………………………………………………………………………… 
 
13. HISTORY OF PULMONARY DISEASE?                                  YES            NO 
DETAILS…………………………………………………………………………………………… 
 
14. HISTORY OF JOINT PROBLEMS?                                          YES            NO 
DETAILS…………………………………………………………………………………………… 
 
15. KNOWN THORACIC/ABDO/AORTIC ANEURYSM?             YES           NO 
DETAILS…………………………………………………………………………………………… 
 
16. HISTORY PNEUMOTHORAX/ HAEMOPTYSIS?                   YES            NO 
DETAILS…………………………………………………………………………………………… 
 
17. RECENT SURGERY (ALL/EYE/THORACIC/ABDO)?              YES            NO 
DETAILS…………………………………………………………………………………………… 
 
18. HISTORY BLOOD CLOT/DVT/PE?                                          YES           NO 
DETAILS…………………………………………………………………………………………… 
 
19. PREGNANT?                                                                              YES          NO 
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MEDICATION OTHER THAN FOR PARKINSON’S DISEASE 
 
 
 
 
 
 
 
ALLERGIES                                                                                 YES              NO 
DETAILS…………………………………………………………………………………………… 
 
FAMILY HISTORY 
PARKINSONISM/ PD/ PD PLUS/ TREMOR/ NEURO/ CARDIAC/ 
STROKE/ 
PULMONARY/ MALIGNANCY 
DETAILS…………………………………………………………………………………………… 
 
SOCIAL HISTORY 
SMOKER                                                             YES                NO              
EX 
PACK 
YEARS……………………………………………………………………………………………. 
COMMENTS (E.G. PIPE ETC)…………………………………………………………… 
OCCUPATIONS..…………………………………………………………………………….. 
PETS………………………………………………………………………………………………. 
ALCOHOL 
(UNITS/WEEK)……………………………………………………………………………….. 
 
EXERCISE HISTORY 
INEXCLUDING WALKING: 
FREQUENCY/ WEEK   0    1    2    3    4    5    6    7    8    9    10 
DURATION (MINS)     10    20    30    40    50    60    70    80    90 
TYPES OF EXERCISE 
DETAILS……………………………………………………………………………………….. 
 
ON EXAMINATION 
 
HEART SOUNDS/JVP                                                      PULSE………………..     
 
LUNGS/ LEGS                                                                  BP……………………… 
 
           ABDOMEN                                                                        SATS………………… 
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SPEECH AND SWALLOW ASSESSMENTS 
 
UNPREDICTABLE SENTENCES  
RECORDED                      YES                   NO 
 
Practice: Do many magazines these days have long stories 
 
Insert unique 5 McHenry Parle unpredictable sentences 
 
 
 
 
Will you leave the ravioli in the oven. 
 
SUSTAINED VOWEL 
 
MAXIMUM……………………………..DECIBELS 
DURATION………………………………SECONDS 
 
150ML WATER SWALLOW 
 
COMPLETED                  YES                     NO 
DURATION………………………………SECONDS 
SWALLOWS…………………………….NUMBER 
PAUSES…………………………………..NUMBER 
 
ACCELEROMETER  
 
ON                                   YES                    NO 
NUMBER 
 
SWALLOW DETECTION  
 
ON                                   YES                    NO 
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BLOODS 
 
BLOOD TEST DATE TAKEN/ N/A 
CBG  
FBC  
BDNF GENOTYPE  
BASELINE BDNF LEVEL  
BDNF PRE EXERCISE 1  
BDNF POST EXERCISE 1  
BDNF PRE EXERCISE 2  
BDNF PRE EXERCISE 2  
 
GROUP 1 – VISIT 1 CBG/FBC/GENOTYPE/BDNF LEVEL 
GROUP 2 – VISIT 1 CBG                  HLC – FBC/BDNFX2 
 
CBG RESULT 
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Appendix D. Additional work resulting from thesis and 
ongoing analyses 
 
Physical Activity; Accelerometer data 
Physical activity in research settings has traditionally been quantified using 
subjective measures, such as questionnaires, these are open to bias and often 
unreliable. Accelerometry has become an accepted method of objectively 
quantifying physical activity levels, but minimal studies have used this method 
to measure the effects of exercise interventions. Accelerometers are motion 
sensors that can objectively measure movement by measuring acceleration 
along reference axes and across three planes. Accelerometer outputs are 
usually expressed in units referred to as ‘counts’. Different processing 
algorithms and equations for signal processing exist to produce a numerical 
figure to represent the accelerometer output and hence physical activity.  
In the RCT arm of the study, participants in both the control and intervention 
groups wore two personal GeneActiv tri-axial capacitive accelerometers (one on 
each wrist) for 48 hours at baseline and then again after the 12 week control 
period or intervention respectively to measure the effects of a twelve week 
exercise intervention on physical activity levels. The equation used for signal 
processing was that described by van Hees et al, termed Euclidean norm minus 
one (ENMO) which resulted in a numerical output unit (ENMO) which reflected 
physical activity (van Hees et al., 2013). Although not reaching statistical 
significance, the ENMO data for the intervention group showed a trend towards 
higher activity after the intervention. In the control group, activity levels based 
on ENMO did not increase. 
 
Brain Derived Neurotrophic Factor  
Exercise is known to provoke a surge of molecular and cellular processes that 
support brain plasticity. Activity dependent neuroplasticity is supported by 
neurotrophins, which have the ability to signal neurons to survive, differentiate 
and grow (Hennigan et al., 2007, Johnston, 2009, Neeper et al., 1995, Neeper 
et al., 1996, Vaynman and Gomez-Pinilla, 2005). Brain derived neurotrophic 
factor (BDNF) seems to be the most susceptible neurotrophin to regulation by 
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exercise (Johnston, 2009, Neeper et al., 1995, Vaynman and Gomez-Pinilla, 
2005). Studies have shown decreased BDNF expression within the substantia 
nigra of PD brains as compared to controls (Howells et al., 2000, Parain et al., 
1999).  
Part of this study aimed to evaluate the impact of an acute episode of exercise 
on BDNF levels and the effect of 12 weeks of exercise training on BDNF levels 
in PD. In the RCT arm of the study, blood was taken for BDNF levels in the 
control group at baseline and after 12 weeks and in the intervention group 
immediately before and after the 1st exercise intervention in week 1 and 
immediately before and after the final exercise intervention in week 12. Plasma 
samples were assayed for BDNF levels using a commercially available 
sandwich ELISA kit from Promega (Sweden) according to the manufacturer’s 
instructions. 
While analysis of BDNF results is ongoing, the BDNF levels appear to vary 
notably from one analysis to the next and provisional results indicate there was 
no difference in the control group from start to finish. In the intervention group 
there was no significant difference from the start to the end of the 1st or 12th 
session or when comparing the start of session samples at week 1 and week 12 
or the end of session samples at week 1 and week 12.   
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